Pr ot oc ol : J 2 X- M C- P Y A D( d) 
A P hase 3 Ra n d o mize d, D o u ble- Bli n d, Place b o- C o ntr olle d Trial t o E val uate t he Efficac y 
a n d Safet y of L Y 3 8 1 9 2 5 3 Al o ne a n d i n C o m bi nati o n Wit h L Y 3 8 3 2 4 7 9 i n Pre ve nti n g 
S A R S- C o V- 2 I nfecti o n a n d C O VI D- 1 9 i n S kille d N ursi n g a n d Assiste d Li vi n g Facilit y 
Resi de nts a n d Staff; a NI AI D a n d Lill y C olla b orati ve St u d y 
N C T 0 4 4 9 7 9 8 7 
A p pr o val Date: 2 2-Ja n- 2 0 2 1 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
1Title P a ge 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of 
Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al 
i n v e sti g ati o n of L Y 3 8 1 9 2 5 3 , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d C o m p a n y or it s 
s u b si di ari e s.  
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a a n d/ or c o m m er ci all y c o nfi d e nti al 
i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e.  Eli Lill y a n d C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y 
p u bli c r el e a s e.  I n t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) E x e m pti o n 4 a n d m a y n ot b e 
r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
Pr ot oc ol Title: A P hase 3 Ra n d o mize d, D o u ble -Bli n d, Place b o -C o ntr olle d Trial t o E val uate t he 
Efficac y a n d Safet y of  L Y 3 8 1 9 2 5 3 al o n e a n d in c o m bi nat i o n wi t h  L Y 3 8 3 2 4 7 9 i n 
Pre ve nt i n g S A R S -C o V - 2 i nfect i o n a n d C O VI D - 1 9 i n S kille d N ursi n g a n d 
Assiste d Li vi n g Facilit yResi de nts a n d Staff ; a NI AI D a n d Lill y C olla b orati ve 
St u d y 
Pr ot oc ol N u m ber: J 2 X -M C -P Y A D ; C o V P N # 3 5 0 1 
A me n d me nt N u m ber: d
C o m p o u n d: L Y 3 8 1 9 2 5 3 
St u d y P h ase: 3
S h ort Title: A St u d y  t o E v al uate L Y 3 8 1 9 2 5 3 al o ne a n d i n c o m bi nat i o n wi t h  L Y 3 8 3 2 4 7 9 f o r t he 
Pre ve nt i o n of S A R S -C o V -2 i nfect i o n a n d C O VI D - 1 9 ; a NI AI D a n d Lill y 
C olla b orati ve St u d y 
S p o ns or N a me: El i Lill y  a n d C o m pa n y 
Le g al Re gistere d A d dress: I n dia na p o lis, I n dia na ,U S A 4 6 2 8 5 
Re g ul at or y A ge nc y I de ntifier N u m ber(s) 
I N D: 1 5 0 4 4 0 
A p pr o v al D ate: Pr ot oc ol A me n d me nt ( d)El ectr o nicall y Si g ne d a n d A p pr o ve d b y Lill y o n date 
pr o vi de d bel o w. 
A p pr o v al D at e: 2 2- J a n- 2 0 2 1 G M T 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
2Medical Monitor Name and Contact Information will be provided separately.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment (c) 04 Dec 2020
Amendment (b) 06 Nov 2020
Amendment (a) 27 Oct 2020
Original Protocol 28 Jun 2020
Amendment d
Overall Rationale for the Amendment:
This amendment willallow part icipants with COVID -19to enroll in Part 3 (treatment only) of
Study PYAD who haverecovered fro m prior COVID -19 infect ion, or hav ereceived pri or 
administration of convalescent plasma, monoclonal antibody , or vaccine for SARS -CoV -
2.Inclusio n will allow for collection of data to explore safet y of treatm ent of LY3819253 alone 
or in co mbination wit h LY3832479 in any o f these parti cipant popul ations. 
Section # and Name Description of Change Brief Rationale
Section 1.3.1 Part 1 and 
Preventio n Co hort of 
Part 2Updated “Prior treatments of special 
interest ”to collect prior use of 
SARS -CoV -2 vaccine.The SARS -CoV -2 vaccine is now allowed .
Section 1.3.2 Part 2 
Treatment Cohort and 
Part 3
2.2 Background Added background on PYAB interim 
results.Emerging data.
2.3 Benefit/Risk 
AssessmentUpdated risk information for 
LY3819253.Emerging data.
4.2 Scientific Rationale 
for Study DesignAdded rationale for participants who
have received the SARS -CoV -2 
vaccine.
Added language for Part 3 to reflect 
that participants who were in 
independent living situations at the 
facilities could be enrolled.Vaccines are now available to the public and 
those who received a vaccine are allow ed in 
the study .
Clarification.
5.2 Exclusion Criteria Updated Criteria 7, 8, 9, 11, 12, and 
13.This amendment will allow participants with 
COVID -19 to enroll in Part 3 (treatment 
only) of the study  having recovered from 
prior COVID -19 infection, or havi ng 
received prior administration of convalescent 
plasma, monoclonal antibody, or vaccine for 
COVID -19. Inclusion will allow for 
collection of data to explore safety of 
treatment of LY3819253 alone or in 
combinatio n with LY3832479 in any of th ese 
participan t populations.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
4Section # and Name Description of Change Brief Rationale
6.3 Measures to 
Minimize Bias: 
Randomization and 
BlindingAdded stratification factor for 
whether a participant received a 
vaccine or not prior to screeningThe SARS -CoV -2 vaccine is now allowed
11 References Added Chen et al.2020 reference Source for information in Section 2.3
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
5T a ble of C o nte nts 
1. Pr ot oc ol S u m m ar y ...................................................................................................... 8
1. 1. S y n o psis ....................................................................................................................... 8
1. 2. Sc he ma ....................................................................................................................... 1 5 
1. 3. Sc he d ule of Act i v it ies ( S o A) ...................................................................................... 1 7 
1. 3. 1. Part 1 a n d Pre ve nt i o n C o h ort of Part 2 ........................................................................ 1 7 
1. 3. 2. Part 2 Treat me nt C o h ort a n d Part 3 ............................................................................. 2 4 
2. I ntr o d ucti o n .............................................................................................................. 2 8 
2. 1. St u d y  Rati o nale .......................................................................................................... 2 8 
2. 2. Bac k gr o u n d ................................................................................................................ 2 8 
2. 3. Be nefit/ Ris k Assess me nt ............................................................................................ 2 9 
3. O bjecti ves a n d E n d p oi nts ......................................................................................... 3 1 
4. St u d y Desi g n ............................................................................................................. 3 7 
4. 1. O verall Desi g n............................................................................................................ 3 7 
4. 1. 1. Scree ni n g Peri o d ......................................................................................................... 3 7 
4. 1. 2. E val uat i o n Peri o d ....................................................................................................... 3 7 
4. 1. 3. F ol l o w- u p Peri o d ........................................................................................................ 4 0 
4. 2. S ci e nt ific Rati o nale f or St u d y  Desi g n ......................................................................... 4 1 
4. 3. J ust ificati o n f or D ose .................................................................................................. 4 2 
4. 4. E n d of St u d y  Defi nit i o n.............................................................................................. 4 2 
5. St u d y P o p ul ati o n ...................................................................................................... 4 3 
5. 1. I ncl usi o n Cri t eri a........................................................................................................ 4 3 
5. 2. E xcl u si o n  Cri t eri a....................................................................................................... 4 4 
5. 3. Lifest yle C o nsi derat i o ns ............................................................................................. 4 4 
5. 4. Scree n Fail ures ........................................................................................................... 4 4 
6. St u d y I nt er ve nti o n .................................................................................................... 4 6 
6. 1. St u d y  I nter ve nt i o n(s) A d mi nistere d ............................................................................ 4 6 
6. 1. 1. S peci al Treat m e nt C o nsi derat i o ns ............................................................................... 4 7 
6. 2. Pre parati o n/ Ha n dli n g/ St ora ge/ Acc o u nta bilit y............................................................. 4 8 
6. 3. Meas ures t o Mi ni mize Bias: Ra n d o mizat i o n a n d Bli n di n g .......................................... 4 8 
6. 4. St u d y  I nter ve nt i o n C o m plia nce ................................................................................... 5 0 
6. 5. C o nc o mita nt T hera p y ................................................................................................ . 5 0 
6. 6. I nter ve nti o n after t he E n d of t he St u d y ........................................................................ 5 1 
7. Disc o nti n u ati o n of St u d y I nter ve nti o n a n d P artici p a nt 
Disc o nti n u ati o n/ Wit h dr a w al .................................................................................... 5 2 
7. 1. Di sc o nti n ua ti o n of  St u d y  I nter ve nt i o n........................................................................ 5 2 
7. 2. P arti ci pa nt Disc o nti n uati o n/ Wit h dra wal fr o m t h e St u d y ............................................. 5 2 
7. 2. 1. Di sc o nti n uati o n of  I na d verte nt l y E nr olle d Partici pa nts ............................................... 5 2 
7. 3. L ost t o F oll o w u p ....................................................................................................... 5 3 
8. St u d y A ssess me nts a n d Pr oce d ures ......................................................................... 5 4 
8. 1. Efficac y Assess me nts ................................................................................................ . 5 4 
8. 1. 1. S A R S -C o V -2 Vi ral S wa b a n d Ser ol o g y ...................................................................... 5 4 
8. 1. 2. P arti ci pa nt S y m pt o m s Q uest i o n naire .......................................................................... 5 4 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
68. 2. S af et y Assess me nts .................................................................................................... 5 5 
8. 2. 1. P h ysical E xa mi nat i o ns, Cli nical Si g ns a n d S y m pt o ms ................................................ 5 5 
8. 2. 2. Vi t al  Si g ns.................................................................................................................. 5 5 
8. 2. 3. Cli nical Safet y  L a b orat or y  A ssess me nts ..................................................................... 5 6 
8. 2. 4. H os pitalizati o n e ve nts ................................................................................................ . 5 6 
8. 2. 5. Pr oce d ures of S pecial I nterest ..................................................................................... 5 7 
8. 3. A d verse E ve nts a n d Seri o us A d verse E ve nts .............................................................. 5 7 
8. 3. 1. Ti me Peri o d a n d Fre q ue nc y  f or C ollect i n g A E a n d S A E 
I nf or m at i o n................................................................................................................. 5 7 
8. 3. 2. Met h o d of Detecti n g A Es a n d S A Es ........................................................................... 5 8 
8. 3. 3. F o ll o w- u p of  A Es a n d S A Es ....................................................................................... 5 8 
8. 3. 4. Re g ulat or y  Re p orti n g Re q uire me nts f or S A Es ............................................................ 5 8 
8. 3. 5. Pre g na nc y ................................................................................................................... 5 8 
8. 3. 6. H y perse nsi ti vi t y  R e a cti o ns ......................................................................................... 5 8 
8. 3. 7. I nf usi o n- r el ate d Reacti o ns .......................................................................................... 5 9 
8. 3. 8. Pr o d uct C o m plai nt s.................................................................................................... 5 9 
8. 4. Treat me nt of O ver d ose ............................................................................................... 6 0 
8. 5. Phar mac o ki net ics ........................................................................................................ 6 0 
8. 5. 1. Bi oa nal y ti c al .............................................................................................................. 6 1 
8. 6. P har mac o d y na mics ..................................................................................................... 6 1 
8. 7. Ge net ic s..................................................................................................................... 6 1 
8. 8. Bi o m ar kers ................................................................................................................. 6 1 
8. 9. I m m u n o ge nicit y Assess me nts ..................................................................................... 6 2 
8. 1 0. Heal t h  Ec o n o mics ....................................................................................................... 6 2 
9. St atistic al C o nsi der ati o ns ......................................................................................... 6 3 
9. 1. Stati st ical H y p ot heses ................................................................................................ . 6 3 
9. 2. Sa m ple Si ze Deter mi nat i o n......................................................................................... 6 3 
9. 3. P o p ul at i o ns f o r A nal yses ............................................................................................ 6 4 
9. 4. Stati st ical A nal yses ..................................................................................................... 6 6 
9. 4. 1. Ge neral C o nsi derati o ns ............................................................................................... 6 6 
9. 4. 2. P arti ci pa nt Dis p osi ti o n ................................................................................................ 6 7 
9. 4. 3. P arti ci pa nt C haracteristics ........................................................................................... 6 7 
9. 4. 4. C o nc o mita nt T hera p y ................................................................................................ . 6 7 
9. 4. 5. Pri mar y E n d p o i nt ........................................................................................................ 6 7 
9. 4. 6. Sec o n dar y  E n d p o i nt s.................................................................................................. 6 8 
9. 4. 7. E x pl or at or y  E n d p o i nt s................................................................................................ 6 9 
9. 4. 8. Ot her Safet y A nal yses ................................................................................................ 6 9 
9. 4. 9. I m m u n o ge nicit y A nal yses ........................................................................................... 6 9 
9. 5. I nteri m A nal yses ......................................................................................................... 7 0 
9. 6. Data M o nit ori n g C o m mittee ( D M C) ........................................................................... 7 0 
1 0. S u p p orti n g D oc u me nt ati o n a n d O per ati o n al C o nsi der ati o ns ................................ 7 1 
1 0. 1. A p pe n di x 1: Re g ulat or y , Et hical , a n d St u d y  O versi g ht 
C o nsi derati o ns ............................................................................................................ 7 1 
1 0. 1. 1. Re g ulat or y  a n d Et hi cal  C o nsi derat i o ns ........................................................................ 7 1 
1 0. 1. 2. Fi na ncial Discl o s ure ................................................................................................... 7 1 
1 0. 1. 3. I nf or m e d C o nse nt Pr ocess .......................................................................................... 7 2 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
71 0. 1. 4. Data Pr otecti o n ........................................................................................................... 7 2 
1 0. 1. 5. C o m mittees Str uct ure ................................................................................................ . 7 3 
1 0. 1. 6. Di sse mi nat i o n of Cli nical St u d y  Data ......................................................................... 7 3 
1 0. 1. 7. Data Q ualit y Ass ura nce .............................................................................................. 7 3 
1 0. 1. 8. S o urce D oc u me nts ...................................................................................................... 7 4 
1 0. 1. 9. St u d y  a n d Si te Start a n d Cl os ure ................................................................................. 7 5 
1 0. 1. 1 0. P u blicat i o n P olic y ....................................................................................................... 7 5 
1 0. 1. 1 1. I n vest i gat or I nf or mat i o n............................................................................................. 7 5 
1 0. 1. 1 2. L o n g -Ter m  Sa m ple Rete nt i o n..................................................................................... 7 5 
1 0. 2. A p pe n di x 2: Cli nical La b orat or y  Tests ........................................................................ 7 7 
1 0. 3. A p pe n di x 3: A d verse E ve nts: Defi nit i o ns a n d Pr oce d ures f or 
Rec or di n g, E val uat i n g, F oll o w -u p, a n d Re p orti n g ....................................................... 8 0 
1 0. 3. 1. Defi nit i o n o f A E ......................................................................................................... 8 0 
1 0. 3. 2. Defi nit i o n o f S A E ....................................................................................................... 8 1 
1 0. 3. 3. Rec or di n g a n d F o ll o w- U p of A E a n d/ or S A E ............................................................. 8 2 
1 0. 3. 4. Re p orti n g of S A Es ...................................................................................................... 8 4 
1 0. 4. A p pe n di x 4: C o ntrace pti ve G ui da nce a n d C o llect i o n of 
Pre g na nc y I nf or mati o n ............................................................................................... 8 5 
1 0. 4. 1. W o me n....................................................................................................................... 8 5 
1 0. 4. 2. Me n ............................................................................................................................ 8 6 
1 0. 4. 3. C ollect i o n of Pre g na nc y  I nf or m at i o n.......................................................................... 8 7 
1 0. 5. A p pe n di x 5: Ge neti cs ................................................................................................ . 8 8 
1 0. 6. A p pe n di x 6: Rec o m me n de d La b orat or y Test i n g f o r 
H y perse nsi ti vi t y  E ve nts .............................................................................................. 8 9 
1 0. 7. A p pe n di x 7: Li ver Safet y:  S u g geste d Acti o ns a n d F oll o w - u p 
Assess me nts ............................................................................................................... 9 1 
1 0. 8. A p pe n di x 8: A b bre viat i o ns ......................................................................................... 9 5 
1 0. 9. A p pe n di x 9: Pr ot oc ol A me n d me nt Hist or y ................................................................ . 9 8 
1 1. Refere nces ............................................................................................................... 1 0 8 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
81. Protocol Summary
1.1. Synopsis
Protocol Title: A Phase 3 Rando mized, Double -Blind, Placebo -Controlled Trial to Evaluate the 
Efficacy and Safet y ofLY3819253 aloneandin combinat ion withLY3832479 in Prevent ing 
SARS -CoV -2 infect ion and COVID -19in Skilled Nursing andAssisted Living Facil ity
Residents and Staff ; a NIAID and Lilly  Collaborative Study
Short Title: A Study  to Eval uate LY3819253 alone and in combinat ion with LY3832479 for the 
Prevent ion ofSARS -CoV -2 infect ion and COVID -19; a NIAID and Lilly Co llaborative Study
Rationale :
The efficient communit y spread of SARS -CoV -2 has resulted in the current pandemic of 
Coronavirus Disease –2019 ( COVID -19), whi ch in severe and crit ical cases resul ts in 
progressive pulmo nary infect ion, com plicated by  respi ratory  failure, wi th a high prevalence of 
acute respiratory  distress syndrome.  Of all age groups , older adul ts have the greatest risk of 
severe COVID -19 and the associated complicat ions (CDC 2020 ;Grabowski and Mor 2020 ).
Globally ,there are m any reports of the rapi d spread of COVID- 19 am ongst resi dents of skilled 
nursing facilit ies fo llowing ident ificat ion of an index case, with high associated rates of 
morbidity and m ortali ty (Arons et al .2020; Grabowski and Mor 2020; Graham et al . 2020 ).  In 
the USA, at least 153,000 residents and emplo yees of nursing ho mes have contracted 
COVID -19, accounting for 35% of the coun try’s deaths ( Werner et al. 2020 ).  Wi th over 1.3 
millio n residents in nursing home care in the USA (CDC 2016 ), there is an urgent need for 
therapeuti c strategi es to prevent COVID -19 in these populat ions.
This study  aims to eval uate the impact of LY3819253 alone and in combinat ion with 
LY3832479 in preventing SARS-CoV -2 infect ion andCOVID -19 in facilitystaff and residents 
in skilled nursing and assisted living facilit ies with a hi gh risk of SARS -CoV -2 exposure.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
9O bjecti ves a n d E n d p oi nt s
P art 1 
T o facilitate ra pi d pr o p h yla xis a n d tr e at m e nt of resi de nts a n d fa cilit ystaff, parti ci pa nts will be 
e nr o lle d pri or t o assess me nt of baseli ne S A R S -C o V - 2 re verse tra nscri pt i o n –p ol y merase c hai n 
reacti o n ( R T -P C R )or ser ol o g y  res ul ts ;t h us, m ult i pl e a nal ysis p o p ul at i o ns will e xist.  T his 
i ncl u des se parate pre ve nt i o n a n d treat me nt a nal ys is p o p ul at i o ns ( defi ne d i n t he ta bles bel o w) a n d 
baseli ne ser ol o g y  p osi ti ve partici pa nts.   E x pl orat or y  e n d p oi nts, i ncl u di n g t he treat me nt a nal ysis 
p o p ul at i o n, are descri be d i n Sect i o n 3.
S af et y,  p har mac o ki net ics ,a n d a nt i dr u g a nt i b o dies will be c haracterize d i n t he o verall i nte nt t o 
treat p o p ulat i o n a n d i n t he a nal ysis p o p ulat i o ns. 
A d dit i o nal p o p ulat i o n s u bset a nal yses are d etaile d i n Secti o n  9a n d/ or i n t he stati st ical a nal ysis 
pl a n. 
Pre ve nti o n P o p ulati o n O bjecti ves a n d E n d p oi nts 
Partici pa nts ne gati ve at baseli ne f or S A R S -C o V - 2 R T -P C R a n d s e r ol o g y 
C o m paris o n Gr o u ps: Place b o vs L Y 3 8 1 9 2 5 3 4 2 0 0 m g 
O bjecti ves E n d p oi nts 
Pri mar y 
C o m pare t he i nci de nce of C O VI D - 1 9 C u m ulati ve i nci de nce of C O VI D -1 9 defi ne d 
as t he detecti o n of S A R S -C o V -2 b y R T -P C R 
A N D mil d or w orse disease se verit y awit hi n 
2 1 da ys of detecti o n 
Ti me fra me f or e n d p oi nt e val uati o n: 8 
wee ks fr o m ra n d o mizati o n 
Ke y Sec o n dar y 
C o m pare t he i nci de nce of m o derate or w orse 
se verit y C O VI D - 1 9 C u m ulati ve i nci de nce of m o derate or w orse 
se verit y C O VI D -1 9; defi ne d as t he detecti o n 
of S A R S -C o V -2 b y R T -P C R A N D m o derate 
or w orse disease se verit y awit hi n 2 1 da ys of 
detecti o n 
Ti me fra me f or e n d p oi nt e val uati o n: 8 
wee ks fr o m ra n d o mizati o n 
C o m pare t he i nci de nce of S A R S -C o V - 2 
i nfecti o n C u m ulati ve i nci de nce of S A R S -C o V - 2 ; 
defi ne d as t he detecti o n of S A R S -C o V -2 b y 
R T -P C R 
Ti me fra me f or e n d p oi nt e val uati o n: 4 
wee ks fr o m ra n d o mizati o n 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
1 0 Ot her Sec o n dar y 
[ti me fra me f or e n d p oi nt e val uati o n:  8 wee ks fr o m ra n d o mizati o n] 
C o m pare t he i nci de nce of S A R S -C o V - 2 
i nfecti o n C u m ulati ve i nci de nce of S A R S -C o V - 2 
i nfecti o n defi ne d as t he detecti o n of S A R S -
C o V -2 b y R T -P C R 
C o m pare t he fre q ue nc y of h os pitalizati o n or 
deat h d ue t o C O VI D - 1 9 Pr o p orti o n of partici pa nts w h o are 
h os pitalize d or ha ve die d d ue t o C O VI D - 1 9 
C haracterize cli nical stat us f or partici pa nts.  Pr o p orti o n ( perce nta ge) of partici pa nts w h o 
e x perie nce t hese e ve nts: 
oC O VI D -1 9 relate d h os pitalizati o n 
( defi ne d as ≥ 2 4 h o urs of ac ute care), 
oC O VI D -1 9 relate d e mer ge nc y r o o m visit, 
or 
odeat h 
C o m pare t he m ortalit y d ue t o C O VI D - 1 9 Pr o p orti o n of partici pa nts w h o die d ue t o 
C O VI D -1 9 (acc or di n g t o t he i n vesti gat or) 
A b bre viati o ns : C O VI D -1 9 = c o r o na vir us disease –2 0 1 9; R T -P C R = re verse tra nscri pti o n –p ol y merase c hai n 
reacti o n; S A R S -C o V -2 = se vere ac ute res pirat or y s y n dr o me c or o na vir us 2. 
aAs defi ne d i n  Ta ble 1. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
1 1 P art 2 Pre ve nti o n 
P arti ci pa nts will be teste d wi t h  p oi nt of care S A R S -C o V -2 P O C test t o deter mi ne S A R S -C o V - 2 
stat us. Parti ci pa nts wi t h  a ne gat i ve P O C test will ra n d o mize t o t he Pre ve nti o n C o h ort.  T h ose 
wi t h  a p osi ti ve test will e nr o ll t o t he Treat me nt C o h ort. 
S af et y,  p har mac o ki net ics, a n d a nt i dr u g a nt i b o dies will be c haracterize d i n t he o verall i nte nt t o 
treat p o p ulat i o n a n d i n t he a nal ysis p o p ulat i o ns. 
A d dit i o nal p o p ulat i o n s u bset a nal yses are detaile d i n Secti o n  9a n d/ or i n t he stati st ical a nal ysis 
pl a n. 
Part 2 Pre ve nti o n P o p ulati o n O bjecti ves a n d E n d p oi nts 
Partici pa nt ne gati ve o n scree ni n g P oi nt of Care Test 
&
ne gati ve at baseli ne f or S A R S -C o V -2 R T -P C R a n d ser ol o g y 
C o m paris o n Gr o u ps: 
Place b o vs L Y 3 8 1 9 2 5 3 7 0 0 m g 
Place b o vs L Y 3 8 1 9 2 5 3 3 5 0 m g + L Y 3 8 3 2 4 7 9 7 0 0 m g 
O bjecti ves E n d p oi nts 
Pri mar y 
C o m pare t he i nci de nce of C O VI D - 1 9 C u m ulati ve i nci de nce of C O VI D -1 9 defi ne d as 
t he detecti o n of S A R S -C o V -2 b y R T -P C R A N D 
mil d or w orse disease se verit y awit hi n 2 1 da ys 
of detecti o n 
Ti me fra me f or e n d p oi nt e val uati o n: 8 
wee ks fr o m ra n d o mizati o n 
Ke y Sec o n da r y 
C o m pare t he i nci de nce of m o derate or w orse 
se verit y C O VI D - 1 9 C u m ulati ve i nci de nce of m o derate or w orse 
se verit y C O VI D -1 9; defi ne d as t he detecti o n of 
S A R S -C o V -2 b y R T -P C R A N D m o derate or 
w orse disease se verit y awit hi n 2 1 da ys of 
detecti o n 
Ti me fra me f or e n d p oi nt e val uati o n: 8 
wee ks fr o m ra n d o mizati o n 
C o m pare t he i nci de nce of S A R S -C o V - 2 
i nfecti o n C u m ulati ve i nci de nce of S A R S -C o V -2; defi ne d 
as t he detecti o n of S A R S -C o V -2 b y R T -P C R, 
Ti me fra me f or e n d p oi nt e val uati o n: 
4wee ks fr o m ra n d o mizati o n 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
1 2 Ot her Sec o n dar y 
C haracterize t h e p har m ac o ki net ics of 
L Y 3 8 1 9 2 5 3 a n d L Y 3 8 1 9 2 5 3 i n 
c o m bi nat i o n wi t h  L Y 3 8 3 2 4 7 9 Mea n c o nce ntrati o n of L Y 3 8 1 9 2 5 3 a n d 
L Y 3 8 1 9 2 5 3 i n t he prese nce of L Y 3 8 3 2 4 7 9 o n 
Da y 2 9 
Mea n c o nce ntrati o n of L Y 3 8 3 2 4 7 9 i n t he 
prese nce of L Y 3 8 1 9 2 5 3 o n Da y 2 9 
A b bre viati o ns: C O VI D -1 9 = c or o na vir us disease –2 0 1 9; R T -P C R = re verse tra nscri pti o n –p ol y merase c hai n 
reacti o n; S A R S -C o V -2 = se vere ac ute res pirat or y s y n dr o me c or o na vir us 2. 
aAs defi ne d i n  Ta ble 1. 
Part 3 o bject i ves are e x pl orat or y a n d t heref ore descri be d i n Sect i o n 3.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
13Overall Design
Study  J2X-MC-PYAD is a r ando mized, double -blind, placebo -controlled, prophylaxis study to 
evaluate the efficacy  and safety of intravenous LY3819253 , alone and in combinat ion with 
LY3832479, in prevent ing SARS -CoV -2 infect ion andCOVID -19, com pared to pl acebo.  An 
independent Data Safety  Moni tory Board (DSMB ) will act ively monitor interim  data to m ake 
recommendat ions about early study  closure or chang es to sam ple size.
Disclosure Statement : This is a three-part, 9-arm intervent ional study  that is doubl e-blinded.
Number of Participant s:
For Part1, a total of approximately 1700 participants (intent-to-treat [ ITT]populat ion) will be 
rando mlyassigned to study  intervent ion such that approximately 1300 SARS-CoV -2 RT-PCR 
and sero logy negative participants are randomized in the study with the goal  of achieving 
approximately  33 events (in each of the primary and key  secondary  endpoints ) in the pre vention 
popul ation.
For Part 2, a total of approximately  2000 participants will be randomly assigned to study  
intervent ion based on rapid point of care (POC) testing such that approximately  1700
participants SARS -CoV -2 RT -PCR and serology  negative participants are randomized in the 
Prevent ion Cohort with the goal o f achieving approximately  56 events oneach of the primary 
and key  secondary endpoints .  
Part 3 will enro ll at least 30 participants and up to appr oximately  500 partici pants randomized to 
study  interventi on.
The m aximum  sample size for this study  is approximately  5000 participants in the ITT 
popul ation.
Intervention Groups and Duration:
Parti cipants will receive one intravenous infusio n of study  intervent ion.  
The m aximum  total  durati on of  study  participat ion for each participant of the prevent ion groups 
is 24 weeks.
The m aximum  total  durati on of  study  participat ion for each participant of the treatment group is 
12 weeks.
Part 1 :
Eligible partici pants will be randomized to one of two arms: placebo or LY3819253 4200 mg.
Parti cipants will continue to enroll to Part 1 until the needed events for the primary and key 
secondary  endpoints are achieved and the minimum number of residents enro ll.  
The evaluation period for Part 1 is 8weeks, wi th follow -up to 24 weeks.
Part 2:
The Sponsor will decide when to trigger activat ion of Part 2.  Activat ion of Part 2 will be 
communicated to sites.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
14All participant swill be screen ed for SARS CoV -2 with a poin t of care (POC) test .  Participants 
who are neg ative will be assigned to the “Prevention Cohort”, while those who test posit ive will 
be assigned to the “Treatm ent Cohort ”.
Prevent ion Cohort: Participants who are SARS -CoV -2 negative during screening on the 
POC testwill be rando mized to one of three arms: placebo , LY381 9253 700 mg,or 
LY3819253 -350 m g + LY3832479- 700 m g.
If enro lling to a placebo -controlled trial is challenged by an effective medication 
beco ming available for prevent ion of COVID- 19 and SARS -CoV -2, then the placebo arm 
may be dropped.
Note:  It is possible that so me partici pants have SARS -CoV -2 negat ive resul t on the 
screening point of care test ,but could bepositive on the baseline SARS -CoV -2 PCR test.  
The results from th e baseline testwill not be available until after the participant is 
rando mized .  Once posi tive results are known from the baseline test, these participants 
will be unblinded and have the option to continue to be fo llowed for safet yaccording to 
the Prevent ion Cohort SoA.   Unblinded part icipants will not be included as part of the 
defined prevent ion popul ation.  
The evaluation period for the Prevent ion Cohort is 8 weeks, wi th follow-up to Day  169.
Treatment Cohort: Participants who test SARS -CoV -2 positive during screening with the 
POC test will be rando mized to one of two arms:  LY3819253 700mg, or LY3819253
700 mg + LY3832479 1400 mg.  
The evaluation period for the Treatment Cohort is 4weeks, with fo llow-up to Day  85.
Part 3
The Sponsor will decide when to tri gger activat ion of Part 3.  Activat ion of Part 3 will be 
communicated to sites.  Part 3 may be activated prior to Part 2.
Eligible participants will be rando mized to one of two arms:  LY3819253 700 mg or LY3819253 
700 m g + LY3832479 1400 mg.  The evaluat ion peri od for Part 3 i s 4 weeks, wi th follow-up to 
Day 85.
Data Monitoring Committee: Yes.  Equi valent to Data Safet y Moni toring Board for this study .
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
1 5 1. 2. Sc he m a 
P art 1 : 
A b bre viati o ns:  P B O = place b o .
P art 2 :
A b bre viati o ns:  P B O = place b o. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
1 6 P A R T 3 :
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
1 7 1. 3. Sc he d ule of Acti vities ( S o A) 
Scree ni n g pr oce d ures ma y be c o n d ucte d o ver m ore t ha n 1 da y , as l o n g as all  act i vit ies are c o m plete d wi t hi n t he all o we d i nter val 
t ol era nce.  Scree ni n g a n d Da y 1 pr oce d ures ma y occ ur o n t he sa me da y. 
P arti ci pa nts w h o test p osit i ve f o r S A R S -C o V -2 d uri n g t he E val uat i o n P eri o d m a y  h a ve t hei r sc he d ule d visit(s) c o n d ucte d as a re m o t e 
healt h assess me nt .  Refer t o t he st u d y  d a y  a n d visi t t y p e t a bl e i n Sect i o n 4. 1. 2 f o r a d dit i o nal clarificat i o n .
Earl y Ter mi nat i o n Visits are c o n d ucte d w he n t he partici pa nt is wit h dra w n fr o m t h e st u d y pri or t o t he p ost -e val uat i o n f o ll o w- u p .
1. 3. 1. P art 1 a n d Pre ve nti o n C o h ort of P a rt 2 
Pr oce d ures Scree ni n g E v al u ati o n Peri o d E T V P ost- E v al u ati o n F oll o w -U p C o m me nts 
St u d y Da y Ma x 
7-da y 
wi n d o w 12- 7 8 1 5 2 2 2 9 3 6 4 3 5 0 5 7 8 5 1 4 1 1 6 9 
Visit wi n d o w 
( ± n u m ber of d a ys) -- -- -- 2 2 2 2 2 2 2 2 7 7 7
Ra n d o mizati o n X
A d mi nister st u d y 
i nter ve nti o n 
(I V i nf usi o n) X
I nf or me d C o nse nt X
I ncl usi o n a n d 
e xcl usi o n criteria 
re vie w X
De m o gra p hics XI n cl u di n g a ge, ge n der, race, 
et h nicit y 
Pree xisti n g 
c o n diti o ns a n d 
me dical hist or y XO btai ne d fr o m i nter vie w or 
a vaila ble i nf or mati o n. 
F or p artici pa nts wit h s y m pt o ms 
s u g gesti ve of C O VI D - 1 9, o btai n 
ti mi n g of o nset of s y m pt o ms 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
1 8 Pr oce d ures Scree ni n g E v al u ati o n Peri o d E T V P ost- E v al u ati o n F oll o w -U p C o m me nts 
St u d y Da y Ma x 
7-da y 
wi n d o w 12- 7 8 1 5 2 2 2 9 3 6 4 3 5 0 5 7 8 5 1 4 1 1 6 9 
Visit wi n d o w 
( ± n u m ber of d a ys) -- -- -- 2 2 2 2 2 2 2 2 7 7 7
Pri o r treat me nts of 
s pecial i nterest 
XWit hi n t he last 2 wee ks: N S AI Ds, 
a nti virals, a nti bi otics, a nti -malarials, 
c ortic oster oi ds, i m m u n o m o d ulat ors ,
or ot her i n vesti gati o nal treat me nts .
At a n y ti me: S A R S -C o V -2 vacci ne 
T o bacc o use X Ne ver/ f or mer/ c urre nt use 
C o nc o mita nt 
me dicati o ns X  X  X  X  X  X  X  X  X  X  X  X  X 
A d verse e ve nts 
( A Es) X  X  X  X  X  X  X  X  X  X  X  X  X  X  X A n y e ve nts t hat occ ur after si g ni n g 
t he i nf or me d c o nse nt are c o nsi dere d 
A Es as defi ne d i n Secti o n  1 0 . 3,  
A p pe n di x 3. 
P h y sical 
e xa mi nati o n X
S y m pt o m -directe d 
p h y sical e xa m X X  X  X As i n dicate d base d o n partici pa nt 
stat us a n d sta n dar d of care.  
Hei g ht X
Wei g ht X
Vital si g ns X Dail y X  X  X D oc u me ntati o n of h os pital -base d 
e xa m is acce pta ble. 
I n cl u des: b o d y te m perat ure, p ulse 
rate, B P, S p O 2 ,res pirat or y rate, 
Fi O 2 if k n o w n, a n d met h o d of 
deli ver y, if a p plica ble. 
Rec or d w hile partici pa nt is at rest. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
1 9 Pr oce d ures Scree ni n g E v al u ati o n Peri o d E T V P ost- E v al u ati o n F oll o w -U p C o m me nts 
St u d y Da y Ma x 
7-da y 
wi n d o w 12- 7 8 1 5 2 2 2 9 3 6 4 3 5 0 5 7 8 5 1 4 1 1 6 9 
Visit wi n d o w 
( ± n u m ber of d a ys) -- -- -- 2 2 2 2 2 2 2 2 7 7 7
H os pitalizati o n 
e ve nts Dail y X  X XRec or d if t he f oll o wi n g e ve nts 
occ ur: 
E mer ge nc y r o o m visits 
h os pitalize d 
I C U a d mitta nce, 
E xte n de d care facilit y 
a d mitta nce, 
a n d disc har ge f or a n y of t he 
a b o ve 
Cli nical stat us a n d 
c o nc o mita nt 
pr oce d ures of 
s pecial i nterest i n 
h os pitalize d 
partici pa nts Dail y X  X XD oc u me ntati o n fr o m h os pital 
rec or ds is acce pta ble. 
I n cl u des: 
c o nsci o us ness stat us ( A C V P U), 
li mitati o n o n acti vities d ue t o 
C O VI D -1 9, a n d re q uire me nts f or 
O n g oi n g h os pital me dical care 
S u p ple me ntal o x y ge n 
n o n -i n vasi ve ve ntilati o n or a 
hi g h fl o w o x y ge n de vice 
mec ha nical ve ntilati o n 
e xtrac or p oreal me m bra ne 
o x y ge nati o n, or 
a d diti o nal or ga n s u p p ort (e. g. 
press ors, re nal re place me nt) 
Cli nical s y m pt o ms 
a n d i nter ve nti o ns of 
i nterest Dail y X  X See  Ta ble 1f or cli nical s y m pt o ms 
a n d i nter ve nti o ns of i nterest. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
2 0 Pr oce d ures Scree ni n g E v al u ati o n Peri o d E T V P ost- E v al u ati o n F oll o w -U p C o m me nts 
St u d y Da y Ma x 
7-da y 
wi n d o w 12- 7 8 1 5 2 2 2 9 3 6 4 3 5 0 5 7 8 5 1 4 1 1 6 9 
Visit wi n d o w 
( ± n u m ber of d a ys) -- -- -- 2 2 2 2 2 2 2 2 7 7 7
S y m pt o ms 
Q uesti o n naire X Dail y X  X See Secti o n  8. 1. 2 .
S A R S -C o V -2 P O C 
Test (Nasal S wa b )XA p plies t o partici pa nts i n Part 2 
o nl y .
Res ult m ust be deter mi ne d pri or t o 
c ollecti n g s wa bs f or P C R test. 
S A R S -C o V - 2 
Ser ol o g y X X X  X  X  X  X Da y 1:  pre -d ose. 
assesse d at a ce ntral la b orat or y 
S A R S -C o V - 2 
nas o p har y n geal 
s wa b(f or P C R test) 
ta ke n f r o m b ot h 
n ostrils XDa y 1:  pre -d ose. 
assesse d at a ce ntral la b orat or y 
S A R S -C o V - 2 nasal 
s wa b (f or P C R test) 
ta ke n f r o m b ot h 
n ostrils X  X  X  X  X  X  X  X  X  X  X  X Da y 1:  pre -d ose. 
assesse d at a ce ntral la b orat or y 
N o sa m ples nee de d if partici pa nt is 
h os pitalize d. *
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
2 1 Pr oce d ures Scree ni n g E v al u ati o n Peri o d E T V P ost- E v al u ati o n F oll o w -U p C o m me nts 
St u d y Da y Ma x 
7-da y 
wi n d o w 12- 7 8 1 5 2 2 2 9 3 6 4 3 5 0 5 7 8 5 1 4 1 1 6 9 
Visit wi n d o w 
( ± n u m ber of d a ys) -- -- -- 2 2 2 2 2 2 2 2 7 7 7
Ur i ne pre g na nc y X  X X XO nl y f or W O C B P ( Secti o n  1 0. 4 ,
A p pe n di x 4) L ocal la b orat or y. 
Test perf or me d i n t he 2 4 h o urs pri or 
t o st u d y e ntr y will be acce pte d f or 
deter mi nati o n of eli gi bilit y. 
N o sa m ples nee de d if partici pa nt is 
h os pitalize d. *
He mat ol o g y X X X  X  X  X Da y 1:  pre -d ose. 
Assa y e d b y  Lill y -desi g nate d 
la b orat or y 
N o sa m ples nee de d if partici pa nt is 
h os pitalize d. * 
Cli nical C he mistr y X X X  X  X  X Da y 1:  pre -d ose. 
Assa y e d b y Lill y -desi g nate d 
la b orat or y 
N o sa m ples nee de d if partici pa nt is 
h os pitalize d. *
L D H X X  X Da y 1:  pre -d ose. 
Assa y e d b y  Lill y -desi g nate d 
la b orat or y 
N o sa m ples nee de d if partici pa nt is 
h os pitalize d. *
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
22Procedures Screening Evaluation Period ETV Post- Evaluation Follow -UpComments
Study DayMax 
7-day
window1 2-7 8 15 22 29 36 43 50 57 85 141 169
Visit window 
(± number of days)-- -- -- 2 2 2 2 2 2 2 2 7 7 7
C-reactive 
protein ;high-
sensitivity
Ferritin
D-dimer
Procalcitonin
TroponinX X XDay 1:  pre -dose.
Assay ed by  Lilly -designated 
laboratory
No samples needed if participant is 
hospitalized. *
PK sample X X X X X X XDay 1: pre-dose.
For participants in Part 2, Day 1 
collection is post-dose only (approx. 
30 minutes after end of infusion).
Assay ed by  Lilly -designated 
laboratory
No samples needed if participant is 
hospitalized. *
Immunogenicity 
(ADA) sampleX X X X X X XDay 1:  pre -dose. 
Remaining days: Collect with time -
matched PK sample.
No samples needed if participant is 
hospitalized. *
Explo ratory  
biomarker samplesX X X X X XDay 1: pre -dose
Assay ed by  Lilly -designated 
laboratory
No samples needed if participant is 
hospitalized. *
Pharmacogenetics
sampleXAssay ed by  Lilly -designated 
laboratory
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
23Abbreviations:  ACVPU = alert, confusion, voice, pain, unresponsive; ADA = antidrug antibody; AE = adverse event; BP = blood pressure; COVID -19 = coronavirus disease –
2019; FiO2 = fraction of inspired oxygen in the air; ETV = early termination visit; FiO2 = fraction of ins pired oxygen; ICU = intensive care unit; IV = intravenous; LDH = 
lactate dehydrogenase; NSAID = nonsteroidal anti -inflammatory drug; PCR = polymerase chain reac tion; PK = pharmacokinetic; POC = point of care; SpO2 = saturation of 
peripheral oxygen; SARS -CoV-2 = severe acute respiratory syndrome coronavirus 2; WOCBP = women of child -bearing potential
*Participants will continu e to follow the Schedule of Activities upon discharge from hospital .No local lab result data will be collected in the eCRF while hospitalized.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
2 4 1. 3. 2. P art 2 Tre at me nt C o h ort a n d P art 3 
Scree ni n g f o r Part 2 is descri be d i n t he ta ble a b o ve ( Secti o n  1. 3. 1 ).  Scree ni n g is pr o vi de d bel o w f or refere nce. 
Pr oce d ures Scree ni n g E v al u ati o n 
Peri o d E T V P ost -tre at me nt 
f oll o w -u p C o m me nts 
St u d y Da y Ma x 7 da y 
wi n d o w 1 82 9 8 5 
Visit wi n d o w 
( ± n u m ber of d a ys) -- -- 12 7
Ra n d o mizati o n X
A d mi nister st u d y 
i nter ve nti o n 
(I V i nf usi o n) X
I nf or me d C o nse nt X
I ncl usi o n a n d 
e xcl usi o n criteria 
re vie w XN ote t hat eli gi bilit y criteria f or Part 2 a n d Part 3 are differe nt. 
De m o gra p hics X I n cl u di n g a ge, ge n der, race, et h nicit y 
Pree xisti n g 
c o n diti o ns a n d 
me dical hist or y XO btai ne d fr o m i nter vie w or a vaila ble i n f or mati o n. 
F or partici pa nts wit h s y m pt o ms s u g gesti ve of C O VI D -1 9, o btai n ti mi n g of 
o nset of s y m pt o ms 
Pri o r treat me nts of 
s pecial i nterest XWit hi n t he last 2 wee ks: N S AI Ds, a nti virals, a nti bi otics, a nti -malarials, 
c ortic oster oi ds, i m m u n o m o d ulat ors ,or ot her i n vesti gati o nal treat me nts .
At a n y ti me: S A R S -C o V -2 vacci ne 
T o bacc o use X Ne ver/ f or mer/ c urre nt use 
C o nc o mita nt 
me dicati o ns X  X  X  X  X 
A d verse e ve nts 
( A Es) X  X  X  X  X  X A n y e ve nts t hat occ ur after si g ni n g t he i nf or me d c o nse nt are c o nsi dere d A Es 
as defi ne d i n Secti o n  1 0. 3 , A p pe n di x 3. 
P h y sical 
e xa mi nati o n X
S y m pt o m -directe d 
p h y sical e xa m X X  X As i n dicate d base d o n partici pa nt stat us a n d sta n dar d of care.  
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
25Procedures ScreeningEvaluation 
PeriodETVPost-treatment 
follow -upComments
Study DayMax 7 day
window1 8 29 85
Visit window 
(± number of days)-- -- 1 2 7
Height X
Weight X
Vital signs X X X X X XDocumentation of hospital -based exam is acceptable.
Includes: body temperature, pulse rate, BP, SpO2, respiratory rate, FiO2 if 
known, and method of delivery, if applicable. 
Record while participant is at rest.
Hospitalization 
eventsX X X X XRecord if the following events occur:
 Emergency room visits
 hospitalized
 ICU admittance, 
 Extended care facility admittance, 
 and discharge for any of the above
Clinical status and 
concomitant 
procedures of 
special interest in 
hospitalized 
participantsDaily X XDocumentation from hospital records is acceptable.
Includes: 
consciousness status (ACVPU),
limitation on activities due to COVID -19, and requirements for
 Ongoing hospital medical care
 Supplemental oxygen
 non-invasive ventilation or a high flow oxygen device 
 mechanical ventilation
 extracorporeal membrane oxygenation, or
 additional organ support (e.g. pressors, renal replacement)
SARS -CoV -2 
SerologyX X X XDay 1:  pre -dose.
assessed at a central laboratory
Documentation of 
positive SARS -
CoV-2 viral 
infectionXApplies to participants in Part 3 only.
Sample for first positive test must be collected within 10 days prior to start of 
infusion. 
Local laboratory and/or Point -of-Care testing.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
2 6 Pr oce d ures Scree ni n g E v al u ati o n 
Peri o d E T V P ost -tre at me nt 
f oll o w -u p C o m me nts 
St u d y Da y Ma x 7 da y 
wi n d o w 1 82 9 8 5 
Visit wi n d o w 
( ± n u m ber of d a ys) -- -- 12 7
S A R S -C o V - 2 
nas o p har y n geal 
s wa b ta ke n fr o m 
b ot h n ostrils X  X  X  X  X Da y 1:  pre -d ose. 
assesse d at a ce ntral la b orat or y 
N o sa m ples nee de d if partici pa nt is h os pitalize d. * 
Ur i ne pre g na nc y X  X X  X O nl y f or W O C B P ( Secti o n  1 0. 4 , A p pe n di x 4) L ocal la b orat or y. 
Test perf or me d i n t he 2 4 h o urs pri or t o st u d y e ntr y will be acce pte d f or 
deter mi nati o n of eli gi bilit y. 
N o sa m ples nee de d if partici pa nt is h os pitalize d. * 
He mat ol o g y X  X  X  X Da y 1:  pre -d ose. 
Assa y e d b y  Lill y -desi g nate d la b orat or y 
N o sa m ples nee de d if partici pa nt is h os pitalize d. * 
Cli nical C he mistr y X  X  X  X Da y 1:  pre -d ose. 
Assa y e d b y  Lill y -desi g nate d la b orat or y 
N o sa m ples nee de d if partici pa nt is h os pitalize d. * 
C- reacti ve 
pr otei n; hi g h -
se nsiti vit y 
Ferriti n 
D- di mer 
Pr ocalcit o ni n 
Tr o p o ni n X  X  X Da y 1:  pre -d ose. 
Assa y e d b y  Lill y -desi g nate d la b orat or y 
N o sa m ples nee de d if partici pa nt is h os pitalize d. * 
P K sa m ple X  X  X  X Da y 1:  p ost -d ose o nl y ( a p pr o x. 3 0 mi n ute safter e n d of i nf usi o n ) 
Assa y e d b y  Lill y -desi g nate d la b orat or y 
N o sa m ples nee de d if partici pa nt is h os pitalize d. * 
I m m u n o ge nicit y 
( A D A) sa m ple X  X  X  X Da y 1:  pre -d ose. 
Re mai ni n g da ys: C ollect wit h ti me -matc he d P K sa m ple. 
N o sa m ples nee de d if partici pa nt is h os pitalize d. * 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
27Procedures ScreeningEvaluation 
PeriodETVPost-treatment 
follow -upComments
Study DayMax 7 day
window1 8 29 85
Visit window 
(± number of days)-- -- 1 2 7
Explo ratory  
biomarker samplesX X X XDay 1: pre -dose
Assay ed by  Lilly -designated laboratory
No samples needed if participant is hospitalized.*
Pharmacogenetics 
sampleX Assay ed by  Lilly -designated laboratory
Abbreviations:  ACVPU = alert, confusion, voice, pain, unresponsive; ADA = antidrug antibody; AE = adverse event; BP = blood pressure; COVID -19 = coronavirus disease –
2019; FiO2 = fraction of inspired oxygen in the air; ETV = early termination visit; FiO2 = fraction of inspired oxygen; ICU = intensive care unit; IV = intravenous; NSAID = 
nonsteroidal anti -inflammatory drug; PK = pharmacokinetic; SpO2 = saturation of peripheral ox ygen; SARS -CoV-2 = severe acute respiratory syndrome coronavirus 2; 
WOCBP = women of child -bearing potential .
*Participants will continue to follow the Schedule of Activities upon discharge from hospital.  No local lab result data will be collected in the eCRF while hospitalized.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
282. Introduction
2.1. Study Rationale
The efficient communit y spread of Severe Acute Respiratory  Syndro me Coronavi rus-2 (SARS -
CoV -2)has resulted in the current pandemic ofCoronavirus Disease –2019 ( COVID -19), which 
in severe and crit ical cases results in progressive pulmo nary infect ion, com plicated by  
respi ratory  failure, wi th a high prevalence of acute respiratory  distress syndrome.  Of all age 
groups, older adul ts have the greatest risk of severe COVID -19 and the associated complications 
(CDC 2020; Grabowski and Mor 2020 ).
Globally ,there are m any reports of the rapi d spread of COVID- 19 am ongst resi dents of skilled 
nursing facilit ies following ident ificat ion of an index case, with high associated rates of 
morbidity and m ortali ty (Arons et al. 2020; Grabowski and Mor 2020; Graham et al. 2020 ).  In 
the USA, at least 153,000 residents and emplo yees of nursing ho mes have contracted 
COVID -19, accounting for 35% of the coun try’s deaths ( Werner et al. 2020 ).  Wi thover 1.3 
millio n residents in nursing ho me care in the USA (CDC 2016 ), there is an urgent need for 
therapeuti c strategi es to prevent COVID -19 in these populat ions.
This study  aims to eval uate the impact of LY3819253 and LY3819253 in co mbinat ion with 
LY383 2479 in preventing SARS -CoV -2 infect ion and COVID- 19 in facilit y staff and residents 
in skilled nursing and assisted living facilit ies wi th a hi gh risk of SARS -CoV -2 exposure .
2.2. Background
The SARS -CoV -2 gains entry  to cells through binding of the spike (S) protein to ACE2 receptors 
on cells (Hoffmann 2020).  LY3819253 and LY3832479 are neutralizing immunoglobulin G1 
(IgG1 )monoclonal ant ibodies(mAb) to the spike protein of SARS -CoV -2.  They  are designed to 
block viral attachment and entry  into hum an cells, and to neutralize the virus.  The blocking of 
viral entry  into respi ratory  cells and viral replication is expected to prevent and/or mit igate the 
severit y of disease in peopl e whom  ongoing viral spread and replicat ion is the primary driver of 
COVID -19 path ophysio logy.  For those that become infected, the decrease in viral replicat ion 
may also shorten a patient’s extent and duration of viral shedding and transmissio n, posit ively 
impact ing public healt h.
Lilly is evaluat ing the safet y, tolerabili ty, pharm acok inetics (PK), and pharmacodynamics (PD) 
of LY3819253 in participants hospitalized for COVID -19, in Study J2W -MC-PYAA (PYAA), a 
rando mized, placebo -controlled, double -blind, singl e ascending dose, Phase 1, first in human 
study .  
Lilly is evaluat ing the saf ety, tolerabili ty, PK, and immunogenicit y of LY3832479 in healt hy 
participants, in a rando mized, placebo -controlled, single dose, Phase 1 study  (Study  J2Z-MC-
PGAA [PGAA]) under IND 150707. Concurrent wit h Study  PGAA, LY3832479 is also under 
development in China in an ongoing Phase 1 clinical study  in healt hy participants, Study  JS016 -
001-I. Both studies have started prior to this amendment.
In addit ion, the impact of LY3819253, al one or in combinat ion with LY3832479, on vi ral load 
and clinical outcomes in partici pants with early  mild to m oderate COVID -19 illness is being 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
2 9 i n vesti gate d i n St u d y  J 2 W -M C -P Y A B ( P Y A B), a P hase 2, ra n d o mize d, d o u ble -bli n d st u d y .
I nteri m a nal ysis fr o m t his st u d y  s u g gest streat m e nt wi t h  L Y 3 8 1 9 2 5 3 m a y decrease t he ris k of 
h os pi talizat i o n i n pat ie nt s wi t h  mil d t o m o derate C O VI D -1 9 ( C he n et al . 2 0 2 0 )
A d dit i o nal i nf or mati o n a b o ut t h ese st u di es ca n be f o u n d i n t he I n vest i gat or’s Br oc h ure (I B ). 
2. 3. Be nefit/ Ris k Assess me nt 
A nt ic i pate d ris k is c o nsi dere d l o w a n d is base d o n t he k n o w n mec ha nis m o f act i o n f o r h u m a n 
deri ve d ne utralizi n g a nt i b o dies i n ac ute viral disease states.  L Y 3 8 1 9 2 5 3 a n d L Y 3 8 3 2 4 7 9 c o nsist 
of  a hi g hl y  s pecific m A bs directe d at f orei g n ( n o n -h u ma n) e pit o pe(s) a n d will be gi ve n t o 
parti ci pa nts at a hi g h ri s k of S A R S -C o V - 2 e x p os ure i n a c o ntr olle d setti n g .  T he 
c o m ple me ntari t y  deter mi ni n g re gi o ns o f t h e m A bs were deri ve d fr o m B l y m p h oc y t es of  2 
i n di vi d uall y  c o n valesce nt nat urall y S A R S -C o V - 2 -i nfecte d patie nt sa n d, t h us, ha ve u n der g o ne 
nat ural  p osi ti ve a n d ne gat i ve selecti o n press ures i n vi v o, u nli ke h u ma nize d a nt i b o dies ge nerate d 
i n mice.  N o  cli nicall y rele va nt off -tar get bi n di n g has bee n o bser ve d i n t iss ue cr oss reacti vit y 
st u di es of  m e m bra ne tar gets i n h u ma n tis s ues.  T heref ore, off -tar get bi n di n g a n d tiss ue cr oss -
reacti vit y are c o nsi dere d u nli kel y .  
A t he oretical ris k is t hat t h ese i nter ve nt i o ns ma y ca use a nti b o d y -de pe n de nt e n ha nce me nt ( A D E) 
of  viral  re plicat i o n.  T hi s is base d o n res p o nses o bser ve d t o s o me m o n ocl o nal  a n ti b o d y  t hera pies 
use d i n ot her u nrelate d viral diseases.  U nli ke A D E ass ociate d wit h De n g ue a n d Zi ka vir us 
i nfect i o ns, t his p he n o m e n o n has n ot bee n clearl y  esta blis he d f or c or o na vir us i nfecti o ns, s uc h as 
Se vere Ac ute Res pirat or y  S y n dr o me ( S A R S )a n d Mi d dle East Res pi r at or y  S y n dr o m e, a n d has 
n ot bee n re p orte d t o date wit h S A R S -C o V -2.  A d dit i o nall y , li mi te d e x perie nce wi t h  t he use of 
c o n valesce nt ser u m as a treat me nt f or patie nts wit h se vere C O VI D -1 9 di sease has n ot i n dicate d 
safet y c o ncer ns ( S he n 2 0 2 0; D ua n 2 0 2 0).  
T he ri s k of cli nical A D E f or eit her i nter ve nti o n or i n c o m bi nat i o n is c o nsi dere d l o w d ue t o 
t h e str uct ural feat ures of L Y 3 8 3 2 4 7 9, w hic h is e n gi neere d t o s u p press its bi n di n g t o Fc 
rece pt ors a n d C 1 q m 
t h e a bse nce of A D E fr o m i n vit r o s t u di es, a n d 
t h e a bse nce of A D E fr o m i n vi v o n o n h u ma n pri mate st u dies f or L Y 3 8 1 9 2 5 3 .
T o date, t here is n o e vi de nce of pr o d ucti ve e n ha nce me nt of A D E wi t h  S A R S -C o V - 2. 
A d dit i o nal ma na gea ble ris ks ass ociate d wit h m ost t hera pe utic m o n ocl o nal a nt i b o dies are t he 
p ote nti al  f or i nf usi o n -relate d h y perse nsi ti vi t y  a n d c y t o ki ne release react i o ns.  T he si n gle i nf usi o n 
i n t his st u d y  will  b e a d mi nistere d at a c o n tr olle d rate, t he st u d y  p arti ci pa nts will be m o ni t or e d 
cl os el y , a n d a dj ust m e nts i n t he i nf usi o n rate will be ma de a n d/ or t he i nf usi o n st o p pe d, if 
i n dicate d.  A d diti o nal i nf or mat i o n re gar di n g i nf usi o n reacti o n ma na ge me nt o pti o ns is l ocate d i n 
Secti o n  6. 1. 1. 2 .  As of 3 1 Dece m ber 2 0 2 0 , a p pr o xi matel y 4 0 1 2 parti ci pa nts recei ve d bli n de d 
treat m e nt of L Y 3 8 1 9 2 5 3 7 0 0 m g, 2 8 0 0 m g, or 7 0 0 0 m g, or place b o , of w hic h a p pr o xi matel y  
3 1 8 9 partici pa nts recei ve d L Y 3 8 1 9 2 5 3 .Seri o us i nf usi o n -relate d reacti o ns, i ncl u di n g e ve nts 
c o nsiste nt wit h a na p h yla xis, were re p o rte d i n t hese o n g oi n g st u dies wit h L Y 3 8 1 9 2 5 3 ( F D A E U A 
fact s heet 2 0 2 0). 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
30Clinical worsening of COVID -19 after administratio n of LY3819253 has been reported from 
post-authorizat ion treatm entwithin 24 hours of infusion . Signs and symptom s may include fever, 
hypoxia or increased respiratory  difficul ty, arry thmia (e.g., atri al fibrillat ion, sinus tachycardia, 
and bradycardia), fatigue, and altered mental status. Some of these events required 
hospi talizat ion. It is not known if these events were related to LY3819253 use or were due to 
progression of COVID -19.
Combination of LY3819253 and LY3832479
As of 04 November 2020, 542 part icipants in Study PYAB received blinded treatment of either 
placebo or the combinat ion of 2800 mg LY3819253 and 2800 mg LY3832479 . Three
participants reported single immediate non -serious events of pru ritis(2 events) and dyspnea (1 
event).   
Data from Study PYAB interim analysi s indicate treatment with LY3819253 orthe combinat ion 
of LY3819253 and LY3832479 may decrease the risk of hospitalization in patientswith mild to 
moderate COVID -19 (Chen et al. 2020; Gottli eb et al . 2020 ) thus providing benefit to patients 
with COVID -19.
Given the tota lity of data on LY3819253 and LY3832479, the well -established safety profile of 
other therapeutic mAbs , and the lack of disease directed therapeutic options for pati ents wi th 
COVID -19illness or to prevent the SARS -CoV -2 infect ion, the overall benefit /risk assessment 
of this study  is considered favorable .
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected adverse events of LY3819253 and LY3832479 may  be found in each respect ive IB .
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
3 1 3. O bjecti ves a n d E n d p oi nts 
P art 1 
T o facilitate ra pi d pr o p h yla xis a n d treat me nt of resi de nts a n d facilit y staff , p arti ci pa nts will be 
e nr o lle d pri or t o assess me nt of baseli ne S A R S -C o V -2 re verse tra nscri pt i o n –p ol y merase c hai n 
reacti o n ( R T -P C R) or ser ol o g y  res ul ts; t h us, m ul ti pl e a nal ysis p o p ulat i o ns will e xist.  T his 
i ncl u des se parate pre ve nt i o n a n d treat me nt a nal ysis p o p ulat i o ns ( defi ne d i n t he ta bles bel o w) a n d 
baseli ne ser ol o g y  p osi ti ve partici pa nts. 
S af et y,  p har mac o ki net ics, a n d a nt i dr u g a nt i b o dies will be c haracterize d i n t he o verall  i nt e nt t o 
treat p o p ulat i o n a n d i n t he a nal ysis p o p ulat i o ns. 
A d dit i o nal p o p ulat i o n s u bset a nal yses are detaile d i n Secti o n  9a n d/ or i n t he st ati st ical a nal ysis 
pl a n. 
Pre ve nti o n P o p ulati o n O bjecti ves a n d E n d p oi nts 
Partici pa nts ne gati ve at baseli ne f or S A R S -C o V - 2 R T -P C R a n d s e r ol o g y 
C o m paris o n Gr o u ps: Place b o vs L Y 3 8 1 9 2 5 3 4 2 0 0 m g 
O bjecti ves E n d p oi nts 
Pri mar y 
C o m pare t he i nci de nce of C O VI D - 1 9 C u m ulati ve i nci de nce of C O VI D - 1 9 defi ne d 
as t he detecti o n of S A R S -C o V -2 b y R T -P C R 
A N D mil d or w orse disease se verit y awit hi n 
2 1 da ys of detecti o n
Ti me fra me f or e n d p oi nt e val uati o n: 8 
wee ks fr o m ra n d o mizati o n 
Ke y Sec o n dar y 
C o m pare t he i nci de nce of m o d er ate or w orse 
se verit y C O VI D - 1 9 C u m ulati ve i nci de nce of m o derate or w orse 
se verit y C O VI D -1 9; defi ne d as t he detecti o n 
of S A R S -C o V -2 b y R T -P C R A N D m o derate 
or w orse disease se verit y awit hi n 2 1 da ys of 
detecti o n
Ti me fra me f or e n d p oi nt e val uati o n: 8 
wee ks fr o m ra n d o mizati o n 
C o m pare t he i nci de nce of S A R S -C o V- 2 
i nfecti o n C u m ulati ve i nci de nce of S A R S -C o V - 2 ; 
defi ne d as t he detecti o n of S A R S -C o V -2 b y 
R T -P C R 
Ti me fra me f or e n d p oi nt e val uati o n: 4
wee ks fr o m ra n d o mizati o n
Ot her Sec o n dar y 
[ti me fra me f or e n d p oi nt e val uati o n:  8 wee ks fr o m ra n d o mizati o n] 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
3 2 C o m pare t he i nci de nce of S A R S -C o V - 2 
i nfecti o n C u m ulati ve i nci de nce of S A R S -C o V - 2 
i nfecti o n defi ne d as t he detecti o n of S A R S -
C o V -2 b y R T -P C R 
C o m pare t he fre q ue nc y of h os pitalizati o n or 
de at h d ue t o C O VI D - 1 9 Pr o p orti o n of partici pa nts w h o are 
h os pitalize d or ha ve die d d ue t o C O VI D - 1 9 
C haracterize cli nical stat us f or partici pa nts.  Pr o p orti o n ( perce nta ge) of partici pa nts w h o 
e x perie nce t hese e ve nts: 
oC O VI D -1 9 relate d h os pitalizati o n 
( defi ne d as ≥ 2 4 h o urs of ac ute care), 
oC O VI D -1 9 relate d e mer ge nc y r o o m visit, 
or 
odeat h 
C o m pare t he m ortalit y d ue t o C O VI D - 1 9 Pr o p orti o n of partici pa nts w h o die d ue t o 
C O VI D -1 9 (acc or di n g t o t he i n vesti gat or) 
E x pl orat or y 
[ti me fra me f or e n d p oi nt e val uati o n:  8 wee ks fr o m ra n d o mizati o n] 
C o m pare ti me t o i m pr o ve me nt t o mil d 
se verit y s y m pt o ms i n partici pa nts w h o 
de vel o p m o derate or w orse se verit y a
C O VI D - 1 9 Ti me t o i m pr o ve me nt t o mil d se verit y a
C haracterize C O VI D -1 9 ill ness a n d se verit y 
acc or di n g t o NI AI D or di nal scale(s) W orst sc ore o n NI AI D or di nal scale(s) 
C haracterize S A R S -C o V -2 viral e n d p oi nts i n 
t h ose partici pa nts t hat bec o me R T -P C R 
p ositi ve Pr o p orti o n of partici pa nts t hat ac hie ve S A R S -
C o V -2 cleara nce wit hi n 1, 2, or 3 wee ks of 
p ositi ve R T -P C R 
Ti me t o S A R S -C o V -2 cleara nce 
C haracterize e mer ge nce of viral resista nce t o 
L Y 3 8 1 9 2 5 3 C o m paris o n fr o m t he first p ositi ve sa m ple t o 
at least t he last p os iti ve sa m ple 
C o m pare t he d urati o n of h os pitalizati o n d ue t o 
C O VI D - 1 9 C u m ulati ve da ys of h os pitalizati o n i n t h ose 
w h o are h os pitalize d d ue t o C O VI D - 1 9 
A b bre viati o ns: C O VI D -1 9 = c or o na vir us disease –2 0 1 9; NI AI D = Nati o nal I nstit ute of Aller g y a n d I nfecti o us 
Diseases; R T -P C R = re verse tra nscri pti o n –p ol y merase c hai n reacti o n; S A R S -C o V -2 = se vere ac ute res pirat or y 
s y n dr o me c or o na vir us 2. 
aAs defi ne d i n  Ta ble 1. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
3 3 Treat me nt P o p ulati o n E x pl orat or y O bjecti ves a n d E n d p oi nts 
Partici pa nts p ositi ve at baseli ne f or S A R S -C o V - 2 R T -P C R a n d ne gati ve at baseli ne f or ser ol o g y 
C o m paris o n Gr o u ps: Place b o vs L Y 3 8 1 9 2 5 3 4 2 0 0 m g 
[ti me fra me f or e n d p oi nt e val uati o n: 8 wee ks fr o m ra n d o mizati o n] 
O bjecti ves E n d p oi nts 
C o m pare t he fre q ue nc y of h os pitalizati o n or 
deat h d ue t o C O VI D - 1 9 Pr o p orti o n of partici pa nts w h o are 
h os pitalize d or ha ve die d d ue t o C O VI D - 1 9 
C o m pare t he i nci de nce of m o derate or w orse 
se verit y C O VI D -1 9 i n partici pa nts wit h o ut 
m o derate or w orse se verit y aC O VI D -1 9 at 
baseli ne C u m ulati ve i nci de nce of m o derate or w orse 
se verit y C O VI D -1 9; defi ne d as m o derate or 
w orse disease se verit y awit hi n 2 1 da y s of 
baseli ne 
C o m pare t he i nci de nce of C O VI D -1 9 i n 
partici pa nts w h o are as y m pt o matic abaseli ne C u m ulati ve i nci de nce of C O VI D -1 9; defi ne d 
as m il d or w orse disease se verit y awit hi n 2 1 
da ys of baseli ne 
C o m pare ti me t o i m pr o ve me nt t o mil d se verit y 
s y m pt o ms ai n partici pa nts w h o ha ve at 
baseli ne, or de vel o p, m o derate or w orse 
C O VI D - 1 9 Ti me t o i m pr o ve me nt t o mil d se verit y a
C haracterize cli nical stat us f or partici pa nts.  Pr o p orti o n ( perce nta ge) of partici pa nts w h o 
e x perie nce t hese e ve nts: 
oC O VI D -1 9 relate d h os pitalizati o n 
( defi ne d as ≥ 2 4 h o urs of ac ute care), 
oC O VI D -1 9 relate d e mer ge nc y r o o m 
visit, or 
odeat h 
C haracterize C O VI D -1 9 ill ness a n d se verit y 
acc or di n g t o NI AI D or di nal scale(s) W orst sc ore o n a NI AI D or di nal scale(s) 
C o m pare t he m ortalit y d ue t o C O VI D - 1 9 Pr o p orti o n of partici pa nts w h o die d ue t o 
C O VI D - 1 9 
C haracterize S A R S -C o V -2 viral e n d p oi nts Pr o p orti o n of partici pa nts t hat ac hie ve 
S A R S -C o V -2 cleara nce wit hi n 1, 2, or 3 
wee ks of baseli ne 
Ti me t o S A R S -C o V -2 cleara nce 
C haracterize e mer ge nce of viral resista nce t o 
L Y 3 8 1 9 2 5 3 C o m paris o n fr o m baseli ne t o at least t he last 
p ositi ve sa m ple 
C o m pare t he d urati o n of h os pitalizati o n d ue t o 
C O VI D - 1 9 C u m ulati ve da ys of h os pitalizati o n i n t h ose 
w h o are h os pitalize d d ue t o C O VI D - 1 9 
A b bre viati o ns: C O VI D -1 9 = c or o na vir us disease –2 0 1 9; NI AI D = Nati o nal I nstit ute of Aller g y a n d I nfecti o us 
Diseases; R T -P C R = re verse tra nscri pti o n –p ol y merase c hai n reacti o n; S A R S -C o V -2 = se vere ac ute res pirat or y 
s y n dr o me c or o na vir us 2. 
aAs defi ne d i n  Ta ble 1. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
3 4 P art 2 Pre ve nti o n 
P arti ci pa nts will be teste d wi t h  p oi nt of care S A R S -C o V -2 P OC test t o deter mi ne S A R S -C o V - 2 
stat us. Parti ci pa nts wi t h  a ne gat i ve P O C test will ra n d o mize t o t he Pre ve nti o n C o h ort.  T h ose 
wi t h  a p osi ti ve test will e nr o ll t o t he Treat me nt C o h ort. 
S af et y,  p har mac o ki net ics, a n d a nt i dr u g a nt i b o dies will be c haracterize d i n t he o verall i nte nt t o 
treat p o p ulat i o n a n d i n t he a nal ysis p o p ulat i o ns. 
A d dit i o nal p o p ulat i o n s u bset a nal yses are detaile d i n Secti o n  9a n d/ or i n t he stati st ical a nal ysis 
pl a n. 
Part 2 Pre ve nti o n P o p ulati o n O bjecti ves a n d E n d p oi nts 
Partici pa nt n e gati ve o n scr ee ni n g P oi nt of Care Test 
&
ne gati ve at baseli ne f or S A R S -C o V -2 R T -P C R a n d ser ol o g y 
C o m paris o n Gr o u ps: 
Place b o vs L Y 3 8 1 9 2 5 3 7 0 0 m g 
Place b o vs L Y 3 8 1 9 2 5 3 3 5 0 m g + L Y 3 8 3 2 4 7 9 7 0 0 m g 
O bjecti ves E n d p oi nts 
Pri mar y 
C o m pare t he i nci de nce of C O VI D - 1 9 C u m ulati ve i nci de nce of C O VI D - 1 9 defi ne d as 
t he detecti o n of S A R S -C o V -2 b y R T -P C R A N D 
mil d or w orse disease se verit y awit hi n 2 1 da ys 
of detecti o n 
Ti me fra me f or e n d p oi nt e val uati o n: 8 
wee ks fr o m ra n d o mizati o n 
Ke y S e c o n dar y 
C o m pare t he i nci de nce of m o derate or w orse 
se verit y C O VI D - 1 9 C u m ulati ve i nci de nce of m o derate or w orse 
se verit y C O VI D -1 9; defi ne d as t he detecti o n of 
S A R S -C o V -2 b y R T -P C R A N D m o derate or 
w orse disease se verit y awit hi n 2 1 da ys of 
detecti o n 
Ti me fra me f or e n d p oi nt e val uati o n: 8 
wee ks fr o m ra n d o mizati o n 
C o m pare t he i nci de nce of S A R S -C o V- 2 
i nfecti o n C u m ulati ve i nci de nce of S A R S -C o V - 2 ; defi ne d 
as t he detecti o n of S A R S -C o V -2 b y R T -P C R 
Ti me fra me f or e n d p oi nt e val uati o n: 4  
wee ks fr o m ra n d o mizati o n 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
3 5 Ot her Sec o n dar y 
C haracterize t he p har mac o ki netics of 
L Y 3 8 1 9 2 5 3 a n d L Y 3 8 1 9 2 5 3 i n c o m bi nati o n 
wit h L Y 3 8 3 2 4 7 9 Mea n c o nce ntrati o n of L Y 3 8 1 9 2 5 3 a n d 
L Y 3 8 1 9 2 5 3 i n t he prese nce of L Y 3 8 3 2 4 7 9 o n 
Da y 2 9 
Mea n c o nce ntrati o n of L Y 3 8 3 2 4 7 9 i n t he 
prese nce of L Y 3 8 1 9 2 5 3 o n Da y 2 9 
A b bre viati o ns: C O VI D -1 9 = c or o na vir us disease –2 0 1 9; R T -P C R = re verse tra nscri pti o n –p ol y merase c hai n 
reacti o n; S A R S -C o V -2 = se vere ac ute res pirat or y s y n dr o me c or o na vir us 2. 
aAs defi ne d i n  Ta ble 1. 
P art 2 a n d P art 3 Tre at me nt E x pl or at or y 
For Part 3, res ults fr o m e xter nal, n o n -st u d y  S A R S -C o V - 2 tests will be use d t o deter mi ne 
eli gi bilit y. 
S af et y,  p har mac o ki net ics, a n d a nt i dr u g a nt i b o dies will be c haracterize d i n t he o verall i nte nt t o 
treat p o p ulat i o n a n d i n t he a nal ysis p o p ulat i o ns. 
Treat me nt P o p ulati o n E x pl orat or y O bjecti ves a n d E n d p oi nts 
Partici pa nts p ositi ve o n scree ni n g P oi nt of Care Test ( Part 2) 
&
p ositi ve at baseli ne f or S A R S -C o V - 2 R T -P C R a n d ne gati ve at baseli ne f or ser ol o g y 
[ti me fra me f or e n d p oi nt e val uati o n:  4 wee ks fr o m ra n d o mizati o n] 
O bjecti ves E n d p oi nts 
E val uate t he fre q ue nc y of h os pitalizati o n or 
deat h d ue t o C O VI D - 1 9 Pr o p orti o n of partici pa nts w h o are 
h os pitalize d or ha ve die d d ue t o C O VI D - 1 9 
C haracterize cli nical stat us f or partici pa nts.  Pr o p orti o n ( perce nta ge) of partici pa nts w h o 
e x perie nce t hese e ve nts: 
oC O VI D -1 9 relate d h os pitalizati o n 
( defi ne d as ≥ 2 4 h o urs of ac ute care), 
oC O VI D -1 9 relate d e mer ge nc y r o o m 
vis it, or 
odeat h 
C haracterize C O VI D -1 9 ill ness a n d se verit y 
acc or di n g t o NI AI D or di nal scale(s) W orst sc ore o n a NI AI D or di nal scale(s) 
E val uate t he m ortalit y d ue t o C O VI D - 1 9 Pr o p orti o n of partici pa nts w h o die dd ue t o 
C O VI D - 1 9 
C haracterize S A R S -C o V -2 vir al e n d p oi nts Pr o p orti o n of partici pa nts t hat ac hie ve 
S A R S -C o V -2 cleara nce wit hi n 8or 2 9 da ys 
of baseli ne 
Ti me t o S A R S -C o V -2 cleara nce 
C haracterize e mer ge nce of viral resista nce t o 
L Y 3 8 1 9 2 5 3 or L Y 3 8 3 2 4 7 9 C o m paris o n fr o m baseli ne t o at least t he last 
p ositi ve sa m ple 
E val uate t he d urati o n of h os pitalizati o n d ue t o 
C O VI D - 1 9 C u m ulati ve da ys of h os pitalizati o n i n t h ose 
w h o are h os pitalize d d ue t o C O VI D - 1 9 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
3 6 A b bre viati o ns: C O VI D -1 9 = c or o na vir us disease –2 0 1 9; NI AI D = Nati o nal I nstit ute of Aller g y a n d I nfecti o us 
Diseases; R T -P C R = re verse tra nscri pti o n –p ol y merase c hai n reacti o n; S A R S -C o V -2 = se vere ac ute res pirat or y 
s y n dr o me c or o na vir us 2. 
aAs defi ne d i n  Ta ble 1. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
3 7 4. St u d y Desi g n 
4. 1. O ver all Desi g n 
St u d y  J 2 X -M C -P Y A D is a r a n d o mize d, d o u ble -bli n d, place b o -c o ntr olle d , pr o p h yla xis st u d y  t o 
e val uate t he efficac y  a n d s afet y of  i nt ra ve n o us L Y 3 8 1 9 2 5 3 , al o ne a n d i n c o m bi nat i o n wi t h  
L Y 3 8 3 2 4 7 9, i n pre ve nt i n g S A R S -C o V -2 a n d C O VI D -1 9, c o m pare d t o place b o .  S kille d n ursi n g 
a n d assiste d li vi n g facilit ies will ser ve as t he setti n g t o fi n d part ic i pa nts wi t h  a hi g h ri s k of 
S A R S -C o V -2 e x p os ure. T he Pri nci pal I n vest i gat or a n d site staff ma y be u naffiliate d wit h t he 
facilit y. 
Resi de nts a n d fa cilit ystaff ma y be i ncl u de d i n t his st u d y beca use i nfecte d fa cilit y staff , w h o m a y 
be as y m pt o mat ic, ma y be i m p orta nt i n t he s prea d of S A R S -C o V -2 wi t hi n l o n g t er m  care 
facilit ies ( Gra ha m et al. 2 0 2 0 ).  T heref ore ,pr o vi di n g pr o p h ylact ic treat me nt t o b ot h resi de nts a n d 
facilit y staff ma y be hi g hl y be neficial i n pre ve nt i n g or li mit i n g C O VI D -1 9 o ut brea ks .
A n i n de pe n de nt Data Safet y M o ni t ori n g B oar d C o m mittee ( D S M B ) will act i vel y m o nit or 
i nt eri m data t o m a ke rec o m me n dat i o ns a b o ut earl y st u d y  cl os ure or c ha n ges t o sa m ple size (see 
Secti o n 1 0. 1. 5 , A p pe n di x 1, f o r m ore i nf or m at i o n). 
4. 1. 1. Scree ni n g Peri o d 
I ntereste d partici pa nts or t heir le gal a ut h orize d re prese ntati ve will si g n t he a p pr o priate i nf or me d 
c o nse nt d oc u me nt(s) pri or t o c o m plet i o nof  a n y pr oce d ures. 
T he i n vest i gat or or q ualifie d desi g nee will re vie w s y m pt o ms, ris k fact ors, a n d ot her n o n -i n vasi ve 
i ncl usi o n a n d e xcl usi o n cri t eri a pri or t o a n y  i n vasi ve pr oce d ures.  If t he partici pa nt is eli gi ble 
af ter t hi s re vie w, t he n site staff will p erf or m  t he i n vasi ve p r oce d ures t o c o nfir m eli gi bilit y. 
Part 1 :
T he scree ni n g peri o d f o r eac h site o pe ns w he n ac o nfir me d S A R S- C o V - 2 i n de x case at t he 
facilit yis re p orte d t o st u d y  staff . Scree ni n g, ra n d o mizat i o n a n d i n vesti gati o nal pr o d uct (I P )
a d mi nistrati o n m ust be c o m plete d wit hi n 7 da ys fr o m re p orti n g of t h e i n de x case. 
Part 2 :
Pri or t o ra n d o mizat i o n i n Part 2 ,partici pa nts will recei ve a p oi nt of care ( P O C) test f or S A R S -
C o V -2 i nfect i o n.  P artici pa nts will be all ocate d t o eit her Pre ve nt i o n or Treat me nt C o h orts base d 
o n t he res ult.  Scree ni n g a n d Da y 1 ma y occ ur o n t he sa me d a y .
Part 3 
T he scree ni n g peri o d f or eac h parti ci pa nt starts at t he si g ni n g of t he I C F . Scree ni n g ,
ra n d o mizat i o n, a n d I P a d mi nistrati o n m ust be c o m plete d wit hi n 7 da ys fr o msi g ni n g t he I C F . 
4. 1. 2. E v al u ati o n Peri o d 
T he e val u ati o n p eri o d be gi ns w he n t he parti ci pa nt c o m pletes scree ni n g a n d is e nr olle d i n t he 
st u d y .  Assess me nts a n d pr oce d ures will be c o n d ucte d as descri be d i n t he S o A  ( Secti o n 1. 3 ).
P arti ci pa nts i n Part 1 will be ra n d o mize d t o pl ace b o or L Y 3 8 1 9 2 5 3 .  T he S p o ns or will deci de 
w he n t o tri g ger acti vat i o n of Part 2. Acti vat i o n of Part 2 will be c o m m u nicate d t o sit es .  
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
3 8 P arti ci p a nts i n Part 2 will be assi g ne d t o a c o h ort as f oll o ws: 
Pre ve nt i o n C o h ort: Partici pa nts w h o are S A R S -C o V - 2 ne gati ve d uri n g scree ni n g o n t he 
P O C test will be ra n d o mize d t o o ne of t hree ar ms:  place b o, L Y 3 8 1 9 2 5 3 7 0 0 m g, or 
L Y 3 8 1 9 2 5 3 3 5 0 m g + L Y 3 8 3 2 4 7 9 7 0 0 m g.   
If e nr o lli n g t o a place b o -c o ntr olle d trial is c halle n ge d b y a n effecti ve me dicati o n 
bec o mi n g a vaila ble f or pre ve nt i o n of C O VI D -1 9 a n d S A R S -C o V -2, t he n t he place b o ar m 
ma y be dr o p pe d. 
N ote:  It is p ossi ble t hat s o me partici pa nts ha ve S A R S -C o V -2 ne gat i ve res ult o n t he 
scree ni n g p oi nt of care test, b ut c o ul d be p ositi ve o n t he baseli ne S A R S -C o V -2 P C R test.  
T he res ults fr o m t he baseli ne test wil l n ot be a vaila ble u ntil after t he partici pa nt is 
ra n d o mize d.  O nce p osit i ve res ults are k n o w n fr o m t he baseli ne test, t hese partici pa nts 
will be u n bli n de d a n d ha ve t he o pti o n t o c o nti n ue t o be f o ll o we d f o r safet yacc or di n g t o 
t h e Pre ve nt i o n C o h ort S o A.  Un bli n de d part ic i pa nts will n ot be i ncl u de d as part of t he 
defi ne d pre ve nt i o n p o p ul at i o n
T he e val uati o n peri o d f or t he Pre ve nt i o n C o h ort is 8 wee ks, wi t h  f ol l o w- u p t o Da y  1 6 9. 
Treat me nt C o h ort: Partici pa nts w h o test S A R S -C o V - 2 p osi ti ve d uri n g scree ni n g wit h t he 
P O C test will be ra n d o mize d t o o ne of t w o ar ms:  L Y 3 8 1 9 2 5 3 7 0 0 m g, or L Y 3 8 1 9 2 5 3 
7 0 0 m g + L Y 3 8 3 2 4 7 9 1 4 0 0 m g .  
T he e val uati o n peri o d f or t he Treat me nt C o h ort is 4 wee ks, wit h f o ll o w- u p t o Da y  8 5 .
P arti ci pa nts i n Part 3 wil l be ra n d o mize d t o L Y 3 8 1 9 2 5 3 7 0 0 m g or L Y 3 8 1 9 2 5 3 7 0 0 m g a n d 
L Y 3 8 3 2 4 7 9 1 4 0 0m g . T he e val uat i o n peri o d f or Part 3 i s 4 wee ks, wi t h  f ol l o w- u p t o Da y  8 5. 
T he S p o ns or will deci de w he n t o tri g ger acti vat i o n of Part 3.   Acti vat i o n of Part 3 will be 
c o m m u nicate d t o sites.  Part 3 ma y be acti vate d pri or t o Part 2.   
Part 2 a n d Part 3 c o ul d be act i vate d c o nc urre nt l y.  H o we ver, Part 3 will n ot e nr oll co nc urre nt l y 
wi t h  Part 2 at t he sa me facilit y.   
P arti ci pa nts will recei ve o ne i ntra ve n o us i nf usi o n of st u d y  i nt er ve nt i o n.  
T he m a xi m u m  t ot al  d urati o n of  st u d y  partici pat i o n f or eac h partici pa nt of t he pre ve nt i o n gr o u ps 
is 2 4 wee ks.   See t h e S O A f or pre ve nt i o n gr o u ps i n Secti o n  1. 3. 1 .
T he m a xi m u m  t ot al  d urati o n of  st u d y  partici pat i o n f or eac h partici pa nt of t he treat me nt gr o u p is 
1 2 wee ks.   See t he S O A f or t h e treat m e nt gr o u p i n Secti o n  1. 3. 2 .
T his ta ble descri bes t he visit t y pes f o r t he pre ve nt i o n p o p ulati o n f o r t his st u d y .  
St u d y D a y Acti vit y Visit T y pe 
0, 1 F oll o w S o A O nsite 
8, 1 5, 2 2, 2 9, 3 6, 4 3, 5 0, 5 7 F oll o w S o A 
Vital si g ns * O nsite or H o me ( Virt ual 
[rec or d c ollecti o n] if 
h os pitalize d) 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
39Daily 2 - 57 Vital signs and symptoms 
questionnaire daily*
Vital signs, clinical status, and 
concomitant procedures for 
hospitalized participants. Onsite or Home ( Virtual 
[record collection] if 
hospitalized)
ETV and follow -up (85, 141, 169) Follow SoA Onsite or Home 
*Collected via direct data captu refor onsite or home visits only.
This table describes the visit t ypes for the treatm ent popul ation for this study .
Study Day Activity Visit Type 
0, 1 Follow SoA Onsite 
8, 29 Follow SoA
Vital signs*Onsite or Home (Virtual 
[record collection] if 
hospitalized)
Daily  2-29 Vital signs , clinical status, and 
concomitant procedures for 
hospitalized participants. Virtual (record collection )if 
hospitalized
ETV and follow -up ( 85) Follow SoA Onsite or Home 
*Collected via direct data capture for onsite or home visits only.
Hospitalization
If a participant is hospitalized, efforts will be made to retrieve hospital records and report 
procedures and assessments according to the SoA , as feasible .
Definitions for COVID -19 Severity
This table gives the definit ions for COVID -19 severi ty of illness for those participants who are 
SARS -CoV -2 posi tive as determined by  standard RT -PCR assay or equivalent test.
Table 1 Definitions for COVID -19 Severity
Severity Description 
Mild Mild symptoms that could include: 
• fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, without 
shortness of breath or dyspnea 
AND 
No clinical signs indicative of Moderate, Severe, or Critical Severity
Moderate Symptoms of moderate illness with COVID -19, which could include any symptom of mild illness or 
shortness of breath with exertion
AND 
Clinical signs suggestive of moderate illness with COVID -19, such as :
 respiratory rate ≥ 20 breaths per minute, 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
40 heart rate ≥ 90 be ats per minute 
 O2 utilization increase of ≥ 1L/min (for participants receiving O2 at baseline)*
 IV fluid initiation*
AND 
noclinical signs indicative of Severe or Critical Illness Severity
Severe Symptoms suggestive of severe systemic illness with COVID -19, which could include any symptom of 
moderate illness or shortness of breath at rest, or respiratory distress
AND
Clinical signs indicative of severe systemic illness with COVID -19, such as
 respiratory rate ≥ 30 breaths per minute, 
 heart rate ≥ 125 beats per minute, 
 SpO2 ≤ 93% on room air at sea level or PaO2/FiO2 < 300
AND
No clinical signs indicative of Critical Illness Severity
Critical Evidence of critical illness, defined by at least one of the following:
 Respiratory failure defined based on resource utilization requiring at least one of the following:
 endotracheal intubation and mechanical ventilation, 
 oxygen delivered by high -flow nasal cannula (heated, humidified, oxygen delivered via 
reinforced nasal cannula at flow rates > 20 L/min with fraction of delivered oxygen 
≥0.5), 
 noninvasive positive pressure ventilation, 
 extracorporeal membrane oxygenatio n (ECMO ), or
 clinical diagnosis of respiratory failure (i.e., clinical need for one of the preceding 
therapies, but preceding therapies not able to be administered in setting of resource 
limitation)
 Shock 
 Multi -organ dysfunction/failure
Death   
Abbrevi ations:  COVID -19 = coronavirus disease –2019; FiO2 = fraction of inspired oxygen in the air; IV = intravenous; 
PaO2 = partial pressure of oxygen ; SpO2 = saturation of peripheral oxygen.
Adapted f rom FDA 2020.
*Addition to FDA Guidance applies only to residents at skilled nursing and assisted living facilities.
4.1.3. Follow -up Period
Part 1 and Prevention Cohort of Part 2 
Post-evaluat ion follow-up assessments will be conducted at Day s 85, 141, and 169according to 
the SoA.   Strategies to manage infect ion risks and reduce the burden of return visits may  be used 
by sites, such as remote visits.
Part 2 Treatment Cohort and Part 3
A post -evaluat ion follow-up assessment will be conducted at Day  85 according to the SoA.  
Strategies to manage infect ion risks and reduce the burden of return visits may  be used by si tes, 
such as remote visits.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
4 1 4. 2. Scie ntific R ati o n ale f or St u d y Desi g n 
T his st u d y  i s desi g ne d t o e val uate t he efficac y of a si n gle d ose of L Y 3 8 1 9 2 5 3 , al o ne a n d i n 
c o m bi nat i o n wi th L Y 3 8 3 2 4 7 9, c o m pare d t o pl ace b o i n pre ve nt i n g a n d treati n g S A R S -C o V - 2 
i nfect i o n a n d C O VI D -1 9 i n resi de nts a n d fa cilit ystaff at skille d n ursi n g a n d assiste d li vi n g 
facilit ies .
T he ra n d o mize d, d o u ble -bli n d ,pl ace b o -c o ntr olle d desi g n will all o w a n o bject i ve assess me nt of 
t h e efficac y  a n d safet y of  L Y 3 8 1 9 2 5 3 , al o ne a n d i n c o m bi nati o n wi t h  L Y 3 8 3 2 4 7 9, i n pre ve nt i n g 
S A R S -C o V - 2 i nfect i o n a n d C O VI D - 1 9 .A place b o -c o ntr olle d desi g n is a p pr o priate beca use 
t h ere are c urre ntl y n o t hera pe utic a ge nts wit h pr o ve n be nefit f o r pre ve nt i o n.   T he i nci de nce of  
C O VI D - 1 9 re prese nts a cli nicall y mea ni n gf ul e n d p oi nt f o r a pre ve nt i o n st u d y .
Resi de nts a n d fa cilit ystaff are i ncl u de d i n t his st u d y  as i nfecte d facilit y staff me m bers ma y be 
i m p orta nt i n t he s prea d of S A R S -C o V -2 wi t hi n l o n g t er m  care facilit ies ( Gra ha m  et al . 2 0 2 0 ).  
T heref ore, pr o vi di n g pr o p h ylact ic treat me nt t o b ot h resi de nts a n d facilit ystaff ma y  be hi g hl y  
be neficial i n pre ve nt i n g or li mit i n g C O VI D -1 9 o ut br ea ks. 
St u di es ha ve s h o w n t hat f o ll o wi n g t he i de ntificat i o n of a n i n de x case, i nfect i o n ca n s prea d 
r a pi dl y  a m o n g resi de nts a n d fa cilit y staff i n s kille d n ursi n g facilit ies ( Ar o ns et al . 2 0 2 0; Gra ha m 
et al . 2 0 2 0 ). T heref ore, ra n d o mizat i o n a n d treat me nt of p arti ci pa nts wi t hi n 7 da ys of 
i de nt ificat i o n of t he first c o nfir me d p osit i ve case of S A R S -C o V -2 at a gi ve n facilit y is a 
re q ui re me nt f or st u d y  p arti ci p ati o n at t hat facilit y. 
I n Part 1, t o f acilitate ra pi d pr o p h yla xis a n d treat me nt of resi de nts a n d facilit ystaff, parti ci pa nts 
will be e nr o lle d pri or t o assess me nt of baseli ne S A R S -C o V -2 R T -P C R or ser ol o g y res ults, t h us 
m ult i ple a nal ysis p o p ulat i o ns will e xist.  T his i ncl u des se parate pre ve nt i o n a n d treat me nt 
a nal ysis p o p ulati o ns a n d baseli ne ser ol o g y  p osi ti ve partici pa nts.  H o we ver, t he pri mar y  a nal ysis 
p o p ul at i o n f o r e val uati o n of efficac y i n pre ve nt i n g S A R S -C o V -2 a n d C O VI D -1 9 will be 
restri cte d t o parti ci pa nts w h o are S A R S -C o V -2 ne gati ve b y R T -P C R a n d ser ol o g y  ne gat i ve at 
baseli ne. E x pl orat or y  a nal yses will be c o n d ucte d t o e val uate efficac y o f L Y 3 8 1 9 2 5 3 f or 
treat m e nt i n parti ci pa nts w h o are S A R S -C o V -2 p osit i ve b y R T -P C R a n d ser o l o g y  ne gati ve at 
baseli ne. 
M o n ocl o nal  a nt i b o dies ma y pr o vi de be nefit f or t he treat me nt of mil d t o m o derate C O VI D - 1 9 
(F D A E U A fact s heet 2 0 2 0 ). T heref ore, pri or t o ra n d o mizat i o n i n Part 2, partici pa nts will 
recei ve a P O C test f or S A R S- C o V -2 i nfect i o n. Parti ci pa nts will be assi g ne d t o eit her Pre ve nti o n 
or Treat m e nt C o h orts base d o n t he res ult of t his P O C test. Des pite usi n g a S A R S -C o V -2 P O C 
test d uri n g scree ni n g t o assi g n partici pa nts t o eit her t he Pre ve nti o n or Treat me nt c o h orts, 
baseli ne S A R S -C o V -2 R T -P C R a n d ser ol o g y  test res ul ts will be use d t o det er mi ne t he st u d y 
a nal ysis p o p ulati o ns. Refer t o Secti o n  9. 3 , P o p ul ati o n s f or A nal yses ,f o r f urt her i nf or m at i o n o n 
st u d y  a nal ysis p o p ul at i o ns a n d tre at m e nt ar m s. 
Part 3 of t he st u d y  i s a t w o -ar m, o ut patie nt, o pe n -la bel, e x pl orat or y  c o h ort e val uat i n g t he 
efficac y  a n d safet y  of  L Y 3 8 1 9 2 5 3 a n d L Y 3 8 1 9 2 5 3 i n c o m bi nat i o n wi t h  L Y 3 8 3 2 4 7 9 i n 
parti ci pa nts p osi ti ve f o r S A R S -C o V -2 wi t h  or wi t h o ut s y m pt o m s i n staff a n d resi de nts w h o are 
at hi g her ris k f or m ore se vere di sease a n d h os pitalizati o n i n s kille d n ursi n g a n d assiste d li vi n g 
facilit ies . F or Part 3 o nl y, partici pa nts w h o were i n i n de pe n de nt li vi n g sit uat i o ns at t he facilit ies 
c o ul d be e nr o lle d t o t he st u d y .   
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
42SARS -CoV -2 vaccines are now available to the public. T hose who received a vaccine are now 
allowed in the study  to assess the safet y of LY3819253 and LY3832479 after a person receiv ed a 
SARS -CoV -2 vaccine.
4.3. Justification for Dose
Part 1
The 4200 mg single dose LY3819253 is selected for this study based on preliminary safet y, 
tolerabilit y, PK data fro m the first -in-human Study PYAA ,and preclinical PK/PD m odeling.  
Based on an est imated human half -life o f approximately 19 days, a single dose of 4200 mg may 
be necessary to have a sustained lung concentration above the in vitro IC 90of viral cell -entry  
neutralizat ion in 100% of participants for 4 weeks and in 90% of participants for a minimum o f 
8weeks .
Part 2and Part 3
LY3819253
LY3819253 700 m g was est imated as the maximum therapeut ic dose based on PK/PD viral
dynamics modeling and observed data from Study  PYAB and has a sustained concentration 
above the in vitro IC 90of viral  cell-entry neutralization in the lung t issue (95th percentile of the 
estimates used)for at least 28 days in 90% of the participant populat ion. The l ower dose of 350 
mg was selected to evaluate the lower limit of the confidence interval for clinical IC90, based on 
emerging data from ongoing study .  At dose levels greater than 700 mg, LY3819253 provides 
exposure coverage in at least 90% of participant populat ionfor approximately 8weeks.
LY3832479
The LY3832479 1400 m g dose was selected as the maximum therapeut ic dose based on PK/PD 
viral dynamics modeling , relative IC 90potency to LY3819253, and has a sustained concentration 
above the in vitro IC90of viral cell -entry  neutralizati on in th e lung tissue for at least 28 days in 
90% of the participant populat ion.  The LY3832479 700 mg dose was selected to eval uate the 
lower limi t of the confidence interval forclinical IC 90. On average, the 3dose l evels are 
expected to provide exposure coverage (as described in Part 1) for approximately 8 weeks .  At 
dose l evels greater than 700 mg, LY38 32479 provides exposure coverage in at least 90% of 
participant popul ation for at least 8 weeks.
LY3819253 + LY3832479 Combination
To provi de coverage of the different but overlapping epitopes on SARS -CoV -2 receptor binding
domain sites, the dose sel ection rati onale for each single mAb intervent ion in the combinat ion is
the sam e as for the individual dose ration ale for a single mAb intervent iondescribed above .  
4.4. End of Study Definition
A participant is considered to have co mpleted the study  if they have com pleted all  requi red 
phases of the study  including the last scheduled assessment shown in the SoA .
The end o f the study  is defined as the date of last scheduled assessment shown in the SoA for the 
last parti cipant in the tri al.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
4 3 5. St u d y P o p ul ati o n 
Pr os pecti ve a p pr o val o f pr ot oc ol  de viati o ns t o recr ui t m e nt a n d e nr o ll me nt criteria, als o k n o w n as 
pr ot oc ol  w ai vers or e xe m pt i o ns, i s n ot per mitte d .
D ue t o t he crit ic alit y of part ic i pa nt healt h, ver bal i nter vie w of t he p ote ntial partici pa nt, t heir le gal 
a ut h ori ze d re prese ntati ve, or fa mil y me m ber, ma y  b e t he s o urce f or pre -e xist i n g c o n dit i o ns a n d 
me dical hist or y , u nless ot her wise s pecifie d wit hi n t h e eli gi bilit y cri t eri a. 
5. 1. I ncl usi o n Criteri a 
P arti ci pa nts are eli gi ble t o be i ncl u de d i n t he st u d y o nl y if all of  t h e f ol l o wi n g criteria a p pl y: 
1. Are ≥ 1 8 years of a ge at t he ti me of ra n d o mizat i o n
2. F or Part 1 a n d Part 2 partici pa nts:  Resi de nt or staff i n a s kille d n ursi n g or assiste d li vi n g 
facilit ywi t h  at l east o ne c o nfir me d case of  S A R S -C o V - 2 detecti o n ≤ 7 da ys pri or t o 
ra n d o mizat i o n. 
3. Re pr o d ucti ve a n d C o ntrace pti ve a gree me nts a n d g ui da nce are pr o vi de d i n Sect i o n 1 0. 4 , 
A p pe n di x 4 .  C o nt race pti ve use b y me n or w o me n s h o ul d be c o nsiste nt wit h l ocal 
re g ul at i o ns f o r t h ose partici pat i n g i n cli nical st u dies. 
4. A gree t o t he c ollect i o n of nasal, mi d -t ur bi nate , or o p har y n geal, a n d nas o p har y n geal 
s wa bs ,a n d ve n o us bl o o d as s pecifie d i n t he sc he d ule of act i vit ies .
5. H a ve ve n o us access s ufficie nt t o all o w i ntra ve n o us i nf usi o ns a n d bl o o d sa m pli n g as per 
t h e pr ot oc ol .
6. T he parti ci pa nt or l e gall y  a ut h ori ze d re prese ntati ve gi ve ssi g ne d i nf or me d c o nse nt as 
descri be d i n Secti o n  1 0. 1. 3 , A p pe n di x 1 , w hic h i ncl u des c o m plia nce wit h t he 
re q ui re me nts a n d restrict i o ns liste d i n t he i nf or me d c o nse nt f or m (I C F) a n d i n t his 
pr ot oc ol .
P art 3 p artici p a nts o nl y: 
1 9. Resi de nt or staff i n a skil le d n ursi n g or a ssiste d li vi n g facilit y w h o sati sfies at l east o ne 
of  t he f o ll o wi n g at t he ti me of scree ni n g 
Are ≥ 6 5 y ears of a ge 
Ha ve a B MI ≥ 3 5 
Ha ve c hr o nic ki d ne y disease 
Ha ve t y pe 1 or t y pe 2 dia betes 
Ha ve i m m u n os u p pressi ve disease 
Are c urre nt l y recei vi n g i m m u n os u p pressi ve treat me nt, or 
Are ≥ 5 5 y ears of a ge A N D ha ve 
ocar di o vasc ular di sease, O R 
oh y perte nsi o n, O R 
oc hr o nic o bstr ucti ve p ul m o nar y  disease or ot her c hr o nic res pirat or y  disease 
N ote: B MI i s r o u n de d t o t he nearest w h o le n u m ber, f or e xa m ple, 3 4. 5 i s r o u n de d t o 3 5. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
4 4 2 0. P osi ti ve S A R S -C o V -2 test a n d i nf usi o n wi t h i n 1 0 da ys of s y m pt o m  o nset ,O R p osi ti ve 
S A R S -C o V -2 test a n d i nf usi o n wi t hi n 1 0 da ys of testi n g if as y m pt o m at ic 
5. 2. E xcl usi o n Criteri a 
P arti ci pa nts are e xcl u de d fr o m  t he st u d y  i f a n y of t he f o ll o wi n g cri t eri a a p pl y: 
7. F or Parts 1 a n d 2, r ec o vere d fr o m C O VI D -1 9 diseas eor as y m pt o mat ic i nfect i o n
8. F or P art s1 a n d 2, apri or hi st or y  of  a p osi ti ve S A R S -C o V -2 ser ol o g y test 
9. F or Parts 1 a n d 2, a hist or y  of  C o n valesce nt C O VI D -1 9 pl as ma treat m e nt 
1 0. Are a n i n pat ie nt  i n h os pi t al 
1 1. F or Parts 1 a n d 2, p art ic i pat i o n i n a pre vi o us S A R S- C o V -2 vacci ne trial or recei ve d a n 
a p pr o ve d S A R S -C o V - 2 vacci ne 
1 2. F or Parts 1 a n d 2, p re vi o us recei pt of S A R -C o V - 2 -s pecific m o n ocl o nal  a n ti b o di es 
1 3. H a ve part ic i pate d, wit hi n t h e last 3 0 da ys, i n a cli nical st u d y  i n v o l vi n g a n i n vest i gat i o nal 
pr o d uct.  If t he pre vi o us i n vest i gat i o nal pr o d uct has a l o n g half -life, 5 half -li ves or 
3 0 d a y s ( w hic he ver i s l o n ger) s h o ul d ha ve passe d . T his cri t eri o n d oes n ot a p pl y  t o 
pr o d ucts descri be d i n Cri teria 9, 1 1, a n d 1 2.  
1 4. Are pre g na nt or breast fee di n g 
1 5. A r e c o nc urre nt l y e nr olle d i n a n y ot her t y pe of me dical researc h j u d ge d n ot t o be 
scie ntificall y or me dicall y c o m pati ble wit h t his st u d y 
1 6. Ha ve k n o w n aller gies t o relate d c o m p o u n ds of L Y 3 8 1 9 2 5 3 , L Y 3 8 3 2 4 7 9 or a n y  
c o m p o ne nts of t he f or m ulat i o n
1 7. S us pecte d or pr o ve n seri o us, acti ve bacterial, f u n gal, viral, or ot her i nfect i o n t hat i n t he 
o pi ni o n of t he i n vest i gat or c o ul d c o nsti t ute a ris k w he n ta ki n g i n vest i gat i o nal pr o d uct 
1 8. Ha ve a n y seri o us c o nc o mit a nt s y ste mic disease, c o n dit i o n or dis or der t hat, i n t he 
o pi ni o n of t he i n vest i gat or, s h o ul d precl u de partici pati o n i n t his st u d y .
5. 3. Lifest yle C o nsi der ati o ns 
Re pr o d ucti ve a n d C o ntrace pti ve g ui da nce is pr o vi de d i n Secti o n  1 0. 4 ,A p pe n di x 4. 
P arti ci pa nts s h o ul d r ef rai n fr o m d o nati n g bl o o d or bl o o d pr o d ucts fr o m t he ti me of t heir 
scree ni n g visit u ntil 9 0 da ys f o ll o wi n g t he last d ose of st u d y i nter ve nt i o n. 
5. 4. Scree n F ail ures 
Scree n fail ures are defi ne d as part ic i pa nts w h o c o nse nt t o partici pate i n t he cli nical st u d y  b ut are 
n ot s u bse q ue ntl y e nr olle d i n t he st u d y . A mi ni mal set of scree n fail ure i nf or mat i o n is re q uire d t o 
e ns ure tra ns pare nt re p orti n g of scree n fail ure partici p a nts t o meet t he C o ns oli date d Sta n dar ds of 
Re p orti n g Trials p u blis hi n g re q uire me nts a n d t o res p o n d t o q ueries fr o m re g ulat or y  a ut h ori ti es. 
Mi ni mal i nf or mat i o n i ncl u des de m o gra p h y, scree n fail ure detail s, eli gi bilit y cri t eri a, a n d a n y 
seri o us a d verse e ve nt ( S A E). 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
45Individuals who do not meet the criteria for participation in this study (screen failure) may  not be 
rescreened .  Re-evaluat ion of venous access does not constitute rescreening and is allowable 
within the screening window.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
4 6 6. St u d y I nter ve nti o n 
St u d y  i nt er ve nt i o n is defi ne d as a n y i n vest i gat i o nal i nt er ve nt i o n(s), m ar kete d pr o d uct(s), 
pl ace b o ,or m e dical de vice (s) i nt e n de d t o be a d mi nistere d t o a st u d y  p arti ci pa nt acc or di n g t o t he 
st u d y  pr ot oc ol .
6. 1. St u d y I nter ve nti o n(s) A d mi nistere d 
Eac h partici pa nt will recei ve a si n gle I V i nf usi o n of eit her place b o ,L Y 3 8 1 9 2 5 3 , or a 
c o m bi nat i o n of L Y 3 8 1 9 2 5 3 a n d L Y 3 8 3 2 4 7 9 .
St u d y P art 1 & 2 1 2 & 3 2
( Pre ve nti o n 
O nl y) 2 & 3 
( Treat me nt o nl y) 
I nter ve nti o n 
N a me Place b o L Y 3 8 1 9 2 5 3 L Y 3 8 1 9 2 5 3 L Y 3 8 1 9 2 5 3 + 
L Y 3 8 3 2 4 7 9 L Y 3 8 1 9 2 5 3 + 
L Y 3 8 3 2 4 7 9 
D ose 
F or m ul ati o n 0. 9 % s o di u m 
c hl ori de s ol uti o n S ol uti o n 
D os a ge 
Le vel(s) N ot a p plica ble 4 2 0 0 m g 7 0 0 m g 3 5 0 m g + 
7 0 0 m g 7 0 0 m g + 
1 4 0 0 m g 
Use Place b o E x peri me ntal 
I M P a n d 
NI M P I M P I M P 
S o urci n g C o m merciall y 
a vaila ble 0. 9 % 
s o di u m c hl ori de 
s ol uti o n Fr o m Lill y 
P ac k a gi n g 
a n d L a beli n g C o m merciall y 
a vaila ble 0. 9 % 
s o di u m c hl ori de 
s ol uti o n St u d y I nter ve nti o n will be pr o vi de d i n glass vials a n d will be 
la bele d a p pr o priatel y 
A b bre viati o ns:  I M P = i n vesti gati o nal me dici nal pr o d uct; I V = i ntra ve n o us ; NI M P = n o n- i n vesti gati o nal me dici nal 
pr o d uct .
T he i nf usi o n rate m a y be re d uce d as dee me d necessar y  i f a ni nf usi o n react i o n is o bser ve d 
( Secti o n  6. 1. 1. 2 ).  Partici pa nts will be m o nit ore d f or si g ns a n d s y m pt o ms of i nf usi o n react i o n
e ver y 3 0 mi n utes d uri n g t he i nf usi o nor at least o nce if i nf usi o nti me is < 3 0 mi n utes ,a n d 
f o r at l east 1 h o ur after c o m plet i o n of t he i nf usi o n. 
T he site m ust ha ve res uscitati o n e q ui p me nt, e mer ge nc y dr u gs ,a n d a p pr o priatel y trai n e d si t e staff 
a vaila ble d uri n g t he i nf usi o n a n d f or at least 1h o ur after t he c o m plet i o n of t he i nf usi o n. 
I nf usi o n i nf or mat i o n ma y be f o u n d i n t he D osi n g S ol uti o n Pre parati o n I nstr ucti o ns. 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
476.1.1. Special Treatment Considerations
6.1.1.1. Premedication for Infusions
Prem edicat ion for infusio ns is not pl anned.  However, if the participant has a medical history 
suggest ing a pote ntial benefit fro m prem edicati on, the study  invest igator(s) or qualified designee
shoul d determine the appropriate premedicat ion.
The invest igators and sponsor may decide to use premedicat ion if the frequency o f infusion 
reacti ons am ong parti cipants warran ts it.
If minor infusio n reactions are observed, administration of acetaminophen, 500-mg to 1000- mg, 
antihistamines and/or other appropriately indicated medicat ions may be given prior to the start of 
infusio ns for subsequent participants.
The decisio n to i mplement prem edicat ion for infusio ns in subsequent participants will be made 
by the investigator and sponsor and recorded in the study  documentati on.
Any premedicat ions given will be documented as a concomitant therapy .
6.1.1.2. Management of Infusion Reactions
Allparticipants shoul d be m onitored cl osely, as there is a risk of infusio n reaction and 
hypersensit ivity (incl uding anaphylaxis) wit h any bio logical  agent.
Symptoms and Signs
Symptom s and si gns that m ay occur as part of an infusio n reaction include, but are not limited to 
fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash 
including urticaria, pruritus, myalgia, and dizziness.
Infusio n-related reacti ons severi ty will be assessed and reported using the Divisio n of AIDS
(DAIDS) Table for Grading the Severit y of Adult and Pediatri c Adverse Events, Corrected 
Version 2.1 (July  2017).
This table describes the severit y of react ions according to DAIDS.
Parameter Mild Moderate Severe Severe and 
Potentially 
Life-threatening
Acute Allergic 
ReactionLocalized urticaria 
(wheals) with no 
medical 
interventio n 
indicatedLocalized urticaria with 
interventio n indicated 
OR 
Mild angioedema with 
no intervention indicatedGeneralized Urticaria 
OR
Angioedema with 
interventio n indicate d 
OR
Symptoms of mild 
bronchospasmAcute anaphylaxis 
OR 
Life-threatening 
bronchospasm 
OR
Laryngeal edema
Cytokine 
Release 
SyndromeaMild signs and 
symptoms 
AND
Therapy  (that is, 
antibody infusion )
interruption not 
indicatedTherapy  (that is, 
antibody infusion) 
interruption indicated
AND
Responds promptly to 
symptomatic treatment
ORProlonged severe 
signs and symptoms 
OR
Recurrence of 
symptoms following 
initial improvementLife-threatening 
consequences 
(for example, 
requiring pressor or 
ventilator support)
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
48Prophy lactic 
medications indicated 
for ≤24 hours
aA disorder characterized by nausea, headache, tachycardia, hypotension, rash, and/or shortness of breath.
Source:  DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Correcte d Version 2.1 (July 
2017).
Site Needs
The clinical site should have necessary equipment and medicat ions for the m anagement of any 
infusio n reaction, which may include but is not limited to oxy gen, IV fluids , epinephrine, 
acetaminophen and ant ihistamine.
Management of Infusion Reactions
Invest igators should determine the severit y of the infusio n reaction and manage infusion 
reacti ons based on standard of care and their clinical judgment.  If an infusio n react ion occurs, 
then supporti ve care should be used in accordance with the signs and symptoms.
If a participant permanent ly discontinues fro m study  intervent ion, they  shoul d com plete AE 
monitoring and other procedures as stated in the SoA.
6.2. Preparation/Handling/Storage/Accountability
The invest igator or desi gnee m ust confi rm appropriate tem perature condi tions have been 
maintained during transit for all study  intervent ion received and any discrepancies are reported 
and reso lved before use of the study  intervent ion.
To protect blinding, the intervent ions m ust b e prepared by  an unblinded sitestaff qualified to 
prepare study  intervent ion who are not invo lved in any other study -related procedures.  
Instructi ons for preparation will be provided by  the sponsor.
Only participants enro lled in the study  may receive study  intervent ion and only sitestaff may 
supply or administer study  intervent ion.
All study  intervent ion must be stored in a secure, environmentally controlled, and monitored 
(manual  or autom ated) area in accordance with the labeled storage condit ions wit h access limited 
to the invest igator and authorized sitestaff.
The invest igator, institution, contracted pharmacist, or another appropriate individual who is 
under the supervisio nof the invest igator isresponsible for study  intervent ion accountabilit y, 
reconciliat ion, and record maintenance (i.e., receipt, reconciliat ion, and final disposit ion 
records ).
Further gui dance and information for the final disposit ion of unused study  interventi ons are 
provi dedin the pharmacy manual .
6.3. Measures to Minimize Bias: Randomization and Blinding
Randomization
Parti cipants who m eet all  criteria f or enrollment will be randomized on Day  1as fo llows: 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
49In Part 1, 1:1 to double -blind treatment 
In Part 2, will allocated as f ollows: 
Prevent ion Cohort:  1:1:1 todouble blinded treatment
Treatment Cohort:  1:1 , as described in Part 2 Treatment Cohort below
InPart 3, 1:1 to open label treatment
To achieve between -group com parabilit y, block rando mizat ion within each facilit ywill be used .  
Randomized participants within the facilit ywill be stratified by  role within the facilit y(resident 
versus facilit ystaff) ,by sex, and whether or not the participant received a SARS -CoV -2 vaccine 
prior to screening (in Part 3 only ).
All p articipants will be centrally randomized to study  intervent ion using an Interactive Web 
Response Sy stem  (IWRS). Before the study is init iated, the l og in informat ion and directions for 
the IWRS will be provided to each site.
Blinding
Part 1 and Part 2 Pre vention Cohort
Part 1 and Part 2 are blinded.  Neither parti cipants, nor invest igators, nor the sponsor study team 
will be aware of treatment assignments prior to the final database locks at the conclusio n of the 
study , except as described in the fo llowing note.
Note:  It is possible that some participants willhave theSARS -CoV -2 negative result on the 
screening point of care test, but could be positive on the baseline SARS -CoV -2 PCR test.  The 
resul ts from the baseline PCR test will not be available unt il after the participant is rando mized.  
Once posit ive results are known fro m the baseline PCR test, these participants will be unblinded 
and have the option to continue to be fo llowed for safet yaccording to the Prevent ion Cohort 
SoA.This table describes general procedures for unblinding.
Unblinding (IWRS ) Emergency unblinding for adverse events may be performed through the 
IWRS.  All actions resulting in an unblinding event are recorded and 
reported by the IWRS
In case of a n emergency, the investigator has the sole responsibility for 
determining if unblinding of a participants’ intervention assignment 
iswarranted
Participant safety must always be the first consideration in making such a 
determination.  However, the investig ator should make all attempts to 
contact the Medical Monitor in advance of unblinding
If a participant’s intervention assignment is unblinded, the sponsor must be 
notified immediately after breaking the blind even if consultation occurred 
in advance
The da te and reason that the blind was broken must be recorded in the 
source documentation. 
Participants who test negative at screening POC testing, then test positive at 
baseline PCR testing , will be unblinded .  Unblinding is recorded and 
reported by the IWRS . 
Abbreviations:  IWRS =interactive web -response sy stem.
If an invest igator, site staff performing assessments , or parti cipant i s unblinded while the 
infusio n is ongoing, the participant must be discontinued fro m the study  intervent ion and the 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
5 0 i nf usi o n st o p pe d.  If a n y a m o u nt of st u d y  i nt er ve nti o n was a d mi nistere d, f o ll o w pr oce d ures 
acc or di n g t o t he S o A as descri be d i n Secti o n  7. 1 .
P art 2 Tre at me nt C o h ort 
T he Part 2 Treat me nt C o h ort is bli n de d.  Neit her partici pa nts, n or i n vest i gat ors, n or t he s p o ns or 
st u d y  t e a m  will be a ware of treat me nt assi g n me nts pri or t o t he fi nal data base l oc ks at t he 
c o ncl usi o n  of  t he st u d y .
If t he partici pa nt is assi g ne d t o t h e Part 2 tre at m e nt c o h ort base d o n a p ositi ve P O C test, t he 
parti ci pa nt will be ra n d o mize d t o o ne of t w o ar ms.   T he partici pa nt will be i nf or me d t hat t he y  are 
recei vi n g act i ve st u d y  i nt er ve nt i o n (t hat is, n ot place b o). 
P art 3 
Part 3 i s o pe n l a bel .  
6. 4. St u d y I nter ve nti o n C o m pli a nce 
P arti ci p a nts will recei ve st u d y  i nt er ve nt i o n di rect l y fr o m t h e i n vest i gat or or q ualifie d desi g nee, 
u n der me dical s u per visi o n.  T he date a n d ti me of d osi n g will  b e rec or de d i n t he s o urce 
d oc u m e nts a n d rec or de d i n t he case re p or t f or m  ( C R F ). 
6. 5. C o nc o mit a nt T her a p y 
C o nc o mit a nt T her a p y 
P arti ci pa nts s h o ul d be treate d acc or di n g t o sta n dar d of care, e ve n as it e v o l ves, a n d me dicat i o ns 
ma y be part of t he treat me nt para di g m. 
Re m desi vi r ma y be i ni ti ate d as sta n dar d of care f or partici pa nt s re q ui ri n g h os pi taliz ati o n . 
If t he l ocal sta n dar d of care per writte n p olicies or g ui deli nes (t hat i s, n ot j ust a n i n di vi d ual 
cli nicia n decisi o n) i ncl u des i n vest i gat i o nal a ge nts t o treat C O VI D - 1 9 , t he n starti n g t hese d uri n g 
t h e st u d y  i s per mitte d, b ut ma y re q uire a d dit i o nal s af et y m o nit ori n g. 
C o n valesce nt C O VI D -1 9 pl as ma treat m e nt i s n ot all o we d , e xce pt i n h os pitalize d partici pa nts. 
Va cci ne s f or S A R S -C o V -2 s h o ul d n ot be use d pri or t o Wee k 8 of t he e val uat i o n peri o d f o r t h e 
pre ve nt i o n c o h ort of  P art 2 .
An y me dicat i o n, i n vest i gat i o nal a ge nt, or vacci ne, i ncl u di n g o ver t he c o u nter or prescri pt i o n 
me dici nes, vita mi ns, a n d/ or her bal s u p ple me nts , or ot her s pecific cate g ories of i nterest (s uc h as 
c o n valesce nt C O VI D -1 9 pl as ma treat m e nt) t h at t h e partici pa nt is recei vi n g at t he ti me of 
e nr o ll me nt or recei ves d uri n g t he st u d y m ust be rec or de d al o n g wit h 
Reas o n f or use 
Dates of a d mi nistrati o n i ncl u di n g start a n d e n d dates, a n d 
D osa ge i nf or mati o n i ncl u di n g d ose a n d fre q ue nc y f or c o nc o mita nt t hera p y  of  s pecial  
i nt erest. 
Aceta mi n o p he n a n d c ortic oster oi d use are per mitte d at a n y t i me d uri n g t he st u d y .
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
51Other concomitant medicat ion may be considered on a case -by-case basis by the invest igator in 
consultation wit h the sponsor if required .
The sponsor sh ould be contacted if there are any  questi ons regarding concomitant or prior 
therapy .
6.6. Intervention after the End of the Study
No continued access is planned after complet ion of this study , as addi tional efficacy woul d be 
needed to demonstrate continued acce ss cri teria.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
5 2 7. Disc o nti n u ati o n of St u d y I nter ve nti o n a n d P artici p a nt 
Disc o nti n u ati o n/ Wit h dr a w al 
T hese secti o ns descri be reas o ns f or a partici pa nt’s 
p er m a ne nt or te m p orar y  disc o nt i n uat i o n of st u d y  dr u g, or 
di sc o nti n uat i o n ( wi t h dra wal) fr o m  t he st u d y .
Di sc o nti n uati o n of  s pecific sites or of t he trial as a w h o le are ha n dle d as part of re g ulat or y, 
et hi cal, a n d trial o versi g ht c o nsi derat i o ns i n Sect i o n 1 0. 1. 9 . A p pe n di x 1. 
7. 1. Disc o nti n u ati o n of St u d y I n ter ve nti o n 
I n rare i nsta nces, it ma y be necessar y  f or a partici pa nt t o per ma ne nt l y disc o nt i n ue ( defi nit i ve 
di sc o nti n uat i o n) st u d y  i nt er ve nt i o n. If st u d y i nter ve nt i o n is defi nit i vel y  disc o nti n ue d, t he 
parti ci pa nt will r e m ai n i n t he st u d y  f o r f ol l o w- u p a n d a n y  f urt her e val uat i o ns as descri be d i n t he 
S o A. 
7. 2. P artici p a nt Disc o nti n u ati o n/ Wit h dr a w al fr o m t he St u d y 
A partici pa nt ma y wit h dra w fr o m t h e st u d y :
at a n y  ti me at his/ he r o w n re q uest 
at t he re q uest of his/ her desi g nee (f or e xa m ple, le gal a ut h ori ze d re prese ntati ve )
at t he discreti o n of t he i n vest i gat or f or safet y,  be ha vi or al , c o m plia nce, or a d mi nistrati ve 
reas o ns 
if t he partici pa nt bec o me s pre g na nt d uri n g t he st u d y 
if e nr o ll me nt i n a n y ot her cli nical st u d y i n v o l vi n g a n i n vest i gat i o nal pr o d uct or 
e nr o ll me nt i n a n y ot her t y pe o f me d ical researc h j u d ge d n ot t o be scie nt ificall y or 
me dicall y c o m pat i ble wit h t his st u d y 
Di sc o nti n uati o n is e x pecte d t o be u nc o m m o n. 
At  t he ti me of d isc o nt i n ui n g fr o m t he st u d y , if  p ossi ble, a n earl y disc o nt i n uat i o n visit s h o ul d be 
c o n d ucte d, as s h o w n i n t he S o A.  See t h eS o A f or data t o be c ollecte d at t he ti me of st u d y 
di sc o nti n uat i o n a n d f o ll o w- u p a n d f or a n y  f urt her e val uat i o ns t hat nee d t o be c o m p lete d.  T he 
parti ci pa nt will be per ma ne nt l y disc o nt i n ue d b ot h fr o m t h e st u d y  i nt er ve nt i o n a n d fr o m t h e st u d y  
at t hat ti me. 
If t he partici pa nt , or t he parti ci pa nt’s l e gal a ut h orize d re prese ntati ve, wi t h dra ws c o nse nt f or 
di s cl os ure of f ut ure i nf or mat i o n, t he s p o ns or m a y  retai n a n d c o nti n ue t o use a n y  data c ollecte d 
bef ore s uc h a wit h dra wal o f c o nse nt.  If a partici pa nt wit h dra ws fr o m t he st u d y , he/s he or t h e 
parti ci pa nt’s le g al a ut h ori ze d re prese ntati ve ,ma y re q uest destr ucti o n of  a n y sa m ples ta ke n a n d 
n ot te ste d, a n d t he i n vest i gat or m ust d oc u me nt t his i n t he site st u d y rec or ds. 
7. 2. 1. Disc o nti n u a ti o n of I n a d verte ntl y E nr olle d P artici p a nts 
If t he s p o ns or or i n vest i gat or i de nt if y a partici pa nt w h o di d n ot meet e nr oll me nt criteria a n d was 
i na d verte nt l y e nr o lle d, t he n t he parti ci pa nt s h o ul d be disc o nt i n ue d fr o m st u d y  i nt er ve nt i o nu nless 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
5 3 t h ere are e xte n uati n g circ u msta nces t hat ma ke it me dicall y necessar y f or t he parti ci pa nt t o 
c o nti n ue st u d y  i nt er ve nt i o n.  
If t he i n vest i gat or a n d t he s p o ns or C R P / C R S a gree it is me dicall y a p pr o priate t o c o nti n ue, t he 
i n vesti gat or m ust o btai n d oc u me nte d a p pr o val fr o m t he s p o ns or C R P / C R S t o all o w t he 
i na d verte nt l y e nr o lle d partici pa nt t o c o nti n ue i n t he st u d y wi t h  o r wi t h o ut treat m e nt wi t h  
i n vesti gat i o nal pr o d uct. 
S af et y f o ll o w u p i s as o utli ne d i n 
Secti o n  1. 3 ( Sc he d ule of Act i vit ies) 
Secti o n  8. 2 ( Safet y Assess me nts), a n d 
Secti o n  8. 3 ( A d verse E ve nts a n d Seri o us A d verse E ve nts). 
7. 3. L ost t o F oll o w u p 
A partici pa nt will be c o nsi dere d l ost t o f oll o w -u p if  h e or s he re peate dl y fails t o ret ur n f or 
sc he d ule d visits a n d is u na ble t o be c o ntacte d b y  t he st u d y  si t e. Si te pers o n nel are e x pecte d t o 
ma ke dili ge nt atte m pts t o c o ntact partici pa nt s w h o fail t o ret ur n f or a sc he d ule d visit or were 
ot her wi se u na ble t o be f o ll o we d u p b y t he site. 
Si te pers o n nel, or a n i n de pe n de nt t hir d part y ,will atte m pt t o c ollect t he vital stat us of t he 
parti ci pa nt wi t hi n le gal  a n d et hical b o u n daries f or all parti ci pa nts w h o recei ve d i n vest i gat i o nal 
pr o d uct. P u blic s o urces ma y be searc he d f or vital stat us i nf or mati o n. If vit al  stat us is 
deter mi ne d t o be d ecease d, t his will be d oc u me nte d a n d t he partici pa nt will n ot be c o nsi dere d 
l o st t o f oll o w - u p. S p o ns or pers o n nel will n ot be i n v o l ve d i n a n y atte m pts t o c ollect vital stat us 
i nf or m at i o n. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
5 4 8. St u d y Assess me nts a n d Pr oce d ures 
St u d y  pr oce d ures a n d t heir ti mi n g are s u m marize d i n t he S o A. 
Pr ot oc ol wai vers or e xe m pt i o ns are n ot all o we d. 
M o ni t ori n g of bli n de d safet y data will c o nt i n ue t hr o u g h o ut t he st u d y a n d will be c o n d ucte d b y 
bli n de d st u d y  tea m  m e m bers.  Details of t he bli n de d s af et y re vie ws, i ncl u di n g t he fre q ue nc y  a n d 
a p pr o xi mate ti mi n g, are s pecifie d i n t he trial le vel safet y re vie w pl a n. 
I m me diate safet y c o ncer ns s h o ul d be disc usse d wit h t he s p o ns or i m me diatel y u p o n occ urre nce or 
a ware ness t o deter mi ne if t he partici pa nt s h o u l d c o nt i n ue or disc o nt i n ue st u d y  i nt er ve nt i o n. 
A d here nce t o t he st u d y  desi g n re q ui re me nts, i ncl u di n g t h ose s pecifie d i n t he S o A, is esse nt ia l 
a n d re q uire d f or st u d y  c o n d uct. 
All scree ni n g e val uat i o ns m u st be c o m plete d a n d re vie we d t o c o nfir m t hat p ote ntial part ic i pa nts 
meet all eli gi bilit y cri teria.  T he i n vest i gat or will mai ntai n a scree ni n g l o g t o rec or d details o f all 
parti ci pa nts scree ne d a n d t o c o nfir m eli gi bilit y or rec or d reas o ns f or scree ni n g fail ure, as 
a p plica ble. 
8. 1. Effic ac y Assess me nts 
8. 1. 1. S A R S -C o V -2 V ir al S w a b a n d Ser ol o g y 
F or details c o ncer ni n g viral s wa b, see P har mac o d y na mic s ( Secti o n  8. 6 ). I n Part 1, a n y p osi ti ve 
res ul t f r o m  a baseli ne S A R S -C o V -2 test ( N P or nasal s w a b ) will res ult i n t he partici pa nt bei n g 
decl are d S A R S -C o V - 2 p osit i ve i n t he a nal ysis p o p ulat i o ns. I n Part 2, t he res ult fr o m t he 
scree ni n g P O C test a n d baseli ne S A R S -C o V -2 test are pla n ne d t o be use d t o defi ne S A R S -C o V -
2 stat us f o r t he a nal ys is p o p ul at i o ns.  
Nasal s wa bs are pla n ne d d uri n g t he e val uat i o n a n d p ost -e val uat i o n peri o d at  ti mes descri be d i n 
t h e S o A .  H o we ver, i n t he e ve nt nasal s wa b sca n n ot be s u p plie d , t he S p o ns or ma y s u bst it ut e wit h
or o p har y n geal , mi d -t ur bi nate or nas o p har y n geal s wa b s. F or i nstr ucti o ns relate d t o perf or mi n g 
t h e nas o p har y n geal ,mi d -t ur bi nate , nasal, or or o p har y n geal, s wa b, see g ui da nce pr o vi de d b y 
S p o ns or .
F or Part 3, a n y  p osi ti ve res ult fr o m a baseli ne S A R S -C o V -2 test ( N P) will res ult i n t he 
parti ci pa nt bei n g declare d S A R S -C o V -2 p osit i ve i n t he a nal ysis p o p ulati o ns.  N P s wa bs are 
pl a n ne d d uri n g t he e val uat i o n a n d p ost -e val uat i o n peri o d at ti mes descri be d i n t h e S o A.  
F or details c o ncer ni n g viral ser o l o g y , see P har mac o d y na mics ( Secti o n  8. 6 ).
8. 1. 2. P artici p a nt S y m pt o ms Q uesti o n n aire 
Parti ci pa nts will be as ke d a b o ut t h e prese nce or a bse nce of s y m pt o m s a n d si g ns ass o ci at e d wi t h  
C O VI D - 1 9e x perie nce d d uri n g t he past 2 4 h o urs ,at t he ti me p o i nt s descri be d i n t he S o A .  
Si g ns a n d s y m pt o m s ass ociate d wit h C O VI D -1 9 s h o ul d n ot be ca pt ure d as A Es , u nl ess m or e 
se vere t ha n e x pecte d.  See Secti o n  1 0. 3. 1 . f or a d di ti o n al  i nf or m ati o n A E defi nit i o ns use d i n t his 
st u d y .
Sy m pt o m si ncl u de 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
55shortness of b reath with movement
shortness of breath at rest
cough 
chest pain or disco mfort withbreathing
feeling feverish
chills 
sore throat 
muscle or body aches and pain 
fatigue or loss of energy
headache
nausea
diarrhea
vomiting
loss of appet ite
loss of taste,and
loss of smell .
Participants requi ring a l egally  authori zed representative to provide signed informed consent will 
not be asked to report the presence or absence of symptoms. Only symptoms that maybe 
observed by site staff other than the participant will be recorded , includ ing
shortness of breath with movement
shortness of breath at rest
cough 
diarrhea, and
vomiting.
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA.
8.2.1. Physical Examinations , Clinical Signs and Symptoms 
A co mplete physical examinat ion and medical hist ory (including preexist ing clinical signs and 
symptoms) will be performed at the screening visit . This examinat ion excludes pelvic, rectal, 
and breast examinat ions unless clinically indicated.
A symptom -directed physical  examinat ion will be performed at other visits, as specified in the 
SoA and as clinically indicated.
Invest igators should pay special attention to clinical signs related to COVID -19, to ongoing 
medical condit ions and to previous seri ous illnesses.
8.2.2. Vital Signs
Vital signs will  be measured at rest as specified in the SoA.  Vital signs include
body temperature
blood pressure
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
5 6 pul s e r at e 
res pi rat i o n rate 
sat urati o n of  p eri p h er al  o x y ge n, a n d 
su p ple me ntal  o x y ge n fl o w rate, Fi O 2 if k n o w n, a n d met h o d of deli ver y, if a p plica ble. 
If a vaila ble d uri n g t he st u d y , o pti o nal  r e m ot e vi t al  stat us m o ni t ori n g m a y be use d t o o btai n vital 
data. 
A d dit i o nal vit al si g ns ma y be m eas ure d d uri n g t he st u d y  i f warra nte d, as deter mi ne d b y t he 
i n vesti gat or. 
8. 2. 3.  Cli nic al S afet y L a b or at or y Assess me nts 
See Secti o n  1 0. 2 , A p pe n di x 2 f or t he list of cli nical la b orat or y tests t o be perf or me d a n d t he S o A 
f o r t he ti mi n g a n d fre q ue nc y .  All pr ot oc ol -re q ui re d la b orat or y  assess me nts, as defi ne d i n 
A p pe n di x 2, m ust be c o n d ucte d i n acc or da nce wit h t he l a b orat or y  m a n ual a n d t he S o A. 
Cli nicall y si g nifica nt a b n or mal la b orat or y  f i n di n gs are t h ose w hic h are n ot ass ociate d wi t h  t he 
u n derl yi n g disease, u nless j u d ge d b y t he i n vesti gat or t o be m ore se vere t ha n e x pecte d f or t he 
parti ci pa nt's c o n dit i o n. 
All la b orat or y  tests wi t h  val ues c o nsi dere d cli nicall y  si g nifica ntl y a b n or m al  d uri n g parti ci pat i o n 
i n t he st u d y  or wi t hi n 2 8 da ys af ter t he d ose of st u d y  i nt er ve nt i o n s h o ul d be re peate d u ntil t he 
val ues ret ur n t o n or mal or baseli ne or are n o l o n ger c o nsi dere d cli nicall y si g nifica nt b y t he 
i n vesti gat or or s p o ns or. 
If s uc h val ues d o n ot ret ur n t o n or mal/ baseli ne wit hi n a peri o d of  ti me j u d ge d reas o na ble b y  t he 
i n vesti gat or, t he eti ol o g y  s h o ul d b e i de ntifie d a n d t he s p o ns or n otifie d. 
T he i n vest i gat or m ust re vie w t he la b orat or y res ul ts , d oc u m e nt t his re vie w, a n d rec or d a n y  
cli nicall y rele va nt c ha n ges occ urri n g d uri n g t he st u d y  i n t he C R F. 
T he l a b orat or y  re p orts m ust be file d wit h t he s o urce d oc u me nts. 
If la b orat or y  v al ues fr o m n o n- pr ot oc ol  s pecifie d l a b orat or y  assess me nts perf or m e d at a l o cal  
la b orat or y  t h at re q uire a c ha n ge i n partici pa nt ma na ge me nt or are c o nsi dere d cli nicall y 
si g nifica nt b y t he i n vest i gat or (i.e., S A E or A E), t he n t he A E or S A E will be rec or de d b y t he 
i n vesti gat or i n t he C R F. 
Pre g n a nc y Testi n g 
W o me n of c hil d beari n g p ote ntial ( W O C B P) m ust u n der g o pre g na nc y  testi n g acc or di n g t o t he 
S o A. 
8. 2. 4. H os pit aliz ati o n e ve nts   
If a parti ci p a nt i s a d mi tte d t o t he h os pi t al , t he parti ci pa nt will re mai n i n t he st u d y  a n d f ol l o w t he 
pr oce d ures o utli ne d i n t he S o A.  H os pitalizat i o n is defi ne d as ≥ 2 4 h o urs of ac ute care. 
T he date of h os pitalizati o n e ve nts will be rec or de d i n t he C R F a n d i ncl u des 
hos pi talizati o n 
e m er ge nc y r o o m  visi t 
i nt e nsi ve care u nit a d mitta nce 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
5 7 ext e n de d care facilit y a d mitta nce , a n d 
dis c har ge f o r a n y  of  t he a b o ve .
8. 2. 5. Pr oce d ures of S peci al I nterest 
I n h os pitalize d partici pa nts, cli nical stat us a n d c o nc o mita nt pr oce d ures of s pecial i nterest will be 
rec or de d i n t he C R F a n d i ncl u de c o nsci o us ness stat us usi n g alert, c o nf usi o n, ver bal , pai n, 
u nres p o nsi ve scale ( A C V P U), li mitat i o n o n acti vit ies d ue t o C O VI D -1 9 a n d re q uire me nts f or: 
o n g oi n g h os pital me dical care 
s u p p le me ntal o x y g e n 
n o n- i n vasi ve ve nt ilat i o n or a hi g h fl o w o x y ge n de vice 
mec ha nical ve nt ilat i o n
e xtrac or p oreal me m bra ne o x y ge nat i o n, or 
a d di ti o nal  or ga n s u p p ort (e. g. press ors, re nal re place me nt) .
8. 3. A d verse E ve nts a n d Seri o us A d verse E ve nts 
A d verse e ve nts wil l be re p orte d b y  t he parti ci pa nt ( or, w he n a p pr o pri ate, b y  a care gi ver, 
s urr o gate, or t he partici pa nt's le gall y a ut h orize d re prese ntati ve). 
T he i n vest i gat or a n d a n y q ualifie d desi g nees are res p o nsi ble f or detecti n g, d oc u me nti n g, a n d 
rec or di n g e ve nts t hat m eet t he defi nit i o n of a n A E or S A E a n d re mai n res p o nsi ble f or f o ll o wi n g 
u p A Es t hat are seri o us, c o nsi dere d relate d t o t he st u d y  i nt er ve nt i o n or st u d y  pr oce d ures, or t hat 
ca use d t he partici pa nt t o disc o nt i n ue t he st u d y  i nt er ve nt i o n or st u d y  (see Secti o n  7).
8. 3. 1. Ti me Peri o d a n d Fre q ue nc y f or C ollecti n g A E a n d S A E I nf or m ati o n 
All A Es a n d S A Es will be c ollecte d fr o m t he ti me of si g ni n g of  t he I C F u nt il part ic i pat i o n i n 
st u d y  h as e n de d .
A d verse e ve nts t h at be gi n bef ore t he start of st u d y  i nt er ve nt i o n b ut after si g ni n g of t he I C F will 
be rec or de d o n t he A d verse E ve nt C R F. 
Alt h o u g h all A Es after si g ni n g t he I C F are rec or de d b y t he site i n t he C R F/electr o nic data e ntr y, 
S A E re p orti n g t o s p o ns or wit hi n t he re q uire d t i mefra me be gi ns after t he parti ci pa nt has si g ne d 
t h e I C F a n d has recei ve d st u d y  dr u g.  H o we ver, if a n S A E occ urs after si g ni n g t he I C F, b ut pri or 
t o recei vi n g st u d y  i nt er ve nt i o n, i t nee ds t o be re p orte d wit hi n t he re q uire d ti mefra me O N L Y if i t 
is c o nsi dere d reas o na bl y p ossi bl y  relate d t o st u d y  pr oce d ures. 
All S A Es will be rec or de d a n d re p orte d t o t he s p o ns or or desi g nee i m me diatel y a n d u n der n o 
ci rc u msta nce s h o ul d t hi s e xcee d 2 4 h o urs, as i n dicate d i n Secti o n  1 0. 3. 4 , A p pe n di x 3 . T he 
i n vesti gat or will s u b mit a n y u p date d S A E data t o t he s p o ns or wit hi n 2 4 h o urs of i t bei n g 
a vaila ble. 
I n vest i gat ors are n ot o bli gate d t o acti vel y see k A E sor S A Es aft er c o ncl usi o n  of  t he st u d y  
parti ci pat i o n. H o we ver, if t he i n vest i gat or lear ns of a n y S A E, i ncl u di n g a deat h, at a n y t i me after 
a partici pa nt has bee n disc har ge d fr o m t he st u d y , a n d he/s he c o nsi ders t he e ve nt t o be reas o na bl y  
r el ate d t o t he st u d y i nt er ve nt i o n or st u d y parti ci pati o n , t he i n vest i gat or m ust pr o m pt l y n otif y  t h e 
s p o ns or .
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
5 8 8. 3. 2. Met h o d of Detecti n g A Es a n d S A Es 
T he m et h o d of rec or di n g, e val uat i n g, a n d assessi n g ca usalit y of A E a n d S A E a n d t he pr oce d ures 
f o r c o m plet i n g a n d tra ns mitt i n g S A E re p orts are pr o vi de d i n Sect i o n 1 0. 3 , A p pe n di x 3 .
Care will be ta ke n n ot t o i ntr o d uce bias w he n detecti n g A Es a n d/ or S A Es.  O pe n -e n de d a n d 
n o n- lea di n g ver bal q uest i o ni n g of t he partici pa nt is t he preferre d met h o d t o i n q uire a b o ut A E 
occ urre nces. 
8. 3. 3. F oll o w -u p of A Es a n d S A Es 
After t he i nit ial A E/ S A E re p ort, t he i n vesti gat or is re q uire d t o pr oacti vel y f o ll o w eac h partici pa nt 
at s u bse q ue nt visits/c o nta cts. All S A Es will  b e f ol l o we d u ntil res o l ut i o n, sta bilizat i o n, t he e ve nt 
is ot her wi se e x plai ne d, or t he partici pa nt is l ost t o f o ll o w- u p (as defi ne d i n Sect i o n 7. 3 ). F urt her 
i nf or m at i o n o n f o ll o w- u p pr oce d ures is pr o vi de d i n Secti o n  1 0. 3 , A p pe n di x 3.
8. 3. 4. Re g ul at or y Re p orti n g Re q uire me nts f or S A Es 
Pr o m pt n otificat i o n b y t he i n vest i gat or t o t he s p o ns or of a S A E is esse nt ia l s o t hat l e g al  
o bli gat i o ns a n d et hical res p o nsi bilit ies t o wa r ds t he safet y of  p arti ci pa nts a n d t he safet y of  a st u d y  
i nt er ve nt i o n u n der cli nical i n vesti gat i o n are m et. 
T he s p o ns or has a le gal res p o nsi bilit y t o n otif y b ot h t he l o c al  re g ulat or y  a ut h ori t y  a n d ot her 
re g ul at or y  a ge ncies a b o ut t he safet y of  a st u d y  i nt er ve nt i o n u n der cli nical i n vesti gati o n. T he 
s p o ns or will c o m p l y wi t h  c o u ntr y -s pecific re g ulat or y  r e q ui re me nts relati n g t o safet y re p orti n g t o 
t h e re g ulat or y  a ut h ori t y , I nst it uti o nal  Re vie w B oar ds (I R B)/I n de pe n de nt Et hics C o m mittees 
(I E C) , a n d i n vest i gat ors. 
A n i n vest i gat or w h o recei ves a n i n vest i gat or safet y re p ort descri bi n g a S A E or ot her s pecific 
safet y i nf or mat i o n (e. g., s u m mar y  or list i n g of S A Es) fr o m t he s p o ns or will re vie w a n d t he n file 
it  wi t h  t he I B a n d will n otif y t he I R B/I E C, if a p pr o priate acc or di n g t o l ocal re q uire me nts. 
8. 3. 5. Pre g n a nc y 
Alt h o u g h n or mal pre g na nc y  i s n ot a n a d verse e ve nt, details of all pre g na ncies i n fe male 
parti ci pa nts will be c o llecte d f or 9 0 da y saf ter d osi n g .
If a pre g na nc y  i s re p orte d, t he i n vesti gat or s h o ul d i nf or m t he s p o ns or wit hi n 2 4 h o urs of  l ear ni n g 
of  t he pre g na nc y a n d s h o ul d f o ll o w t he pr oce d ures o utli ne d i n Sect i o n 1 0. 4. 3 , A p pe n di x 4. 
A b n or m al  pre g na nc y o utc o m es , f or e xa m ple, s p o nta ne o us a b orti o n, fetal deat h, still birt h, 
c o n ge nital a n o ma lies, a n d ect o pi c pre g na nc y , are c o nsi dere d S A Es. 
8. 3. 6. H y perse nsiti vit y R eacti o ns 
Bi ol o gi c a ge nts carr y  t he ris k of s yste mic h y perse nsit i vit y r e a cti o ns. 
If s uc h a react i o n occ urs, a d diti o nal details descri bi n g eac h s y m pt o m s h o ul d be pr o vi de d t o t he 
s p o ns or i n t he i nf usi o n- r el ate d reacti o n/ h y perse nsiti vit y C R F. 
If s y m pt o ms a n d/ or si g ns occ ur d uri n g or wi t hi n 6 h o urs after i nf usi o n of L Y 3 8 1 9 2 5 3 a n d are 
belie ve d t o be h y perse nsit i vit y or d ue t o c y t o ki ne rel ease, t he n i n vest i gat ors are e nc o ura ge d t o 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
5 9 re p ort t he e ve nt as i nf usi o n- relate d i m me diate h y perse nsit i vit y react i o n or c y t o ki ne rel ease -
ass oci ate d i nf usi o n  reacti o n, res pect i vel y. 
Si tes s h o ul d ha ve a p pr o pri atel y  trai ne d me dical  staff a n d a p pr o pri ate me dical e q ui p me nt 
a vaila ble w he n st u d y  p arti ci pa nts are recei vi n g i nter ve nt i o n. It is rec o m me n de d t hat partici pa nts 
w h o e x perie nce a s yst e mic h y perse nsit i vit y react i o n be treate d per t he l ocal sta n dar d of care. 
I n t he case of ge neralize d urticaria or a na p h yla xis, a d dit i o nal bl o o d a n d uri ne sa m ples s h o ul d be 
c ollecte d as descri be d i n Secti o n  1 0. 6 , A p pe n di x 6, “Rec o m me n de d La b orat or y  Testi n g f or 
H y perse nsi ti vi t y  E ve nts”. La b orat or y res ults are pr o vi de d t o t he s p o ns or via t he ce ntral 
la b orat or y .
I n case of s ki n lesi o ns or ras h c o nsiste nt wit h vasc ulit is, eff orts s h o ul d be ma de t o perf or m t he 
f o ll o wi n g as s o o n as p ossi ble 
d er m at ol o g y  c o ns ul t ati o n 
s ki n bi o ps y, a n d 
p h ot o gra p hs of lesi o ns of i nterest, i ncl u di n g s ki n bi o ps y site. 
8. 3. 7. I nf usi o n -rel ate d Re acti o ns 
As wi t h  ot her m A bs, i nf usi o n- relate d r eacti o ns ma y occ ur d uri n g or f o ll o wi n g L Y 3 8 1 9 2 5 3 
a d mi nistrati o n.  If a n i nf usi o n- r el ate d reacti o n occ urs, a d di ti o nal data descri bi n g eac h s y m pt o m 
a n d si g n s h o ul d be pr o vi de d t o t he s p o ns or i n t he C R F. 
T his ta ble descri bes t he l ocati o n of i nf usi o n- r el ate d r eacti o n i nf or m at i o n i n t his pr ot oc ol. 
T o pic L oc ati o n 
S pecial treat me nt c o nsi derati o ns Secti o n  6. 1. 1 
Pre me dicati o n f or i nf usi o ns Secti o n  6. 1. 1. 1 
Ma na ge me nt of i nf usi o n reacti o ns Secti o n  6. 1. 1. 2 
D AI D S ta ble descri bi n g se verit y Sec ti o n  6. 1. 1. 2 
Treat me nt g ui deli nes f or i nf usi o n -relate d reacti o ns Secti o n  6. 1. 1. 2 
A b bre viati o n: D AI D S = Di visi o n of AI D S .
S y m pt o m s occ urri n g d uri n g or after i nf usi o n of st u d y  i nt er ve nt i o n ma y als o be defi ne d acc or di n g 
t o A E cate g ories s uc h as ac ute aller gic reacti o n or c y t o ki ne release s y n dr o me ( D AI D S 2 0 1 7 ). 
8. 3. 8. Pr o d uct C o m pl ai nts 
A pr o d uct c o m plai nt is a n y wri tte n, electr o ni c, or oral  c o m m u nicat i o n t hat alle ges deficie ncies 
r el ate d t o t he i de ntit y,  q ualit y, d ura bilit y,  relia bilit y,  s af et y,  effect i ve ness or perf or ma nce o f a 
tri al  i nt er ve nt i o n. 
S p o ns or c ollects pr o d uct c o m plai nts o n st u d y  i nt er ve nt i o n a n d dr u g deli ver y s yste ms use d i n 
cli nical st u dies i n or der t o e ns ure t he safet y of  st u d y  p arti ci pa nts, m o ni t or q uali t y , a n d t o 
facilitate pr ocess a n d pr o d uct i m pr o ve me nts. 
P arti ci pa nts or partici pa nt ’s le gal a ut h orize d re prese ntati ve will be i nstr ucte d t o c o ntact t he 
i n vesti gat or as s o o n as p ossi ble if t he y ha ve a c o m plai nt or pr o ble m wit h t he i nt er ve nt i o ns o t hat 
t h e si t u ati o n ca n be assesse d. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
6 0 N O T E: A E s/ S A E s t h at are ass ociate d wit h a pr o d uct c o m plai nt will als o f o ll o w t he pr ocesses 
o utli ne d i n Sect i o n 8. 3. 3 a n d Secti o n 1 0. 3 , A p pe n di x 3 ,of  t he pr ot oc ol .
Ti me Peri o d f or Detecti n g Pr o d uct C o m pl ai nts 
Pr o d uct c o m plai nts t hat res ult i n a n a d verse e ve nt will be detecte d, d oc u me nte d, a n d re p orte d t o 
t h e s p o ns or d uri n g a ll peri o ds of t he st u d y  i n w hic h t he i nt er ve nt i o n is use d. 
If t he i n vest i gat or lear ns of a n y pr o d uct c o m plai nt at a n y ti me after a partici pa nt has bee n 
di sc har ge d fr o m  t he st u d y , a n d s uc h i nci de nt is c o nsi dere d reas o na bl y relate d t o a n i nter ve nt i o n 
pr o vi de d f or t he st u d y , t he i n vest i gat or will pr o m p tl y  n otif y  t he s p o ns or. 
Pr o m pt Re p orti n g of Pr o d uct C o m pl ai nts t o S p o ns or 
Pr o d uct c o m plai nts will be re p orte d t o t he s p o ns or wit hi n 2 4 h o urs after t he i n vest i gat or bec o mes 
a ware of t he c o m p lai nt. 
T he Pr o d uct C o m plai nt F or m will be se nt t o t he s p o ns or b y  a m et h o d desi g nate d b y  t he s p o ns or. 
F oll o w -u p of Pr o d uct C o m pl ai nts 
F o ll o w- u p a p plies t o all partici pa nts, i ncl u di n g t h ose w h o disc o nt i n ue st u d y  i nt er ve nt i o n. 
T he i n vest i gat or is res p o nsi ble f o r e ns uri n g t hat f oll o w -u p i ncl u des a n y s u p ple me ntal 
i n vesti gat i o ns as i n dicate d t o el uci date t he nat ure a n d/ or ca usalit y of  t he pr o d uct c o m plai nt. 
Ne w or u p date d i nf or mat i o n will be rec or de d o n t he ori gi nall y c o m p lete d f or m wit h all c ha n ges 
si g ne d a n d da te d b y  t he i n vest i gat or a n d s u b mitte d t o t he s p o ns or. 
8. 4. Tre at me nt of O ver d ose 
T here i s n o k n o w n a nt i d ote f or a n o ver d ose of L Y 3 8 1 9 2 5 3 al o ne or i n c o m bi nat i o n wi t h  
L Y 3 8 3 2 4 7 9 . 
I n t he e ve nt of a n o ver d ose, t he i n vest i gat or s h o ul d 
1. c o ntact t he s p o ns or i m me diatel y. 
2. c l o sel y  m o ni t or t he parti ci pa nt f or a n y  A E/ S A E a n d la b orat or y  a b n or m ali ti es 
3. p r o vi de s u p p orti ve care as necessar y , a n d 
4. d oc u m e nt t he q ua nti t y  of  t he e xcess d ose i n t he C R F. 
Decisi o ns re gar di n g i nf usi o n i nt err u pti o ns or m o dificat i o ns will be ma d e b y t he i n vest i gat or , i n 
c o ns ultati o n wit h t he s p o ns or, base d o n t he cli nical e val uat i o n of t he partici pa nt. 
8. 5. P h ar m ac o ki netics 
Ve n o us bl o o d sa m ples will  be c ollecte d as s pecifie d i n t he S o A f or deter mi nati o n of 
c o nce ntrati o ns of L Y 3 8 1 9 2 5 3 a n d L Y 3 8 3 2 4 7 9 use d t o e val uate t he P K f or L Y 3 8 1 9 2 5 3 a n d 
L Y 3 8 3 2 4 7 9 .
A ma xi m u m of 3sa m ples m a y be c ollecte d at a d diti o nal t i me p o i nt s d uri n g t he st u d y  i f 
warra nte d a n d a gree d u p o n bet wee n t he i n vest i gat or a n d t he s p o ns or. 
I nstr ucti o ns f or t he c ollect i o n a n d ha n dli n g of bi o lo gi cal sa m ples will be pr o vi de d b y Lill y. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
6 1 Si t e staff will rec or d 
the date a n d ti me ( 2 4 -h o ur cl oc k ti me) of a d mi nistrati o n (start a n d e n d of i nf usi o n), a n d 
the date a n d ti me ( 2 4 -h o ur cl oc k ti me) of eac h P K sa m ple. 
It i s esse nt ia l t hat t he ti mes are rec or de d acc uratel y. 
8. 5. 1. Bi o a n al ytic al 
S a m ples will  b e a nal yze d at a l a b orat or y  a p pr o ve d b y  t he s p o ns or a n d st ore d at a facilit y 
desi g nate d b y  t he s p o ns or.  C o nce ntrati o ns of L Y 3 8 1 9 2 5 3 a n d L Y 3 8 3 2 4 7 9 will be assa ye d usi n g 
a vali date d bi oa nal y ti cal  m et h o d.  A nal yses of sa m ples c ollecte d fr o m place b o -treate d 
parti ci pa nts are n ot pl a n ne d. 
S a m ple rete nti o n is descri be d i n Sect i o n 1 0. 1. 1 2 , A p pe n di x 1 .Re m ai ni n g sa m ples use d f or P K 
ma y be p o ole d a n d use d f or e x pl orat or y  m eta b o lis m or bi o a n al y ti cal  m et h o d e x peri me nts as 
dee m e d a p pr o pri ate. 
8. 6. P h ar m ac o d y n a mics 
T he S A R S -C o V -2 vi ral R N A le vel  a n d viral  cleara n ce will  b e e val uate d b y  nas o p har y n geal 
a n d/ or mi d -t ur bi nate , nasal, or or o p har y n geal s wa bs.  See Secti o n 1 0. 2 , A p pe n di x 2 ;a n d 
Secti o n 1. 3 , t he S o A ,f o r sa m ple c ollecti o n i nf or mati o n. 
S a m ple rete nti o n is descri be d i n Sect i o n 1 0. 1. 1 2 , A p pe n di x 1 .  Re m ai ni n g sa m ples ma y  b e use d 
f o r a d di ti o nal  e x pl or at or y  st u dies t o better u n dersta n d L Y 3 8 1 9 2 5 3 al o n e a n d i n c o m bi nat i o n wi t h 
L Y 3 8 3 2 4 7 9 ,a n d t he disease, w hic h ma y i ncl u de se q ue nci n g a n d/ or c ult ure of t he vir us f or f ut ure 
st u di es. 
8. 7. Ge netics 
A w h o le bl o o d sa m ple will be c o llecte d f or p har mac o ge net ic a nal ysis w here l ocal re g ulat i o ns 
all o w. 
See Secti o n 1 0. 2 , A p pe n di x 2, a n d Sect i o n 1. 3 , t he S o A ,f o r sa m ple c ollecti o n i nf or mat i o n. 
See Secti o n 1 0. 5 , A p pe n di x 5, f o r ge netic researc h ,c ust o d y , a n d sa m ple rete nti o n i nf or mat i o n. 
8. 8. Bi o m ar kers 
Bl o o d sa m ples will be c ollecte d fr o m all part ic i pa nts f or a nal ysis o f i m m u ne s yste m -relate d 
mar kers. Ser u m, w h o le bl o o d f or cell ular a n d/ or e pi ge net ic a nal ysis, a n d w h ole bl o o d R N A 
sa m ples f or e x pl orat or y  bi o m ar ker researc h will be c ollecte d at t he ti me s pecifie d i n t he S o A 
w here l ocal re g ulat i o ns all o w. 
Sa m ples will  b e st ore d a n d a nal ysis ma y  be perf or me d o n bi o mar kers t h o u g ht t o pla y a r ole i n 
i m m u ne s yste m relate d res p o nses t o viral i nfect i o n i ncl u di n g, b ut n ot li mite d t o , i m m u ne 
pat h wa ys, cell ular c o m p osit i o n, ser u m a nal ytes, or e pi ge net ic bi o mar kers, t o e val uate t hei r 
ass oci at i o n wi t h  o bser ve d cli nical res p o nses t o L Y 3 8 1 9 2 5 3 al o ne a n d i n c o m bi nat i o n wi t h 
L Y 3 8 3 2 4 7 9, a n d t he disease state .
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
6 2 S a m ples ma y  be use d f or researc h t o de vel o p met h o ds, assa ys, pr o g n ostics a n d/ or c o m pa ni o n 
di a g n osti cs r el ate d t o t he i nter ve nti o n tar get ( S pr otei n), t he C O VI D -1 9 di sease state, pat h wa ys 
ass oci at e d wi t h  disease, a n d/ or t he mec ha nis m of  a cti o n of  t he st u d y  i nt er ve nt i o n. 
S a m ple rete nti o n is descri be d i n Sect i o n 1 0. 1. 1 2 , A p pe n di x 1 .
8. 9. I m m u n o ge nicit y Assess me nts 
Visits a n d ti mes 
At t h e visit s a n d t i mes s pecifie d i n t he S o A , v e n o us bl o o d s a m ples will  b e c ollecte d t o deter mi ne 
a nt i b o d y  pr o d ucti o n a gai nst L Y 3 8 1 9 2 5 3 a n d/ or L Y 3 8 3 2 4 7 9 .  T he act ual date a n d ti me ( 2 4- h o ur 
cl oc k ti me) of eac h sa m ple c o llect i o n will be rec or de d. 
S a m ple c ollecti o n, h a n dli n g, a n d use 
I nstr ucti o ns f or t he c ollect i o n a n d ha n dli n g of bl o o d sa m ples will be pr o vi de d b y t he s p o ns or. 
I m m u n o ge nicit y ma y be assesse d b y a vali date d assa y  desi g ne d t o detect a nti dr u g a nt i b o dies 
(A D As )i n t he prese nce o f L Y 3 8 1 9 2 5 3 a n d/ or L Y 3 8 3 2 4 7 9 at a la b orat or y  a p pr o ve d b y t he 
s p o ns or.  A nt i b o dies ma y be f urt her c haracterize d f or t heir a bilit y t o ne utralize t he acti vit y of  
L Y 3 8 1 9 2 5 3 a n d/ or L Y 3 8 3 2 4 7 9 .
S a m ple rete nti o n 
S a m ple rete nti o n is descri be d i n Sect i o n 1 0. 1. 1 2 , A p pe n di x 1 .
8. 1 0. He alt h Ec o n o mic s
T his sect i o n is n ot a p plica ble f or t his st u d y. 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
639. Statistical Considerations
9.1. Statistical Hypothese s
This study  will com pare LY3819253 , alone and in combinat ion withLY3832479 ,versus placebo 
in residents and facilit y staff of skilled nursing and assisted living facilit ies wi th a high risk of 
SARS -CoV -2 exposure. The primary study  objective is to dem onstrate superi or efficacy  of 
LY3819253 alone or in combinat ion with LY3832479 over pl acebo in the prevent ion of COVID -
19.  Efficacy co mparisons will be made without regard to changes to any  background therapi es.
A graphical testing sequence strategy  will be used to adjust for mult iplicit y in the primary and 
key secondary  endpoints within Part 1 and Part 2 of the study .All analyses on Part 3 are 
considered exploratory .
9.2. Sample Size Determination
For Part 1, a n estimated 33 events are needed to show superiorit y of LY3819253 4200 mgover 
placebo in each of the primary  and key  secondary  endpoints, using the formula by  Schoenfeld 
(1983). An average sample size of approximately 1300 participants who are SARS -CoV -2 PCR 
negat ive andserology negative at baseline is expected to obtain the needed number of events for 
each endpo int.
For Part 2, an estimated 56 events in the Prevent ion Cohort are needed to show superiority over 
placebo for either LY3819253 700mg or LY3819253 350mg+LY3832479 700mgin each of 
the primary  and key  secondary  endpoints . Approximately 2000 participants on average will be 
rando mlyassigned to study  intervent ion such that approximately  1700 partici pants are 
rando mized in the Prevent ion Cohort with the goal of achieving app roximately 56 events on each 
of the primary  and key  secondary  endpo ints.
Due to the dynamic nature of the pandemic , Part 3 will enro ll at least30 participants andup to 
approximately  500 partici pants randomized to either LY3819253 700 mg or LY3819253 700 mg
+LY3832479 1400 mg .Part 3 of the study  is considered exploratory  and i s not powered for 
inference between the two treatment arms.
The m aximum  sample size for this study  is approximately  5000 participants in the intent-to-treat 
(ITT)population .
Parti cipants will be residents and staff of skilled nursing and assisted living facilit ies.  Globally ,
there are m any reports of the rapi d spread of COVID -19 amongst residents of skilled nursing 
facilit ies following i dentificat ion of an index case, with hi gh associ ated rates of m orbidity and 
mortalit y (Arons et al. 2020; Grabowski ).  Given that residents at these facilit ies are at higher
risk for having a more severe disease course of COVID -19,this will be an important populat ion 
to parti cipate in the stud y.  Therefore, a minimum of 300 residents will be enro lled.  
Operati onally , this will be acco mplished, when possible, by ident ifying facilit ieswhere 
approximately  halfof the parti cipant sinterested in the study  are residents.
For sample size determinat ion for Part 1, the following assumpt ions were used:
1) two-sided significance level o f 0.05; 
2)90% power for the primary and key  secondary  endpoint s; 
3) a n 8-week placebo group event rate of 4.0% for moderate or worse severit y COVID -19; 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
644)a risk ratio of 0.33 between LY3819253 and pl acebo in terms of the primary  and key 
secondary  endpo ints.
For sample size determinat ion for Part 2, the fo llowing assumpt ions were used:
1)two-sided significance level o f 0.025; 
2)90% power for the primary and key  secondary  endpoints; 
3)an 8-week pl acebo group event rate of 5.3% for moderate or worse severit y COVID -19; 
4)a risk ratio of 0.33 between active drug and placebo in terms of the primary  and key  
secondary  endpoints .
9.3. Populatio ns for Analyses
The fo llowing popul ations are defined:
Population Description
Entered All participants who provide informed consent.
Enrolled/ITT All participants assigned to treatment, regardless of whether 
they take any  doses of study  treatm ent, or if they  took the 
correct treatment.  Participants will be analyzed according to 
the treatment group to which they  were assigned.
Facilit y Staff All pa rticipants in the Enrolled/ ITTpopulat ion who are 
staff/emplo yees of the facilit y. 
Residents All participants in the Enrolled/ ITTpopulat ion who are 
residents of the facilit y.
Part 1 Safet y All participants rando mly assigned to study  intervent ion in 
Part 1 and who take at least 1 dose of study intervent ion. 
Parti cipants will be analyzed according to the intervent ion they 
actually received .
Part 2 Safet y All participants rando mly assigned to study  intervent ion in 
Part 2 and who take at least 1 dose of study  intervent ion. 
Parti cipants will be analyzed according to the intervent ion they 
actually received .
Part 3 Safet y All participants rando mly assigned to study  intervent ion in 
Part 3 and who take at least 1 dose of study intervent ion. 
Parti cipants will be analyzed according to the intervent ion they 
actually received .
Fully  Dosed All participants in the Safet y popul ation who receive a 
complete infusi on of study  intervent ion.
Part 1 Prevent ion All participants in the Enrolled/Intent -to-Treat populat ion in 
Part 1 who are SARS -CoV -2 RT -PCR negat ive and serol ogy 
negat ive at baseline.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
65Population Description
Part 1 Treatment All participants in the Enrolled/ ITTpopulat ion in Part 1 who 
are SARS -CoV -2 RT -PCR positive at baseline and serology  
negat ive. 
Part 2 Prevent ion All partic ipants in the Enrolled/Intent -to-Treat populat ion in 
the Prevent ion Cohort in Part 2who are SARS -CoV -2 POC 
and RT-PCR negative and sero logy negat ive at baseline.
Part 2 Treatment All participants in the Enrolled/ITT populat ion in the 
Treatment Cohort in Part 2who are SARS -CoV -2 POC and 
RT-PCR positive and serol ogy negative at baseline . 
Part 3 Treatment All participants in the Enrolled/ITT populat ion in Part 3 who 
are SARS -CoV -2 RT -PCR positive and sero logy negative at 
baseline.
Serol ogy-Positive All p articipants in the Enrolled/ ITTpopulat ion who are SARS -
CoV -2 serology  posi tive at baseline .
POC -Positive/RT -PCR 
NegativeAll participants in the Enrolled/ITT populat ion in Part 2 who 
are SARS -CoV -2 POC posit ive and RT -PCR negative at 
baseline.
POC -Negative/RT -PCR 
PositiveAll participants in the Enrolled/ITT populat ion in Part 2 who 
are SARS -CoV -2 POC negative and RT -PCR positive at 
baseline.
PK Analysis All rando mized participants who received study intervent ion 
and have evaluable PK sample. Participants will be analyzed 
according to the intervent ion they received .
Abbreviations:  ITT = intent to treat; PK = pharmacokinetics; RT-PCR = reverse transcription –polymerase chain 
reaction; SARS -CoV -2 = severe acute respiratory syndrome coronavirus 2.
Throughout the document, the term  “the Prevention populati ons” will be used to describe both 
the Part 1 Prevent ion and Part 2 Prevent ion populati ons. Analyses on the Prevent ion populat ions 
will be conducted on each Prevent ion population separately .The terms“the Treatment 
popul ations” and “the Safet y popul ations” are defined similarly.
The fo llowing study  arms are defined for the purposes of comparison:
Study Arm Study Part Dose Intervention
1 Part 1 4200 mg LY3819253
2 Part 1 --- Placebo
3 Part 2 (Prevent ion Cohort) 700mg LY3819253
4 Part 2 (Prevent ion Cohort) 350mg + 700 mg LY3819253 +LY3832479
5 Part 2 (Prevent ion Cohort) --- Placebo
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
66Study Arm Study Part Dose Intervention
6 Part 2 (Treatment Cohort) 700mg LY3819253
7 Part 2 (Treatment Cohort) 700mg + 1400mg LY3819253 +LY3832479
8 Part 3 700mg LY3819253
9 Part 3 700mg + 1400 mg LY3819253 +LY3832479
9.4. Statistical Analyse s
Statistical analysis o f this study  will be the responsibilit y ofSponsor or its desi gnee.
All tests of treatment effects will be conducted at a 2-sided al pha level of 0 .05, unl ess otherwise 
stated, and all confidence intervals will be given at a 2- sided 95% level.
For subgroup analyses, all tests of interactions between treatment groups and other factors will 
be conducted at a 2 -sided alpha level of 0.10.
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification fo r making the change, will be described 
in the statist ical analysis plan ( SAP)and the clinical study  report (CSR) .  Additional exploratory 
analyses o f the data will be conducted as deemed appropriate.
The stati stical analysis plan will be finalized prior t o un- blinding and it will include a more 
technical and detailed description o f the stati stical analyses described in this sect ion. This sect ion 
is a summary  of the pl anned stati stical analyses of the most important endpoints including 
primary  and key  secon dary endpoints.
For analyses on the Part 2 Prevent ion population, LY3819253 700mg andLY3819253 350mg+
LY3832479 700mg will be assessed against pl acebo separately. 
For analyses on the Part 3 Treatment populat ion, resul ts will be summari zed separately  for 
LY3819253 700 mg and LY381 9253 700 mg + LY3832479 1400 mg.Part 3 is not powered for 
inference between the t wo treatment arms.
If enro lling to a placebo -controlled trial is challenged by an effective medication beco ming 
available for prevention o f COVID -19 and SARS -CoV -2, then the placebo arm may be dropped.
9.4.1. General Considerations
Baseline values for all measurements will be the last measurement taking prior to receiving study  
intervent ion, unless otherwise specified.
The primary  analyses of the primary  endpoints and key  secondary  endpoints will be based on 
events that occurred after randomizat ion.
The analysis model for time -to-event analys es will be a Cox proportional hazards regressio n 
model for the time to the fi rst occurrence of the relevant event, with treatment as a fixed effect.
For continuous measures, analysis o f covariance (ANCOVA) and /or mixed- effects m odel for 
repeated m easures (MMRM) will be used to analyze changes from baseline with the baseline 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
67value as the covariate.  The MMRM mode l will include fixed effects for treatment, visit, 
treatm ent-by-visit interaction, the baseline as a covariate and the participant as a rando m effect.  
Summary  statistics will include sample size, mean, standard deviation, median, 10thand 90th
percent ilesfor both the actual and the change fro m baseline measurements.  Least -squares mean 
(LS mean ) and standard error derived from the model will also be displayed for the change from 
baseline measurement.  Treatment comparisons will be displayed showing the tr eatment 
difference LS Mean and the 95% confidence limits along with the p -value.
For continuous lab measurements, an analysis of variance (ANOVA) on ranks will be used and 
p-values for the difference between each study  intervent ionand placebo will be repo rted.
For categorical measures, summary  stati stics will include sample size, frequency, and 
percentage.  For primary and secondary analyses, a logist ic regressio n model will be used. The 
model will include fixed effects for treatment and stratificat ion factors such as facilit y. For other 
analyses, f requencies will be analyzed using Chi -square tests if the expected count is at least 5, in 
at least 80% of the cells, otherwise a Fisher’s exact Test will be used.
All analyses will be implemented using SAS®Vers ion 9.4 or hi gher, or R versi on 3.6.3 or 
higher .
9.4.2. Participant Disposition
A listing of participant discont inuat ion will be presented for all rando mized participants .  
Summary  analyses will  be conducted for the Prevent ion, Treatment, and Safet y popu lations.
Frequency counts and percentages will be presented for each treatment group and compared 
across treatment groups using Chi -square tests or Fisher’s exact tests.
9.4.3. Participant Characteristics
Dem ographic and baseline characterist ics will be summarized by trea tment group for the 
Prevent ion, Treatment, and Safety  popul ations.  For continuous measures, summary statist ics 
will include sample size, mean, median, 10thand 90thpercentiles and standard deviat ions.  Means 
will be analyzed using ANOVA.  For categorical measures, summary statist ics will include 
sample size, frequency , and percentages.
9.4.4. Concomitant Therapy
Concomitant medicat ions will be summarized by  classes of m edicati ons and by treatm ent group 
using the ITT population. Frequencies will be analyzed usin g Chi -square tests or Fisher’s exact 
tests.
9.4.5. Primary Endpoint
The endpo int for the primary  analysis in the prevent ion populat ionsis defined as cumulative
incidence of COVID -19,defined as the detection of SARS -CoV -2 by RT-PCR AND mild or 
worse disease severi ty within 21 days of detecti on, up to 8 weeks after randomizat ion.
The primary  analysis m odel will be a logisti c regressio n modelwhich will include occurrence of 
a primary  endpoint event as the response variable, and treatment and stratificat ion factors such as 
facilit y as explanatory  variables.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
689.4.6. Secondary Endpoints
As key  secondary  analyses , the proporti on of  partici pants who experience each of the fo llowing 
will be assessed on the Prevention popul ation:
Cum ulative incidence of moderate or worse seve rity COVID -19 (wi thin 8 weeks fro m 
rando mizat ion)
Cum ulative incidence of SARS-CoV -2 infect ion(within 4 weeks from randomizat ion)
The analysis model for the key  secondary  analyses will be similar to the primary  analysis model.
To control  for multiplicity, a fixed -sequence approach will be used to test the primary and key  
secondary  endpoints. A separate testing sequence will be used for each part of the study . The 
final testing sequences will be specified in the SAP.
Addit ionally , the following secondary analyses will be conducted on the Prevent ion populat ion:
The proporti on of  parti cipants who experience each of the fo llowing will be compared 
across treatments:
oCum ulative incidence of SARS-CoV -2 infect ion, up to 8 wee ks fro m 
rando mizat ion
oHospitalization or death due to COVID -19, up to 8 weeks from rando mization
oHospitalization due to COVID -19, COVID -19 related emergency visit, or death
oDeath due to COVID -19, up to 8 weeks fro m randomizat ion
9.4.6.1. Safety Analyses
Unless otherwise noted, all safet y analyses will be conducted on the Safet y popul ation.
All AEs will be listed by  participant and may include informat ion on treatment group, visit, 
preferred term, severit y, seriousness, and relat ionship to the study  medicati on, p rocedure, or 
device.
Treatment -emergent adverse events (TEAEs) will be defined as events that first occur or worsen 
(increase in severit y) after the fi rst inject ion of study  drug fo llowing rando mization.  The count 
and proportion of participant with TEAEs will be summarized for each treatment group.  Overall 
treatm ent group differences will be co mpared using Chi -square tests or Fisher’s exact tests.
Serious adverse events will also be summarized.  The counts and proportion of participants
experiencing the event of interest will be reported for each treatment arm.  Treatment groups will 
be co mpared by Chi -square tests or Fisher’s exact tests.
Perm anent d iscont inuat ions of study  drug due to AEs will be listed.  The count and proportion of 
discontinuat ions of study drug due to AE swill be reported.  Time to discont inuat ion (due to 
AEs) will be com pared between treatm ent groups using a Cox proportional hazard regression 
model with treatm ent as a fixed effect.  Kaplan -Meier curves for both treatment groups will be
reported.
9.4.6.2. Pharmacokinetic Analyses
Pharmacokinet ic analyses will be conducted on data fro m all participants who receive 
intervent ion and have evaluable PK.  Pharmacokinetic estimates for LY3819253 and LY3832479 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
6 9 ma y be s u m marize d b y sa m ple ti me, s uc h as, o n Da y  2 9 . A p o p ul at i o n a p pr oac h usi n g a 
n o nli near mi xe d -effects m o deli n g ( N O N M E M) pr o gra m ma y als o be perf or me d. 
St u d y data ma y be p o ole d wit h t he res ults of ot her st u dies f or p o p ulat i o n P K a n d P K/ P D a nal ysis 
p ur p oses. 
9. 4. 7. E x pl or at or y E n d p oi nts 
As e x pl orat or y a nal yses, t he pri mar y a n d sec o n dar y  a n al yses ma y be re peate d o n t he Treat me nt 
p o p ul at i o ns a n d o n all partici pa nts w h o are i n eit her t he Pre ve nti o n or Treat me nt p o p ulat i o ns i n 
Part 1 a n d 2 .
A d dit i o nal e x pl or at or y  a nal yses f o r Part 1 a n d Part 2 ma yi ncl u de 
ti me t o i m pr o ve me nt of  C O VI D -1 9 disease t o mil d se verit y,  i n t he s u bset of t he 
parti ci pa nts w h o ha ve at baseli ne, or de vel o p ,m o derate or w orse C O VI D - 1 9 
w orst sc ore acc or di n g t o NI AI D or di nal scale(s) 
e xa mi nat i o n of vir o l o g y  f or parti ci pa nts w h o bec o me S A R S -C o V -2 p osit i ve, 
e xa mi nat i o n of viral resista nce t o eac h st u d y  i nt er ve nt i o n, 
d urati o n of  h os pi t ali z ati o n i n parti ci pa nts w h o are h os pitalize d d ue t o C O VI D - 1 9, a n d 
s u b gr o u p a nal yses of pri mar y a n d k e y  sec o n dar y  e n d p oi nts wi t hi n resi de nts vers us staff .
For Part 3 , e x pl orat or y  a nal yses are liste d i n Secti o n  3 .
A d dit i o nal e x pl or at or y  a nal yses o n Part 3 ma y be c o n d ucte d. 
Details o n t hese a nal yses will be descri be d i n t he S A P. 
9. 4. 8. Ot her Safet y A n al yses 
Ot her safet y a nal yses will i ncl u de vital si g ns a n d la b orat or y  a nal y t es. Cate g orical safet y 
meas ures will be s u m marize d wit h c o u nts a n d pr o p orti o ns of  p arti ci pa nts, a n d c o m pare d b y 
treat m e nt usi n g ei t h er a C h i- s q uare test or a Fis her’s e xact test. C o nti n u o us safet y me as ures will 
be s u m marize d as mea n c ha n ge b y visit a n d will be a nal yze d usi n g a n M M R M m o del wit h 
treat m e nt i ncl u de d as a n e x pla nat or y  varia ble. E x p os ure t o st u d y i nter ve nt i o n will be calc ulate d 
f o r eac h partici pa nt a n d s u m marize d b y  tr e at m e nt gr o u p. 
9. 4. 9. I m m u n o ge nicit y A n al yses 
If data fr o m vali date d i m m u n o ge nicit y assa ys are a vaila ble, treat m e nt -e m er ge nt a nti dr u g 
a nt i b o dies ( T E -A D As )ma y be assesse d. 
Treat me nt -e mer ge nt A D As are defi ne d as partici pa nt s
wi t h  a 2 -f o l d ( 1 dil uti o n) i ncrease i n t it er t ha n t he mi ni m u m re q uire d dil ut i o n if n o A D As 
were detecte d at baseli ne (treat me nt -i n d uce d A D A) or 
wi t h  a 4 -f o l d ( 2 dil uti o ns) i ncrease i n titer c o m pare d wit h baseli ne if A D As were detecte d 
at baseli ne (treat m e nt -b o oste d A D A). 
T he fre q ue nc y a n d perce nta ge of partici pa nts wit h pree xist i n g A D A a n d w h o are T E -A D A 
p osi ti ve ( T E -A D A +) t o eac h st u d y  i nt er ve nt i o nwill be ta b ulate d. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
7 0 T he distri b ut i o n of titers a n d fre q ue nc y o f ne utralizi n g a nti b o dies (if assesse d) f or t h e T E -A D A + 
parti ci pa nt sma y als o be ta b ulate d. 
T he rel at i o ns hi p bet wee n t he prese nce of a nt i b o dies a n d P K para meters, efficac y res p o nse or 
safet y t o eac h st u d y  i nt er ve nt i o nma y als o be assesse d.  A d dit i o nal details ma y  b e pr o vi de d i n 
t h e S A P. 
9. 5. I nteri m A n al ys es 
M o ni t ori n g of u n bli n de d safet y data (i ncl u di n g A Es, S A Es, a n d selecte d la b orat or y  
meas ure me nts) will occ ur t hr o u g h o ut t he st u d y  a n d will be c o n d ucte d b y  a n e xter nal  D S M B . 
T he D S M B will ma ke rec o m me n dati o ns c o ncer ni n g t he c o n d uct of t he st u dies, i ncl u d i n g 
c ha n ges t o t he i nf or me d c o nse nt f or m. 
O nl y t he D S M B is a ut h orize d t o e val uate u n bli n de d i nteri m efficac y a n d safet y a nal yses.  St u d y  
si tes will recei ve i nf or mati o n a b o ut i nteri m res ults o nl y  if  t he y nee d t o k n o w f or t he safet y of  
t h ei r p arti ci pa nts. 
U n bli n di n g details are s pecifie d i n t he u n bli n di n g pla n sect i o n of t he S A P or i n a se parate 
u n bli n di n g pla n d oc u me nt. 
T he S A P a n d D S M B c harter will descri be t he pla n ne d i nteri m a nal yses , i ncl u di n g ti mi n g of a n y  
i nt eri m a nal yses, i n greater detail .
9. 6. D at a M o n it ori n g C o m mittee ( D M C) 
T he s p o ns or will f or m a D S M B t o a nal yze t he i nteri m st u d y  data. T o mi ni mize a n y bias 
i nt r o d uce d i nt o t he a nal ysis of t he st u d y  res ul ts, a nal ysis pla ns will be fi nalize d a n d a p pr o ve d 
pri or t o t he i nteri m a nal yses. 
T he pri mar y  g o al  o f t h e D S M B is t o re vie w t he i nteri m res ult s re gar di n g t he c o nti n ui n g safet y  of  
st u d y  partici pa nts a n d t he c o nti n ui n g vali dit y a n d scie nt ific merit of t he st u d y. I nf or m at i o n t hat 
ma y u n bli n d t he st u d y  d uri n g t he a nal yses will n ot be re p orte d t o st u d y  si t es or t he bli n de d st u d y  
tea m  u ntil t he st u d y  has bee n u n bli n de d. 
O verall c o m mittee str uct ure i nf or mati o n is i n Sect i o n 1 0. 1. 5 , A p pe n di x 1. Details of t he D S M B 
will be pr o vi de d i n t he D S M B c harter. 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
7110. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in acco rdance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
International Ethical Guidelines
Appli cable Internat ional Council for Harmoni sation Good Clinical Practice (GCP) 
Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, IB, and other relevant documents (e.g., advertisements) 
must be submitted to an IRB/IEC by  the invest igator and reviewed and approved by the IRB/IEC 
before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immedi ate 
hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with the requirements, policies, and procedures establ ished by 
the IRB/IEC
Notifying the IRB/IEC of SAEs or other significant safet y findings as required by 
IRB/IEC procedures
Provi ding oversight of the conduct of the study  at the site and adherence to requirements 
of 21 CFR, ICH gui delines, the IRB/IEC, Euro pean regulat ion 536/2014 for clinical 
studi es (if applicable), and all other applicable local regulat ions
Invest igator sites are compensated for participat ion in the study  as detailed in the clinical trial 
agreem ent.Facilit y sites are com pensated for the use of the grounds and building as outlined in 
the approved agreement.
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete an d accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators are 
responsible for providing informat ion on financial interests during the study  and f or 1 year after 
completion of the study .
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
7210.1.3. Informed Consent Process
The invest igator or their representative will explain the nature of the study, including the risks 
and benefits, to the participant or their legally authorized representative and answer all quest ions 
regarding the study .
Parti cipants m ust b e informed that thei r parti cipat ion is vo luntary.  Parti cipants or thei r legally 
authori zed representative will be required to sign a statement of informed consent that meets the 
requi rements of 21 CFR 50, local regulations, ICH guidelines, Health Insuranc e Portabilit y and 
Accountabilit y Act requirements, where applicable, and the IRB/IEC or study center.
Due to strict respiratory  isolation policies, limited access to COVID -19 participants rooms, and 
SARS -CoV -2 transmissibilit y via droplet -contaminated pape r, verbal consent and alternat ive 
methods of obtaining consent (for example, by phone) will be allowed if approved by  the IRB.  
This includes obtaining the appropriate signatures and dates on the ICF prior to the performance 
of any protocol  procedures and prior to the administration of invest igational product.
Any variation fro m the standard consent process due to iso lation and infect ion control should be 
sent to the IRB for approval prior to enrollment. The site will document the process in their 
regul atory files and demonstrate that the process has IRB concurrence or approval.
The participant record m ust document how consent was obtained before the participant was 
entered in the study  and the date the written consent was obtained.  The authorized person 
obtaining the informed consent and, if applicable, the individual designated to witness a verbal 
consent, m ust use the appropriate measure (that is, electronic, written) to provide signature and 
date.
Parti cipants m ust be re -consented to the most current ver sion of the ICF(s) during their 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  authori zed 
representative and is kept on file.
10.1.4. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any  parti cipant records, datasets 
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information which would make the participant identifiable will not be transferred.
The par ticipant must be inform ed that hi s/her personal  study -related data will  be used by  the 
sponsor in accordance wit h local data protecti on law.  The l evel of discl osure must al so be 
explained to the participant who will be required to give consent for their d ata to be used as 
described in the informed consent.
The participant must be inform ed that hi s/her m edical  records m ay be examined by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
The sponsor has processes in place to ensure data protection, informat ion securit y and data 
integrity.  These processes include appropriate contingency plan(s) for appropriate and timely 
response in t he event of a data securit y breach.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
7310.1.5. Committees Structure
The D SMB will consist of members external to Lilly .  DSMB membership will include, at a 
minimum, a statist ician and two phy sicians wi th expert ise in the appropriate specialt ies.Details 
about the DSMB membershi p, purpose, responsibilities, and operation will be described in a 
DSMB charter.
10.1.6. Dissemination of Clinical Study Data
A clinical study  report will be provided for this study  and a summary  of study  information 
provi ded on publicly  available webs ites. 
10.1.7. Data Quality Assurance
Investigator Responsibilities
All participant data relat ing to the study  will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e.g., laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  physically  or electroni cally 
signing the CRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct access to source data documents.
Data Monitoring and Management
The Monitoring Plan includes
monitoring details describing strategy , for example, risk-based init iatives in operations 
and qualit y such as Risk Management and Mit igation Strategies and Analyt ical Risk -
Based Monitoring
methods
responsibilit ies and requi rements
handling of nonco mpliance issues and
monitoring techniques.
The sponsor or designee is responsible for the data management of this study  including qualit y 
checking o f the data.  The sponsor assumes accountabilit y for acti ons del egated to other 
individuals (e.g., Contract Research Organizat ions).
Study  monitors will perform  ongoin g source data verification to confirm that data entered into 
the CRF by  authori zed si te personnel  are accurate, com plete, and verifiable fro m source 
docum ents.  They  will also ensure that the safet y and ri ghts of  parti cipants are being protected; 
and that the study  is being conducted in accordance with the currently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regulatory  requi rements.
If on -site monitoring activit ies cannot occur, alternative measures will be used.  Examples of 
alternat ive measures are use of techno logy for off -site monitoring or provi ding pseudonymized 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
74copies of  source documents to the monitor electronically.  The remote source data verificat ion 
will be focused on crit ical efficacy data and important safet y data.
Records Retention and Audits
Records and documents, including signed ICFs, pertaining to the conduct of this study  must be 
retained by the invest igator for the time period outlined in the Clinical Trial Agreement (CTA) 
unless local regulat ions or ins titutional policies requi re a l onger retenti on peri od.
No records may be destroy ed during the retention period without the written approval of the 
sponsor. No records may  be transferred to another locat ion or party  without wri tten notificat ion 
to the spons or.
The sponsor or its representatives will periodically check a sample of the participant data 
recorded against source documents at the study  site.  The study  may be audi ted by  Sponsor or i ts 
representatives, and/or regulatory  agencies at any  time.  Inves tigators will be given notice before 
an audit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system , except for vital signs and symptom assessment.  
Vital signs and s ymptom  assessments will be direct data captured in the EDC sy stem , and will 
serve as the source documentation.  The invest igator does not maintain a separate written or 
electroni c record of these data .  If there are clinical or business cont inuity needs th at do not 
enable these data to be direct data captured, these data will be captured as source via paper and 
transcribed into EDC.  The invest igator is responsible for the ident ification o f any data to be 
considered source and for the confirmat ion that data reported are accurate and complete by 
signing the CRF .
Data collected via the sponsor -provided data capture system swill be stored at third-p arties.The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture system s.  Prior to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s dat abase system and resul tswill be provided to the investigator for review 
and retention.  Data will subsequent ly be transferred fro m the central  vendor to the Sponsor data 
warehouse.
Data from co mplaint forms submitted to Sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed bythe invest igator’s site.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
7 5 Data re p orte d o n t he C R F t hat are tra nscri be d fr o m s o urce d oc u me nts m ust be c o nsiste nt wit h 
t h e s o urce d oc u me nts or t he discre pa ncies m ust be e x plai ne d. T he i n vest i gat or ma y nee d t o 
re q uest pre vi o us me dical rec or ds or tra nsfer rec or ds, de pe n di n g o n t he st u d y .
D ef i nit i o n o f w hat c o nstit utes s o urce data ca n be f o u n d i n  1 0. 1. 7 .
1 0. 1. 9. St u d y a n d Site St art a n d Cl os ure 
T he st u d y  start date is t he date o n w hic h t he cli nic al  st u d y  will be o pe n f or recr uit me nt  of  
parti ci pa nts. 
Site Cl os ure 
T he s p o ns or desi g nee reser ves t he ri g ht t o cl ose t he st u d y  si te or ter mi nate t he st u d y  at a n y  ti me 
f o r a n y  reas o n at t he s ol e discret i o n of t he s p o ns or. St u d y  si tes will  b e cl ose d u p o n st u d y  
c o m plet i o n. A st u d y  si te is c o nsi dere d cl ose d w he n all re q uire d d oc u me nts a n d st u d y  s u p plies 
ha ve bee n c o llecte d a n d a st u d y -si t e cl os ure visi t has bee n perf or m e d. 
T he i n vest i gat or ma y i nit iate st u d y -si t e cl os ure at a n y  ti me, pr o vi de d t he r e i s reas o na ble ca use 
a n d s ufficie nt n otice is gi ve n i n a d va nce of t he i nte n de d ter mi nat i o n. 
Reas o ns f or t he earl y cl os ure of a st u d y  si te b y t he s p o ns or or i n vesti gat or ma y  i ncl u de b ut are 
n ot li mite d t o: 
Fail ure of t he i n vest i gat or t o c o m pl y wit h t he pr ot oc ol , t he re q ui re me nts of t he I R B/I E C 
or l o c al  h eal t h  a ut h ori ti es, t he s p o ns or's pr oce d ures, or G C P g ui deli nes 
I na de q uate recr uit me nt  of  p arti ci pa nts b y  t he i n vesti gat or 
Di sc o nti n uati o n of  f urt her st u d y  i nt er ve nt i o n de vel o p m e nt 
If t he st u d y  i s pre m at urel y  t er m i nate d or s us pe n de d, t he s p o ns or s hall pr o m pt l y i nf or m  t he 
I n vest i gat ors, t he I E Cs/I R Bs, t he re g ulat or y a ut h orit ies, a n d a n y c o ntract researc h 
or ga ni zat i o n(s) use d i n t he st u d y  of  t he reas o n f or ter mi nat i o n or s us pe nsi o n, as s pecifie d b y t he 
a p plica ble re g ulat or y  r e q ui re me nts. T he I n vest i gat or s hall pr o m ptl y i nf or m t he part ic i pa nt a n d 
ass ures a p pr o priate partici pa nt t hera p y  a n d/ or f oll o w- u p. 
1 0. 1. 1 0. P u blic ati o n P olic y 
I n acc or da nce wit h t he s p o ns or’s p u blicati o n p o lic y t he res ults of t his st u d y will be s u b mitte d f o r 
p u blicat i o n b y a peer -re vie we d j o ur nal. 
1 0. 1. 1 1. I n vesti g at or I nf or m ati o n 
Lice nse d p h ysicia ns wi t h  a s pecialt y i n i nt er nal  m e di ci ne, ger o nt ol o g y ,i nfecti o us disease, 
cri ti cal  care, or p ul m o n ar y  disease or ot her s peci al t y  dee me d t o be a p pr o pri ate b y  t he s p o ns or 
ma yparti ci pate as i n vesti gat ors. 
1 0. 1. 1 2. L o n g -Ter m S a m ple Rete nti o n 
S a m ple rete nti o n e na bles use of ne w tec h n o l o gi es, res p o nse t o re g ul at or y  q uest i o ns, a n d 
i n vesti gat i o n of varia ble res p o nse t hat ma y n ot be o bser ve d u nt il later i n t he de vel o p me nt of  t he 
i nt er ve nt i o n or after  t he i nter ve nt i o n  bec o me s c o m merciall y  a vaila ble. 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
76This table describes the retention period for potential sample t ypes.
Sample Type Custodian Retention Period After Last Patient Visit
Pharmacodynamic Samples Sponsor or designee up to 7 years
Pharmacogenetics sample Sponsor or designee up to 7 years
Explo ratory  Biomarker Samples Sponsor or designee up to 7 years
Immunogenicity (ADA) sample Sponsor or designee up to 7 years
Pharmacokinetic sample Sponsor or designee up to 2 years
Abbreviation: ADA = antidrug antibody.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
7 7 1 0. 2.  A p pe n di x 2: Cli nic al L a b or at or y Tests 
Cli nical la b orat or y  tests will  b e p erf or m e d acc or di n g t o t he S o A.  
A d dit i o nal tests ma y be perf or me d at a n y  ti me d uri n g t he st u d y  as deter mi ne d necessar y  b y t he 
i n vesti gat or o r re q uire d b y l ocal re g ulat i o ns. 
Ce ntral  a n d l o c al  l a b orat ori es will be use d. T he S o A a n d ta bl e bel o w descri bes w he n t he l ocal or 
ce ntral  l a b orat or y  will be use d. 
La b orat or y  res ul ts t hat c o ul d u n bli n d t he st u d y  will  n ot be re p orte d t o i n vest i gat i ve sites o r ot her 
bli n de d pers o n nel. 
Pr ot oc ol -s pecific re q uire me nts f or i ncl usi o n or e xcl usi o n of partici pa nts are detaile d i n Sect i o n 5
of  t he pr ot oc ol. 
Pre g na nc y testi n g will be perf or me d acc or di n g t o t he S o A. 
I n vest i gat ors m ust d oc u me nt t heir re vie w of la b orat or y  safet y  res ul ts .
Refer t o Secti o n  1 0. 6 , A p pe n di x 6, f o r rec o m me n de d la b orat or y  testi n g f or h y perse nsi ti vi t y  
e ve nts. 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
78Clinical Laboratory Tests Comments  
Hematology Assay ed by Lilly -designated laboratory
Hemoglobin
Hematocrit
Erythrocy te count ( Red Blood Cells -RBCs)
Mean cell volume 
Mean cell hemoglobin
Leukocytes ( White Blood Cells -WBCs) 
Differential
   Neutrophils, segmented
   Lymphocy tes
   Monocytes
   Eosinophils
   Basophils
Platelets
Cell Morphology (RBC and WBC)
Clinical Chemistry Assay ed by Lilly -designated laboratory
Sodium
Potassium
Chloride
Bicarbonate
Total bilirubin
Direct bilirubin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT)
Blood urea nitrogen (BUN)
Creatinine 
Creatine kinase (CK)
Uric acid
Total protein
Albumin
Calcium
Phospho rus
Glucose
Amylase
Lipase
Lactate dehydrogenase (LDH)
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
79Clinical Laboratory Tests Comments  
Calculations
eGFR calculated by CKD -EPI equation.
Calculated by Lilly -designated laboratory.
Results will not be provided to the investigative sites.
SARS-Cov -2 Panel
C-Reactive Protein
Ferritin
D-dimer
Procalcitonin 
Troponin 
Hormones (female)
Urine Pregnancy Local laboratory
Pharmacokinetic Samples  Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Pharmacodynamic sample Assay ed by Lilly -designated laboratory. 
   SARS -Cov -2 swab (nasopharyngeal, mid-
turbinate, nasal, or oropharyngeal)Negative results will not be provided to the investigative sites.
SARS -Cov -2 Serology Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Pharmacogenetics sample Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Exploratory Biomarker Samples Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Serum
   RNA (PAXGene)
   Whole Blood (EDTA) Epigenetics
Immunogenicity (ADA) Samples Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
   Anti-LY3819253 antibodies
  Anti-LY3832479 antibodies
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
8 0 1 0. 3. A p pe n di x 3: A d verse E ve nts: Defi niti o ns a n d Pr oce d ures f or 
Rec or di n g, E v al u ati n g, F oll o w -u p, a n d Re p orti n g 
1 0. 3. 1. Defi niti o n of A E 
A E Defi niti o n 
A n A E i s a n y  u nt o war d m e dical occ urre nce i n a patie nt or cli nical st u d y  p arti ci pa nt, 
t e m p orall y  ass o ci at e d wi t h  t he use of st u d y  i nt er ve nt i o n, w het her or n ot c o nsi dere d 
r el ate d t o t he st u d y  i nt er ve nt i o n. 
N O T E: A n A E ca n t heref ore be a n y u nfa v ora ble a n d u ni nte n de d si g n (i ncl u di n g a n 
a b n or m al  l a b orat or y  f i n di n g), s y m pt o m, or disease ( ne w or e xacer bate d) te m p orall y 
ass oci at e d wi t h  t he use of st u d y  i nt er ve nt i o n. 
E ve nts Meeti n g t he A E Defi niti o n 
A n y a b n or mal la b orat or y  test res ul ts ( he mat ol o g y , cli nical c he mistr y , or uri nal ysis) or 
ot her safet y assess me nts (e. g., electr ocar di o gra m , ra di ol o gi cal sca ns, vital si g ns 
meas ure me nts), i ncl u di n g t h ose t hat w orse n fr o m baseli ne, c o nsi dere d cli nicall y 
si g nifica nt i n t he me dical a n d scie ntific j u d g me nt of t he i n vesti gat or (i .e., n ot rel ate d t o 
pr o gressi o n of u n derl yi n g disease). 
E xacer bat i o n of a c hr o nic or i nter mitte nt pre -e xist i n g c o n dit i o n i ncl u di n g eit her a n 
i ncrease i n fre q ue nc y a n d/ or i nte nsit y of  t he c o n di ti o n .
Ne w c o n dit i o ns detecte d or dia g n ose d after st u d y  i nter ve nt i o n a d mi nistrati o n e ve n 
t h o u g h it m a y  h a ve bee n prese nt bef ore t he start of t he st u d y .
Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d dr u g -dr u g i nteracti o n. 
Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d o ver d ose of eit her st u d y 
i nt er ve nt i o n or a c o nc o mita nt me dicat i o n. O ver d ose per se will n ot be re p orte d as a n 
A E/ S A E u nless it is a n i nte nti o nal o ver d ose ta ke n wit h p ossi ble s uici dal/self -har mi n g 
i nt e nt. S uc h o ver d ose s h o ul d be re p orte d re gar dless of se q uelae. 
“ Lac k of efficac y ” or “fail ure of e x pecte d p har mac ol o gical act i o n” per se will n ot be 
re p orte d as a n A E or S A E. S uc h i nsta nces will be ca pt ure d i n t he efficac y assess me nts. 
H o we ver, t he si g ns, s y m pt o ms, a n d/ or cli nical se q uelae res ult i n g fr o m lac k of efficac y 
will be re p or te d as A E or S A E if t he y f ulfill t he defi nit i o n of a n A E or S A E. 
E ve nts N O T Meeti n g t he A E Defi niti o n 
T he f o ll o wi n g st u d y -s pecific cli nical e ve nts relate d t o C O VI D -1 9 are e xe m pt fr o m 
a d verse e ve nt re p orti n g u nless t he i n vest i gat or dee ms t he e ve nt t o be relate d t o t he 
a d mi nistrati o n of st u d y  dr u g: 
oH y p o xe mia d ue t o C O VI D -1 9 re q uiri n g s u p ple me ntal o x y ge n; 
oH y p o xe mia d ue t o C O VI D -1 9 re q uiri n g n o n -i n vasi ve ve nt ilati o n or hi g h fl o w 
o x y ge n de vices; 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
8 1 oRes pirat or y  f ail ure d ue t o C O VI D -1 9 re q uiri n g i n vasi ve mec ha nic al  ve nt ilat i o n 
or E C M O 
A n y cli nicall y  si g nifica nt a b n or mal la b orat or y  f i n di n gs or ot her a b n or mal safet y 
assess me nts w hic h are ass ociate d wit h t he u n derl yi n g disease, u nless j u d ge d b y t he 
i n vesti gat or t o be m ore se vere t ha n e x pecte d f or t he partici pa nt’s c o n dit i o n. 
T he disease/ dis or der bei n g st u die d or e x pecte d pr o gressi o n, si g ns, or s y m pt o m s of t he 
di sease/ dis or der bei n g st u die d, u nless m ore se vere t ha n e x pecte d f or t he partici pa nt’s 
c o n di ti o n. 
Me dical or s ur gical pr oce d ure (e. g., e n d osc o p y , a p pe n dect o m y): t h e c o n di ti o n t hat 
lea ds t o t he pr oce d ure is t he A E. 
Si t u ati o ns i n w hic h a n u nt o war d me dical occ urre nce di d n ot occ ur (s ocial a n d/ or 
c o n ve nie nce a d missi o n t o a h os pital). 
A nt ic i pate d da y -t o -da y fl uct uati o ns of pre -e xist i n g disease(s) or c o n dit i o n(s) prese n t or 
detecte d at t he start of t he st u d y  t hat d o n ot w orse n. 
1 0. 3. 2. Defi niti o n of S A E 
If a n e ve nt is n ot a n A E per defi nit i o n a b o ve, t he n it ca n n ot be a n S A E e ve n if seri o us c o n dit i o ns 
are met (e. g., h os pitalizat i o n f o r si g ns/s y m pt o ms of t he disease u n der st u d y , deat h d ue t o 
pr o gressi o n of disease). 
A n S A E is defi ne d as a n y u nt o w ar d me dic al occ urre nce t h at, at a n y d ose: 
a. Res ults i n de at h 
b. Is i m me di atel y life -t hre ate ni n g 
T he ter m  “ life -t h reate ni n g” i n t he defi nit i o n of “s eri o us ”refers t o a n e ve nt i n w hic h t he 
parti ci pa nt was at ri s k of deat h at t he ti me o f t h e e ve nt. It d oes n ot refer t o a n e ve nt, w hic h 
h y p ot heti call y  mi g ht ha ve ca use d deat h, if it were m ore se vere. 
c. Re q uires i n p atie nt h os pit aliz ati o n or pr ol o n g ati o n of e xisti n g h os pit aliz ati o n 
I n ge neral, h os pitalizat i o n si g nifies t hat t he partici pa nt has bee n a d mitte d t o h os pital 
f o r o bser vat i o n a n d/ or treat me nt t hat w o ul d n ot ha ve bee n a p pr o priate i n t he 
p h ysicia n’s office or o ut patie nt setti n g. C o m plicat i o ns t hat occ ur d uri n g h os pi talizati o n 
are A Es. If a c o m plicat i o n pr ol o n gs h os pi talizati o n or f ulfills a n y  ot her seri o us cri t eri a, 
t h e e ve nt is seri o us. W he n i n d o u bt as t o w het her “ h os pitalizati o n” occ urre d or was 
necessar y , t he A E s h o ul d be c o nsi dere d seri o us. 
H os pitalizati o n f o r el ect i ve treat me nt of a pre -e xisti n g c o n dit i o n t hat di d n ot w orse n 
fr o m baseli ne is n ot c o nsi dere d a n A E. 
d. Res ults i n persiste nt dis a bilit y/i nc a p acit y 
T he ter m disa bili t y  m ea ns a s u bsta nt ial disr u pt i o n of a pers o n’s a bilit y t o c o n d uct 
n or m al  life f u nct i o ns. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
8 2 T his defi nit i o n is n ot i nte n de d t o i ncl u de e x perie nces of relat i vel y mi n or me dical 
si g nifica nce s uc h as u nc o m p licate d hea dac he, na usea, v o mit i n g, di arr hea, i nfl ue nza, 
a n d acci de ntal tra u ma (e. g., s prai ne d a n kle) w hic h ma y i nterfere wit h or pre ve nt  
e ver y da y life f u ncti o ns b ut d o n ot c o nstit ute a s u bsta ntial disr u pt i o n. 
e. Is a c o n ge nit al a n o m al y/ birt h defect 
f. Ot her sit u ati o ns: 
Me dical or scie nt ific j u d g me nt s h o ul d be e xercise d i n deci di n g w het her S A E re p orti n g 
is a p pr o priate i n ot her sit uati o ns s uc h as i m p orta nt me dical e ve nts t hat ma y n ot be 
i m me diatel y  life -t h reate ni n g or res ult i n deat h or h os pitalizati o n b ut ma y je o par dize t he 
parti ci pa nt or m a y re q ui r e m e dical or s ur gi cal i nter ve nt i o n t o pre ve nt o ne of t he ot her 
o utc o m es liste d i n t he a b o ve defi ni ti o n . T hese e ve nts s h o ul d us uall y be c o nsi dere d 
seri o us. 
E xa m ples of s uc h e ve nts i ncl u de i nte nsi ve treat me nt i n a n e mer ge nc y  r o o m  or at h o m e 
f o r aller gic br o nc h os pas m, bl o o d d yscrasias or c o n v ulsi o ns t hat d o n ot res ult i n 
h os pi talizati o n, or de vel o p m e nt of  dr u g de pe n de nc y  or dr u g a b use. 
1 0. 3. 3. Rec or di n g a n d F oll o w -U p of A E a n d/ or S A E 
A E a n d S A E Rec or di n g 
W he n a n A E/ S A E occ urs, it is t he res p o nsi bilit y of t he i n vesti gat or t o re vie w all 
d oc u m e nt ati o n (e. g., h os pi t al  pr o gress n otes, l a b orat or y  re p orts, a n d di a g n osti cs 
re p orts) relate d t o t he e ve nt. 
T he i n vest i gat or will t he n rec or d all rele va nt A E/ S A E i nf or mat i o n i n t he C R F. 
It i s n ot acce pta ble f or t he i n vest i gat or t o se n d p h ot oc o pies of t he partici pa nt’s me dical 
rec or ds t o S p o ns or or desi g nee i n lie u of c o m p let i o n of t he A E/ S A E C R F pa ge. 
T here m a y be i nsta nces w he n c o pies of me dical rec or ds f or certai n cases are re q ueste d 
b y S p o ns or or desi g nee. I n t his case, all part ic i pa nt i de ntifiers, wit h t he e xce pti o n o f 
t h e partici pa nt n u m ber, will be re dacte d o n t he c o pies of t he me dical rec or ds bef ore 
s u b missi o n t o S p o ns or or desi g nee. 
T he i n vest i gat or will atte m pt t o esta blis h a dia g n osis of t he e ve nt base d o n si g ns, 
s y m pt o ms, a n d/ or ot her cli nical i nf or mat i o n. W he ne ver p ossi ble, t he dia g n osis ( n ot t he 
i n di vi d ual si g ns/s y m pt o m s) will be d oc u m e nte d as t he A E/ S A E. 
Assess me nt of I nte nsit y 
T he i n vest i gat or will ma ke a n assess me nt of i nte nsit y f o r eac h n o n- i nf usi o n- r el ate d A E a n d 
S A E re p orte d d uri n g t he st u d y  a n d assi g n it t o o ne of t he f o ll o wi n g cate g ori es, w hic h t o get her 
wi t h  seri o us (i .e., S A E) cri t eri a o n t he A E C R F (“res ults i n deat h” a n d “life -t h reate ni n g”), are 
ali g ne d wit h t h e D AI D S T a ble f or Gr a di n g t he Severity of A d ult a n d Pe di atric A dverse 
Eve nts, C orrecte d Versi o n 2. 1 ( J uly 2 0 1 7) .
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
8 3 Mil d: Mil d s y m pt o ms ca usi n g n o or mi ni mal i nterfere nce wit h us ual s ocial a n d f u ncti o nal 
acti vit ies, wit h i nter ve nti o n n ot i n dicate d. 
M o der ate: M o derate s y m pt o ms ca usi n g greater t ha n mi n i mal i nterfere nce wit h us ual 
s o ci al  a n d f u n cti o n al  act i vit ies, wit h i nter ve nti o n i n dicate d. 
Se vere: Se vere s y m pt o ms ca usi n g i na bilit y t o perf or m us ual s ocial a n d f u ncti o nal 
acti vit ies, wit h i nter ve nti o n or h os pitalizati o n i n dicate d. 
I nf usi o n- r el ate d A E/ S A E i nt e nsi t y /se veri t y  s h o ul d be assesse d a n d gra de d acc or di n g t o 
pr ot oc ol  Secti o n  6. 1. 1. 2 .
A n e ve nt is defi ne d as “s eri o us ”w he n i t m eets at least 1 of t he pre defi ne d o utc o mes as 
descri be d i n t he defi nit i o n o f a n S A E, N O T w he n it is rate d as se vere. 
Assess me nt of C a us alit y 
T he i n vest i gat or is o bli gate d t o assess t he relati o ns hi p bet wee n st u d y i nter ve nt i o n a n d 
eac h A E/ S A E. 
A “reas o na ble p ossi bilit y” o f a r el at i o ns hi p c o n ve ys t hat t here are facts, e vi de nce, 
a n d/ or ar g u me nts t o s u g gest a ca usal relat i o ns hi p, rat her t ha n a relat i o ns hi p ca n n ot be 
r ul e d o ut. 
T he i n vest i gat or will use cli nical j u d g me nt t o deter mi ne t he relat i o ns hi p. 
Alt er nat i ve ca uses, s uc h as u n derl yi n g disease(s), c o nc o mita nt t hera p y, a n d ot her ris k 
fact ors, as well as t he te m p oral relati o ns hi p of t he e ve nt t o st u d y  i nt er ve nt i o n 
a d mi nistrati o n will be c o nsi dere d a n d i n vest i gate d. 
T he i n vest i gat or will als o c o ns ult t he I B a n d/ or Pr o d uct I nf or mati o n, f or mar kete d 
pr o d ucts, i n his/ her assess me nt. 
F or eac h A E/ S A E, t he i n vest i gat or m ust d oc u me nt i n t he me dical n otes t hat he /s he has 
re vie we d t he A E/ S A E a n d has pr o vi de d a n assess me nt of ca usalit y. 
T here m a y be si t u ati o ns i n w hic h a n S A E has occ urre d a n d t he i n vest i gat or has 
mi ni mal i nf or mat i o n t o i ncl u de i n t he i nit ial re p ort t o S p o ns or or desi g nee. H o we ver, it 
is ver y  i m p orta nt  t hat t he i n vesti gat or al wa ys ma ke a n assess me nt of ca usalit y f o r 
e ver y e ve nt bef ore t he i nit ial tra ns missi o n of t he S A E data t o S p o ns or or desi g nee. 
T he i n vest i gat or ma y c ha n ge his/ her o pi ni o n of ca usalit y i n li g ht of f o ll o w- u p 
i nf or m at i o n a n d se n d a S A E f oll o w -u p re p ort wi t h  t h e u p date d ca usalit y assess me nt. 
T he ca usalit y assess me nt is o ne of t he cri t eri a use d w he n deter mi ni n g re g ulat or y  
re p orti n g re q uire me nts. 
F oll o w -u p of A Es a n d S A Es 
T he i n vest i gat or is o bli gate d t o perf or m or arra n ge f or t he c o n d uct of s u p ple me ntal 
meas ure me nts a n d/ or e val uat i o ns as me dicall y i n dicate d or as re q ueste d b y S p o ns or or 
desi g nee t o el uci date t he nat ure a n d/ or ca usalit y of  t he A E or S A E as f ull y as p ossi ble . 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
8 4 T his m a y i ncl u de a d dit i o n al  l a b orat or y  tests or i n vesti gati o ns, hist o pat h ol o gical 
e xa mi nat i o ns, or c o ns ultati o n wit h ot her healt h care pr ofessi o nals. 
If a partici pa nt dies d uri n g partici pati o n i n t he st u d y or d uri n g a rec o g nize d f o ll o w- u p 
p eri o d, t he i n v esti gat or will pr o vi de S p o ns or or desi g nee wit h a c o p y  of  a n y 
p ost -m o rte m fi n di n gs i ncl u di n g hist o pat h ol o g y . 
Ne w or u p date d i nf or mat i o n will be rec or de d i n t he ori gi nall y c o m p lete d C R F. 
T he i n vest i gat or will s u b mit a n y u p date d S A E data t o S p o ns or or desi g nee wit hi n 2 4 
h o urs of recei pt of t he i nf or mat i o n. 
1 0. 3. 4. Re p orti n g of S A Es 
S A E Re p orti n g vi a a n Electr o nic D at a C ollecti o n T o ol 
T he pri mar y  m ec ha nis m  f or re p orti n g a n S A E will be t he electr o nic data c ollect i o n 
t o ol .
If t he electr o nic s yste m is u na vaila ble, t he n t he site will use t he pa per S A E data 
c ollect i o n t o ol  (see ne xt secti o n) i n or der t o re p ort t he e ve nt wit hi n 2 4 h o urs. 
T he site will e nter t he S A E data i nt o t he electr o nic s y st e m  as s o o n as i t b e c o m es 
a vaila ble. 
After t he st u d y  i s c o m plete d at a gi ve n site, t he electr o nic data c ollect i o n t o ol  will  b e 
ta ke n off -li ne t o pre ve nt t he e ntr y  of  n e w data or c ha n ges t o e xist i n g data. 
If a site recei ves a re p ort of a ne w S A E fr o m a st u d y  p arti ci pa nt or recei ves u p date d 
da ta o n a pre vi o usl y  re p orte d S A E after t he electr o nic data c ollecti o n t o ol has bee n 
ta ke n off -li ne, t he n t he site ca n re p ort t his i nf or mati o n o n a pa per S A E f or m (see ne xt 
sect i o n) or t o t he s p o ns or b y tele p h o ne. 
C o ntacts f or S A E re p orti n g ca n be f o u n d i n si te trai ni n g d oc u me nts .
S A E Re p orti n g vi a P a per C R F 
Facsi mile tra ns missi o n of t he S A E pa per C R F is t he preferre d met h o d t o tra ns mit t his 
i nf or m at i o n t o t he s p o ns or. 
I ni ti al  n otificati o n via tele p h o ne d oes n ot re place t he nee d f or t he i n vest i gat or t o 
c o m plete a n d si g n t he S A E C R F pa ges wit hi n t he desi g nate d re p orti n g ti me fra mes. 
C o ntacts f or S A E re p orti n g ca n be f o u n d i n si te trai ni n g d oc u me nts .
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
8510.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
10.4.1. Women
Woman of Childbearing Potential
A wo man is considered fertile fo llowing menarche and unt il beco ming post -menopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before fir st dose of study  intervent ion, addi tional eval uation shoul d be considered.
Woman not of Childbearing Potential
Women in the fo llowing categori es are not considered WOCBP
1.Premenarchal
2.Prem enopausal  female wi th either
a.Docum ented hysterectomy
b.Docum ented bilat eral salpingectomy , or
c.Docum ented bilateral  oophorectomy .
For individuals wit h perm anent infert ility due to an alternate medical cause other than the above, 
(e.g., m ullerian agenesis, androgen insensit ivity), investigator discret ion shoul d be applied to 
determining study  entry . 
Note: Determination can co me from the site personnel’s review of the participant’s medical 
records, medical examinat ion, or m edical history  interview. 
3.Postmenopausal  female is defined as, women with:
a.12 m onths of amenorrhea for wom en >55, with no need for FSH
b.12 m onths of amenorrhea for women >40 y ears old wi th FSH ≥40 m IU/mL and 
no other m edical condit ion such as anorexia nervosa and not taking medicat ions 
during the amenorrhea (e.g. oral contraceptives, hormones, gonadotropin 
releasing hormone, ant i-estrogens, select ive estrogen receptor modulators 
(SERMs), or chemotherapy  that induced amenorrhea)
Participation in the Study
Women of child- bearing potenti al may part icipate in this study.
Women of child- bearing potenti al must test negative for pregnancy prior to init iation of 
treatm ent as indicated by  a negative urine pregnancy  test at the screening visit.
Women of child- bearing potenti al who are com pletely  abstinent or in a same sex relat ionship, as 
part of their preferred and usu al lifest yle, must agree to either remain abst inent or stay  in a same 
sex rel ationship wit hout sexual relat ionships with males.
All other women of child- bearing potential must agree to use two forms of effective 
contraception, where at least one form is highly effective (less than 1% failure rate), for the 
entirety of the study .  
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
86Abstinence or contraception must continue for 90 days after the last dose of intervent ion.
Acceptable Methods of Contraception
Highly effect ive methods of contraception (less t han 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives 
implanted con tracepti ves, or 
intrauterine devices. 
Effect ive methods of contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges.  
Not Acceptable Methods of Contraception
Use of male and female condoms as a double barrier method is not considered acceptable due to 
the high failure rate when these barrier methods are combined. 
Barri er protecti on m ethods wi thout concomi tant use of a s permicide are not an effect ive or 
acceptable method of contraception.  
Periodic abst inence (e.g., calendar, ovulat ion, symptothermal, post -ovulation methods), 
declaration of abst inence just for the duration of a trial, and withdrawal are not acceptable 
methods of  contracepti on.
10.4.2. Men
Men, regardless of their fertilit y status, m ust agree to ei ther remain abstinent (if this is their 
preferred and usual lifest yle) or use condoms as well as one addit ional highly effect ive method 
of contracepti on (less than 1% fa ilure rate) or effective method of contraception with non -
pregnant women of child bearing potential partners for the duration of the study and until their 
plasma concentrations are below the level that could result in a relevant potential exposure to a 
possible fetus, predicted to be 90 day s after the l ast dose.
Men wi th pregnant partners should use condoms during intercourse for the duration of the study  
and until the end of est imated relevant potential exposure to the fetus, predicted to be 90 days 
after the last dose.
Acceptable Methods of Contraception
Highly effect ive methods of contraception (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives 
implanted con tracepti ves, or 
intrauterine devices. 
Effect ive methods of contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges.  
Men and their partners may  choose to use a double –barrier m ethod of contraception that must 
include use of a spermicide.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
8 7 Ot her G ui d a nce 
Me n s h o ul d r ef r ai n f r o m  s per m  d o nat i o n f o r t he d urati o n of  t he st u d y  a n d u nt il t heir plas ma 
c o nce ntrati o ns are bel o w t he le vel t hat c o ul d res ult  i n a r el e va nt p ote nti al  e x p os ure t o a p ossi ble 
fet us , pre di cte d t o be 9 0 da ys after t he last d ose. 
1 0. 4. 3. C ollecti o n of Pre g n a nc y I nf or m ati o n 
M ale p artici p a nts wit h p art ners w h o bec o me pre g n a nt 
T he i n vest i gat or will atte m pt t o c ollect pre g na nc y i nf or mat i o n o n a n y male partici pa nt’s fe male 
part ner w h o bec o mes pre g na nt w hile t he male partici pa nt is i n t his st u d y . T his a p plies o nl y t o 
male partici pa nts w h o recei ve st u d y  i nt er ve nt i o n. 
After o btai ni n g t he necessar y  si g ne d i nf or me d c o nse nt fr o m t he pre g na nt fe male part ner direct l y, 
t h e i n vest i gat or will rec or d pre g na nc y i nf or mat i o n o n t he a p pr o priate f or m a n d s u b mit it t o t he 
s p o n s or wi t hi n 2 4 h o urs of  l ear ni n g of t he part ner’s pre g na nc y. 
T he fe male part ner will als o be f o ll o we d t o deter mi ne t he o utc o me of t he pre g na nc y . I nf or mati o n 
o n t he stat us of t he m ot her a n d c hil d will be f or war de d t o t he s p o ns or. Ge nerall y, t he f o ll o w- u p 
wi ll be n o l o n ger t ha n 6 t o 8 wee ks f oll o wi n g t he esti mate d deli ver y  date. A n y  ter mi nati o n of  t he 
pre g na nc y will be re p orte d i ncl u di n g fetal stat us ( prese nce or a bse nce of a n o malies) a n d 
i n dicat i o n f o r t he pr oce d ure. 
Fe m ale P artici p a nts w h o bec o me pre g n a nt 
T he i n vest i gat or will c o llect pre g na nc y i nf or mati o n o n a n y fe male partici pa nt w h o bec o mes 
pre g na nt w hile part ic i pat i n g i n t his st u d y .  T he i nit ial i nf or mati o n will be rec or de d o n t he 
a p pr o priate f or m a n d s u b mitte d t o t he s p o ns or wit hi n 2 4 h o urs of  l ear ni n g of  a partici pa nt's 
pre g na nc y. 
T he parti ci pa nt will be f o ll o we d t o deter mi ne t he o utc o me of t he pre g na nc y . T he i n vest i gat or 
will c o llect f o ll o w- u p i nf or m at i o n o n t he partici pa nt a n d t he ne o nate a n d t he i nf or mat i o n will be 
f o r war de d t o t he s p o ns or. Ge neral l y, f o ll o w- u p will n ot be re q uire d f or l o n ger t ha n 6 t o 8 wee ks 
be y o n d t he est i mate d deli ver y date. A n y ter mi nat i o n of pre g na nc y will be re p orte d, i ncl u di n g 
fetal  stat us ( prese nce or a bse nce of a n o ma lies) or i n dicat i o n f o r t he pr oce d ure. 
W hile pre g na nc y  i tself is n ot c o nsi dere d t o be a n A E or S A E, a n y  pre g na nc y  c o m plicat i o n or 
el ect i ve ter mi nati o n o f a pre g na nc y  f or m e dical  reas o ns will be re p orte d as a n A E or S A E. 
A s p o nta ne o us a b orti o n ( occ urri n g at < 2 0 wee ks gestati o nal a ge) or still birt h ( occ urri n g at > 2 0 
wee ks gestati o nal a ge) is al wa ys c o nsi dere d t o be a n S A E a n d will be re p orte d as s uc h. 
A n y p ost -st u d y pre g na nc y relate d S A E c o nsi dere d reas o na bl y relate d t o t he st u d y i nter ve nti o n 
b y t he i n vesti gat or will be re p orte d t o t he s p o ns or as descri be d i n Se ct i o n 8. 3. 5 . W hile t he 
i n vesti gat or is n ot o bli gate d t o acti vel y see k t his i nf or mat i o n i n f o r m er st u d y parti ci pa nts, he or 
s he m a y l ear n of a n S A E t hr o u g h s p o nta ne o us re p orti n g. 
A n y fe male part ic i pa nt w h o bec o mes pre g na nt w hile partici pat i n g i n t he st u d y  will be wit h dra w n 
fr o m t h e st u d y  a n d will  f ol l o w t he sta n dar d disc o nti n uat i o n pr ocess.  
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
8 8 1 0. 5. A p pe n di x 5: G e n etics 
S a m ple c ollect i o n i nf or mat i o n is f o u n d i n Sect i o n 1 0. 1. 1 2 , A p pe n di x 1. 
Use/ A n al ysis of D N A 
Ge net ic variat i o n ma y i m pact a partici pa nt’s res p o nse t o st u d y i nt er ve nt i o n, s usce pt i bilit y t o, a n d 
se verit y a n d pr o gressi o n of  disease. Varia ble res p o nse t o st u d y  i nt er ve nt i o n ma y be d ue t o 
ge net ic deter mi na nts t hat i m pact dr u g a bs or pti o n, distri b ut i o n, meta b o li s m , a n d e xcreti o n; 
mec ha nis m o f acti o n of  t he dr u g; di sease et i ol o g y; a n d/ or m ol ec ular s u bt y pe of t he disease bei n g 
treate d. T heref ore, w here l ocal re g ulati o ns a n d I R B/I E C all o w , a bl o o d sa m ple will be c o llecte d 
f o r D N A a nal ysis fr o m c o nse nti n g part ic i pa n ts. 
D N A sa m ples m a y be use d f or researc h relate d t o S A R S -C o V - 2 a n d relate d diseases. T he y ma y 
als o be use d t o de vel o p tests/assa ys i ncl u di n g dia g n ostic tests relate d t o L Y 3 8 1 9 2 5 3 , 
L Y 3 8 3 2 4 7 9, or S A R S -C o V - 2 .  Ge netic researc h ma y  c o nsist of t he a nal ysis o f o ne or m ore 
ca n di date ge nes or t he a nal ysis of ge net ic mar kers t hr o u g h o ut t he ge n o me as a p pr o priate. 
T he sa m ples ma y  be a nal yze d as part of a m ult i- st u d y  assess me nt of ge netic fact ors i n v ol ve d i n 
t h e res p o nse t o L Y 3 8 1 9 2 5 3 , L Y 3 8 3 2 4 7 9, or st u d y  i nt er ve nt i o ns of t his class t o u n dersta n d st u d y  
di sease or rel ate d c o n di ti o ns. 
T he res ults of ge net ic a nal yses ma y be re p orte d i n t he C S R or i n a se parate st u d y s u m mar y. 
T he s p o ns or will st ore t he D N A sa m ples i n a sec ure st ora ge s pace wit h a de q uate meas ures t o 
pr otect c o nfi de nt ia lit y. 
T he sa m ples will be retai ne d at a facilit y selecte d b y t he s p o ns or or its desi g nee w hile researc h 
o n S A R S -C o V - 2 c o nt i n ues b ut n o l o n ger t ha n 7ye ars or ot her peri o d as per l ocal re q uire me nts. 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
8910.6. Appendix 6: Recommended Laboratory Testing f or Hypersensitivity 
Events
Laboratory  assessments should be performed if the participant experiences generalized urticaria 
or if anaphylaxis is suspected.
Collect sample after the participant has been stabilized, and within 1 to 2 hours of the 
event; howev er, sam ples m ay be obtained as late as 12 hours after the event as analytes 
can remain altered for an extended period of time.  Record the time at which the sample 
was collected.
Obtain a fo llow-up sam ple at the next regularly scheduled visit or after appr oximately 4 
weeks, whichever is later.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
90Clinical Lab Tests for Hypersensitivity Events
Hypersensitivity Tests Notes
Selected test may be obtained in the event of anaphylaxis or 
systemic allergic/hypersensitivity reactions.
LY3819253 and LY3832479
antidrug antibodies 
(immunogenicity/ADA)Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
LY3819253 and LY3832479
concentrations (PK)Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Tryptase Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Urine N -methylhistamine testing is performed in addition to 
tryptase testing.  Collect the first void urine following the event. 
Collect a follow -up urine sample after approximately 4 weeks.
Note: If a tryptase sample is obtained more than 2 hours after the 
event (that is, within 2 to 12 hours), or is not obtained because 
more than 12 hours have lapsed since the event, collect a urine 
sample for N -methylhistamine testing. 
N-methylhistamine Assaye d by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Drug -specific IgE Will be performed if a validated assay is available.
Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative s ites.
Basophil activation test Will be performed if a validated assay is available.
Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
NOTE: The basophil activation test is an in vitro cell based assay 
that only requires a serum sample. It is a surrogate assay for drug 
specific IgE but is not specific for IgE.
Complement (C3, C3a and 
C5a)Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Cytokine panel Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Abbreviations: ADA = antidrug antibody; IgE = immunoglobulin E; PK = pharmacokinetic.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
9 1 1 0. 7. A p pe n di x 7: Li ver S afet y: S u g geste d Acti o ns a n d F oll o w -u p 
Assess me nts 
Cl ose He p atic M o nit ori n g 
T his ta ble descri bes w he n cl ose he pat ic m o nit ori n g s h o ul d occ ur. 
If a partici pa nt wit h baseli ne res ults 
of ... de vel o ps t he f oll o wi n g ele vati o ns … 
A L T or A S T < 1. 5 ×U L N A L T or A S T ≥ 3 ×U L N 
A L P < 1. 5 ×U L N A L P ≥ 2 ×U L N 
T B L < 1. 5 × U L N T B L ≥ 2 ×U L N (e xce pt f or partici pa nts wit h Gil bert’s 
s y n dr o me) 
A L T or A S T ≥ 1. 5 ×U L N A L T or A S T ≥ 2 ×baseli ne 
A L P ≥ 1. 5 ×U L N A L P ≥ 2 ×baseli ne 
T B L ≥ 1. 5 ×U L N T B L ≥ 2 ×baseli ne (e xce pt f or partici pa nts wit h 
Gil bert’s s y n dr o me) 
A b bre viati o ns:  A L P =al kali ne p h os p hatase; A L T =ala ni ne a mi n otra nsferase; A S T = as partate 
a mi n otra nsferase; T B L =t otal bilir u bi n; U L N =u p per li mit of n or mal. 
T he l a b orat or y  tests liste d i n Sect i o n 1 0. 2 , A p pe n di x 2, i ncl u di n g ala ni ne a mi n otra nsferase 
(A L T ), A S T, A L P, t otal  bilir u bi n ( T B L ), di rect bilir u bi n , ga m ma -gl uta m yl  tr a nsf erase, a n d 
creati ne ki nase, s h o ul d be re peate d w he n m o nit ori n g la bs are perf or me d. 
If t he a b n or malit y persists or w orse ns, cli nical a n d la b orat or y  m o ni t ori n g ,a n d e v al uat i o n f o r t he 
p ossi ble ca uses of t he a b n or mal li ver tests s h o ul d be i nit iate d b y  t he i n vesti g at or i n c o ns ul t ati o n 
wi t h  t he s p o ns or. 
At  a mi ni m u m, t his e val uat i o n s h o ul d i ncl u de a p h ysical e xa mi nat i o n a n d a t h or o u g h me dical 
hist or y , i ncl u di n g s y m pt o ms, r ece nt ill nesses (f or e xa m ple, heart fail ure, s yste mic i nfect i o n, 
h y p ote nsi o n, seiz ures) rece nt tra vel, hist or y of c o nc o mita nt me dicat i o ns (i ncl u di n g o ver -t h e- 
c o u nter), her bal a n d dietar y  s u p ple me nts, hist or y  of alc o h o l use , a n d ot her s u bsta nce a b use. 
I ni ti all y, m o ni t ori n g of  s y m pt o ms a n d he pat ic bi oc he mical tests s h o ul d be d o ne at a fre q ue nc y o f 
bet we e n 3 ti mes wee kl y  a n d e ver y  ot her wee k , base d o n t he partici pa nt’s cli nical c o n dit i o n a n d 
he pat ic bi oc he mical tests.  S u bse q ue ntl y, t he fre q ue nc y o f m o nit ori n g ma y  b e l o were d t o o nce 
e ver y 1 t o 2 wee ks if t he part ic i pa nt’s cli nical c o n dit i o n a n d la b orat or y res ul ts sta bilize.  
M o ni t ori n g of A L T, A S T, A L P, a n d T B L s h o ul d c o nti n ue u nt il le vels n or malize or ret ur n t o 
a p pr o xi mate baseli ne le vels. 
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
9 2 C o m pr e he nsi ve He p atic E v al u ati o n  
A c o m pre he nsi ve e val uat i o n s h o ul d be perf or m e d t o searc h f or p ossi ble ca uses of li ver i nj ur y  i f 
o ne or m ore of t hese c o n dit i o ns occ ur: 
If a partici pa nt wit h baseli ne 
res ults of... de vel o ps t he f oll o wi n g ele vati o ns … 
A L T or A S T < 1. 5 ×U L N A L T or A S T ≥ 3 ×U L N wit h he patic si g ns/s y m pt o ms *, or 
A L T or A S T ≥ 5 ×U L N 
A L P < 1. 5 ×U L N A L P ≥ 3 ×U L N 
T B L < 1. 5 × U L N T B L ≥ 2 ×U L N (e xce pt f or partici pa nts wit h Gil bert’s s y n dr o me) 
A L T or A S T ≥ 1. 5 ×U L N A L T or A S T ≥ 2 ×baseli ne wit h he patic si g ns/s y m pt o ms *, or 
A L T or A S T ≥ 3 ×baseli ne 
A L P ≥ 1. 5 ×U L N A L P ≥ 2 ×baseli ne 
T B L ≥ 1. 5 ×U L N T B L ≥ 1. 5 ×baseli ne (e xce pt f or partici pa nts wit h Gil bert’s s y n dr o me) 
* He p atic si g ns/s y m pt o ms are se vere f ati g ue, n a use a, v o miti n g, ri g ht u p per q u a dr a nt a b d o mi n al p ai n, fe ver, r as h, a n d/ or 
e osi n o p hili a > 5 %. 
A b bre viati o ns:  A L P =al kali ne p h os p hatase; A L T =ala ni ne a mi n otra nsferase; A S T = as partate 
a mi n otra nsferase; T B L =t otal bilir u bi n; U L N =u p per li mit of n or mal. 
At  a mi ni m u m, t his e val uat i o n s h o ul d i ncl u de p h ysical e xa mi nat i o n a n d a t h or o u g h me dical 
hist or y , as o utli ne d a b o ve, as well as tests f or P T -I N R; tests f or viral he pat it is A, B, C, or E; tests 
f o r a ut oi m m u ne he patit is; a n d a n a b d o mi nal i ma gi n g st u d y  (f or e xa m ple, ul tras o u n d or C T sca n). 
Base d o n t he partici pa nt ’s hist or y  a n d i ni ti al  r es ul ts, f urt her testi n g s h o ul d be c o nsi dere d i n 
c o ns ultati o n wi t h  t he Lill y -desi g nate d m e dical m o ni t or , i ncl u di n g tests f or he patit is D vir us 
( H D V), c y t o m e gal o vi r us ( C M V), E pstei n -Barr vi r us ( E B V), aceta mi n o p he n le vels, 
aceta mi n o p he n pr otei n a d d ucts, uri ne t o xic o l o g y  scree n, W ils o n’ s disease, bl o o d alc o h o l le vels , 
uri nar y  et h yl  gl uc ur o ni de, a n d ser u m p h os p hat i d ylet ha n o l. 
Base d o n t he circ u msta nces a n d t he i n vest i gat or ’s assess me nt of t he partici pa nt ’s cli nical 
c o n di ti o n, t he i n vest i gat or s h o ul d c o nsi der referri n g t he partici pa nt f or a he pat ol o gist or 
gastr oe nter ol o gi st c o ns ul t ati o n, m a g net ic res o na nce c h o la n gi o pa ncreat o gra p h y  ( M R C P), 
e n d osc o pi c retr o gra de c h ola n gi o pa ncreat o gra p h y  ( E R C P), car di ac ec h ocar di o gra m , or a li ver 
bi o ps y .
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
9 3 A d diti o n al He p atic D at a C ollecti o n ( He p atic S afet y C R F) 
A d diti o nal he patic safet y d ata c ollecti o n i n he patic safet y C R Fs s h o ul d be perf or me d i n st u d y partici pa nts 
w h o eit her ha ve a he patic e ve nt c o nsi dere d t o be a n S A E or meet 1 or m ore of t hese c o n diti o ns: 
If a p artici p a nt wit h b aseli ne... h as t he f oll o wi n g ele v ati o ns … 
A L T < 1. 5 × U L N A L T ≥ 5 × U L N o n 2 or m ore c o nsec uti ve bl o o d tests 
A L P < 1. 5 × U L N A L P ≥ 2 × U L N o n 2 or m ore c o nsec uti ve bl o o d tests 
T B L < 1. 5 × U L N T B L ≥ 2 × U L N, e xce pt f or cases of k n o w n Gil bert’s s y n dr o me 
A L T ≥ 1. 5 × U L N A L T ≥ 3 × baseli ne o n 2 or m ore c o nsec uti ve bl o o d tests 
A L P ≥ 1. 5 × U L N A L P ≥ 2 × baseli ne o n 2 or m ore c o nsec uti ve bl o o d tests 
T B L ≥ 1. 5 × U L N T B L ≥ 2 × baseli ne 
A b bre viati o ns:  A L P =al kali ne p h os p hatase; A L T =ala ni ne a mi n otra nsferase; A S T = as partate 
a mi n otra nsferase; T B L =t otal bilir u bi n; U L N =u p per li mit of n or mal. 
N ote:  T he i nter val bet wee n t he 2 c o nsec uti ve bl o o d tests s h o ul d be at least 2 da ys. 
He p atic E v al u ati o n Testi n g 
T he Lill y -desi g nate d ce ntral la b orat or y  m ust c o m plete t he a nal ysis of all selecte d testi n g e xce pt 
f o r micr o bi ol o g y  testi n g. 
L ocal  testi n g m a y be perf or me d i n a d dit i o n t o ce ntral testi n g w he n necessar y f or i m me diate 
parti ci pa nt m a na ge me nt. 
Res ults will be re p orte d if a vali date d test or calc ulati o n is a vaila ble. 
He m at ol o g y Cli nic al C he mistr y 
He m o gl o bi n T otal bilir u bi n 
He mat ocrit Direct bilir u bi n 
Er y t hr oc y tes ( R B Cs -re d bl o o d cells) Al kali ne p h os p hatase ( A L P) 
Le u k oc ytes ( W B Cs -w h ite bl o o d cells) Ala ni ne a mi n otra nsferase ( A L T) 
Differe ntial: As partate a mi n otra nsferase ( A S T) 
    Ne utr o p hils, se g me nte d Ga m ma -gl uta m yl tra nsferase ( G G T) 
    L y m p h oc ytes Creati ne ki nase ( C K) 
    M o n oc yt es Ot her C he mistr y 
    Bas o p hils Aceta mi n o p he n 
    E osi n o p hils Aceta mi n o p he n pr otei n a d d ucts 
Platelets Al kali ne p h os p hatase is oe nz y mes 
Cell m or p h ol o g y ( R B C a n d W B C) Cer ul o plas mi n 
C o a g ul ati o n C o p per 
Et h y l alc o h ol ( Et O H) 
Pr ot hr o m bi n ti me, I N R ( P T -I N R) Ha pt o gl o bi n 
Ser ol o g y I m m u n o gl o b uli n I g A ( q ua ntitati ve) 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
94Hepatitis A virus (HAV) testing: Immunoglobulin IgG (quantitative)
    HAV total antibody Immunoglobulin IgM (quantitative)
    HAV IgM antibody Phosphatidylethanol (PEth)
Hepatis B virus (HBV) testing: Urine Chemistry
    Hepatitis B surface antigen (HBsAg) Drug screen
    Hepatitis B surface antibody (anti -HBs) Ethyl glucuronide (EtG)
    Hepatitis B core total antibody (anti -HBc) Other Serology
    Hepatitis B core IgM antibody Anti- nuclear antibody (ANA)
    Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA) a
    HBV DNA b Anti- actin antibody c
Hepatis C virus (HCV) testing: Epstein -Barr virus (EBV) testing:
    HCV antibody     EBV antibody
    HCV RNA b     EBV DNA b
Hepatitis D virus (HDV) testing: Cytomegalovirus (CMV) testing:
    HDV antibody     CMV antibody
Hepatitis E virus (HEV) testing:     CMV DNA b
    HEV IgG antibody Herpes simplex virus (HSV) testing:
    HEV IgM antibody     HSV (Type 1 and 2) antibody 
    HEV RNA b     HSV (Type 1 and 2) DNA b
Microbiology d Liver kidney microsomal type 1 (LKM -1) antibody
Culture:
    Blood
    Urine
aNot required if anti -actin antibody is tested.
bReflex/confirmation dependent on regulatory requirements, testing availability, or both.
cNot required if anti -smooth muscle antibody (ASMA) is tested.
dAssay ed ONLY by investigator -designated local laboratory; no central testing available.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
9510.8. Appendix 8: Abbreviations
Term Definition
ADA antidrug antibody
ADE antibody -dependent enhancement
AE adverse event
ALT alanine aminotransferase
ANOVA analysis of variance 
AST aspartate aminotransferase
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the participant is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the participant are not.
A double -blind study is one in which neither the participant nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.
Com panion diagnostic An in vitro diagnostic device (assay or test) that provides information that is essential for 
the safe and effective use of a corresponding therapeutic product
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
COVID -19 Coronavirus disease - 2019
CRF Case report form
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safe ty physician o r other medical officer.
CRS Clinical research scientist
CSR clinical study report
CTA Clinical trial agreement
DAIDS Division of AIDS
DMC Data monitoring committee; functionally equivalent to DSMB for this study
DSM B Datasafety monitoring board
Device Deficiencies Equivalent to product complaint
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
96EDC Electronic data capture
enroll The act of assigning a participant to a treatment.  Participants who are enrolled in the study 
are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
Facility The phy sical location for the conduct of study procedures. This will be the skilled nursing 
and ass isted living facilities associated with the nursing home network. 
See also “Skilled nursing andAssisted Living facility”.
Facility staff Participants who are staff of the facility.  For “facility”, see “ Facility” and “Skilled nursing 
andAssisted Living facility”.
Contrast to “Site staff ”
GCP good clinical practice
IB Investigator’s Brochure
ICF informed consent form
IgG1 immunoglobulin G1
Informed consent A process by which a participant voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are relevant 
to the participant’s decision to participate.  Informed consent is documented by means of a 
written, signed and dated informed consent form .
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
IP investigational product
IRB/IEC Institutio nal review board / independent ethics committee 
ITT intent to treat:  The principle that asserts that the effect of a treatment policy can be best 
assessed by evaluating on the basis of the intention to treat a participant (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the consequence 
that participant allocated to a treatment group should be followed up, assessed, and 
analy zed as members of that group irrespective of their compliance to the planned cours e 
of treatment.
IV intravenous
IWRS interactive web -response sy stem
LS mean least-squares mean
mAb monoclonal antibody
MMRM mixed-effects model for repeated measures
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
97NIAID Natio nal Institute of Allergy and Infectious Diseases
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
PK/PD pharmacokinetics/pharmacodynamics
POC Point of care test.  In this study, the POC test is a rap id POC test that returns results in 
minutes.
Prevention Cohort Participants in Part 2 who test negative during screening on the POC test .
Contrast with “Treatment Cohort” .
RT-PCR reverse transcription –polymerase chain reaction
SAE serious adverse event
SAP statistical analysis plan
SARS severe acute respiratory syndrome
SARS -CoV-2 severe acute respiratory syndrome coronavirus 2
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candid ates for participation in a clinical study. 
Site The physical location of the primary  investigato r and associated study staff who will 
conduct study procedures at the facilities. 
Site staff Site personnel who perform study tasks.  
Contrast to “Facility staff”
Skilled nursing and
Assisted Living facilityThis terminology is intended to be br oad and is inclusive of skilled nursing, assisted living, 
long-term care, or nursing home facilities.  Memory care units in any of the above can be 
included .  Also, this terminology include sresidents who may need only short -term care.
SoA Schedule of Activities
TBL total bilirubin
TE-ADA treatment -emergent antidrug antibody
TE-ADA+ treatment -emergent antidrug antibody positive
TEAE treatment -emergent ad verse event:  An untoward medical occurrence that emerges during a 
defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does not necessarily have to have a causal relationship with this 
treatment.
Treatment Cohort Participants in Part 2 who test positive during screening on the POC test.
Contrast with “Prevention Cohort”.
WOCBP women of childbearing potential
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
9810.9. Appendix 9: Protocol Amendment History
The Protocol Amendment Summary of Changes Table fo r the current amendment is located 
directly before the Table of Contents (TOC).
Amendment c
Overall Rationale for the Amendment:
The sponsor is adding Part 3 of Study  PYAD.
Part 3 of the study  is a two arm , outpati ent, open l abel, exploratory  cohort evaluating the efficacy 
and safet y of LY3819253 and LY3819253 in combinat ion with LY3832479 in part icipants 
positive for SARS -CoV -2 with or wi thout symptoms in staff and residents who are at higher risk 
for more severe disease and hospitalizat ion in skilled nursing and assisted living facilit ies.
Section # and Name Description of Change Brief Rationale
1.1 Synopsis Updated text to match the body 
of the protocol for Objectives and 
Endpoints, Overall Design, 
Num ber of Participants, and 
Intervention Groups and 
Duration.Updates were made to the associated 
sections.  
See rationale for these sections below.
1.2 Schema Part 3 schema added. Activation of Part 3.
1.2 Schema
4.1.2 Evaluatio n Period
6.1 Study Intervention(s) 
Administered
9.3 Populations for 
Analy sesModified dose for Part 2 Treatment To align to the current dosing strategy being 
evaluated in the treatment studies evaluating 
monotherapy and combination therapy.
1.3.2 Part 2 Treatment 
Cohort and Part 3Modified subsection title to reflect 
addition of Part 3.  
Added note for inclusion and 
exclusion criteria review, “Note that 
eligibility criteria for Part 2 and Part 
3 are different.”
Added row for documentation of 
positive SARS -CoV -2 infection. Activation of Part 3. 
Clarification.
Activation of Part 3.
3 Objectives and 
EndpointsAdded Part 3 exploratory treatment 
objectives
Added, “ Safety, pharmacokinetics, 
and antidrug antibodies will be 
characterized in the overall intent to 
treat population and in the analysis 
populatio ns” to Part 2 and Part 3 
exploratory objectives and endpoints 
table.  Updated Part 2 heading.Activation of Part 3.
Clarification. 
4.1.1 Screening Period Added screening description for Part 
3.Activation of Part 3.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
99Section # and Name Description of Change Brief Rationale
4.1.2 Evaluation Period Modified description of Part 2 
activatio n.
Added evaluation period description 
for Part 3.Clarification on activation of Part 2.
Activation of Part 3.
4.1.3 Follow -up Period Added Part 3 to subheader : Part 2 
Treatment Cohort and Part 3 .Activation of Part 3. 
4.2 Scientific Rationale 
for Study DesignAdded rationale for study design of 
Part 3. Activation of Part 3.
4.3 Justification for Dose Added justification for doses chosen 
for Parts 2 and 3.Activation of Part 3. 
5.1 Inclusion Criteria Added criteria 19 and 20 for 
participants of Part 3.  
Clarified criterion 2.Part 3 population will consist of participants 
who are at higher risk for more severe 
disease and hospitalization.
Clarification:  only applies to Parts 1 and 2.
6.1 Study Intervention(s) 
AdministeredUpdated dose level for study 
interventio n and Part 3.
Updated monitoring for infusion 
times less than 30 minutes.Activation of Part 3.
6.3 Measures to 
Minimize Bias: 
Randomization and
BlindingAdded statement that Part 3 is open 
label.Activation of Part 3.
8.1.1 SARS -CoV -2 Viral 
Swab and SerologyAdded description of viral swab for 
Part 3.Activation of Part 3.
9.1 Statistical 
HypothesesAdded description of Part 3 analyses.
Clarified Part 1 and Part 2 
information. Activation of Part 3.
Clarification.
9.2 Sample Size 
DeterminationAdded sample size for Part 3. Activation of Part 3.
9.3 Populations for 
Analy sesAdded Part 3 populations and 
treatment groups.Activation of Par t 3.
9.4 Statistical Analyses Added description of Part 3 analyses. Activation of Part 3.
9.4.7 Exploratory 
EndpointsAdded description of Part 3 analyses.
Clarified Part 1 and Part 2 
information.  Activation of Part 3.
Clarification.
11 References Added FDA EUA fact sheet Addition of reference.
Throughout the protocol Minor editorial and formatting 
changesMinor, therefore not described.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
100Amendment b (6 November 2020)
Overall Rationale for the Amendment:
This amendment addresses changes to the fo llow-up peri od for the treatm ent cohort i n Part 2 per 
FDA feedback.  The FDA recommended a fo llow-up period of at least 5 half -lives of the 
intervent ion.  The fo llow-up peri od is changed from Day  57 to Day  85 and t he maximum total 
durati on of  study  for each parti cipant in the treatment cohort is changed fro m 8 weeks to 
12weeks. 
Section # and Name Description of Change Brief Rationale
1.1 Synopsis Post-treatment follow -up changed 
from study day 57 to 85FDA feedba ck
1.1 Synopsis Maximum total duration of study for 
each participant in the treatment 
cohort is changed from 8 weeks to 
12 weeksChange in follow -up period duration
1.2 Schema Part 2 schema updated with change 
in follow -up period from 8 weeks to 
12 weeksChange in follow -up period duration
1.3.2 Part 2 Treatment 
Cohort Schedule of 
Activities (SoA)Post-treatment follow -up changed 
from study day 57 to 85FDA feedback
4.1.2 Evaluation Period Follow -up changed from study day 
57 to 85 FDA feedback
4.1.2 E valuation Period Maximum total duration of study for 
each participant in the treatment 
cohort is changedChange in follow -up period duration
4.1.2 Evaluation Period Treatment cohort visit type table 
updated from study day 57 to 85FDA feedback
4.1.3 Follow -up Period Part 2 Treatment Cohort changed 
post-evaluation follow -up 
assessment from study day 57 to 85FDA feedback
Throughout the protocol Minor editorial and formatting 
changesMinor, therefore not described.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
101Amendment a (27 October 2020)
Overall Rationale for the Amendment:
The sponsor is adding Part 2 of Study  PYAD in order to further invest igate the efficacy and 
safet y of a lower dose l evel of LY3819253 and the combination intervention of LY3819253 and 
LY3832479 in preventing SARS -CoV -2 infect ion and COVID- 19 in skilled nursing and assisted 
living facilit y residents and staff.
The primary  endpoint for Part 1 and Part 2 has been changed to cumulat ive incidence of COVID -
19 defined as the detection of SARS -CoV -2 by RT-PCR AND mild or worse disease severit y 
within 21 days of detection [time frame for endpoint evaluat ion: 8 weeks from rando mization]. 
The c umulative incidence of SARS -CoV -2 infect ion defined as the detection of SARS -CoV -2 by 
RT-PCR wi thin 4 weeks fro m rando mizat ion is now a key secondary  endpoint.  
The changes in the primary endpoint aligns closely to the Guidance for Industry : COVID -19: 
Developing Drugs and Bio logical Products for Treatment or Prevent ion, 
III.C.:  “In prevention trials, the primary  endpoint shoul d be the occu rrence of laboratory-
confirmed SARS -CoV -2 infect ion (wi th or wi thout symptom s) or SARS- CoV -2 infection 
with symptom s (i.e., COVID -19) through a prespecified time po int” (FDA 2020)
Section # and Name Description of Change Brief Rationale
Title Page, Synop sis Title and short title changed to 
include “alone and in 
combination with LY3832479.”Activation of Part 2 includes evaluation 
of combination therapy with LY3819253 
and LY3832479.
1.1 Synopsis Updated text to match the body 
of the protocol for Rationale, 
Objectives and Endpoints, 
Overall Design, Number of 
Participants, and Intervention 
Groups and Duration.Updates were made to the associated 
sections.  
See rationale for these sections below.
In Number of Participants, 
modified description, “… a total 
ofapproximately 1700 
participants… on average will be 
randomly assigned…”.Clarity.
1.2 Schema Added schema for Part 2. Activation of Part 2.
1.3.1 Part 1 and 
Prevention Cohort of 
Part2Added SARS -CoV-2 POC Test 
(nasal swab) at Screening for 
participants in Part 2.Cohort allocation is dependent on the 
POC test result.
Added “(for PCR test)” to the 
SARS -CoV-2 nasopharyngeal 
and nasal swab test descriptions.Clarity.
Added comment to PK sample: 
“For participants in Part 2, Day 1 Collect C maxdata post- infusion in Part 2.
C O N FI D E N TI A L J 2 X -M C -P Y A D( d); C o V P N # 3 5 0 1 
1 0 2 Secti o n # a n d N a me Descri pti o n of C h a n ge Brief R ati o n ale 
c ollecti o n is p ost -d ose o nl y 
(a p pr o x. 3 0 mi n utes after e n d of 
i nf usi o n).” 
1. 3. 2 Part 2 Treat me nt 
C o h ort ( S O A) A d de d se parate S O A ta ble f or t he 
Part 2 Treat me nt C o h ort. Partici pa nts w h o test p ositi ve o n t he 
scree ni n g P O C test f or S A R S -C o V - 2 
will be f oll o we d f or a s h orter d urati o n 
( See Secti o n  1. 3. 2 ), as t he y are n ot 
o bser ve d f or t he pre ve nti o n e n d p oi nt a n d 
ar e  a n e x pl orat or y treat me nt gr o u p. 
2. 1 St u d y Rati o nale A d de d L Y 3 8 1 9 2 5 3 i n 
c o m bi nati o n wit h L Y 3 8 3 2 4 7 9 t o 
descri pti o n of st u d y ai m.  C o m bi nati o n t hera p y has bee n a d de d as a 
st u d y i nter ve nti o n gr o u p. 
2. 2 Bac k gr o u n d A d de d L Y 3 8 3 2 4 7 9 bac k gr o u n d. C o m bi nati o n t hera p y has bee n a d de d as a 
st u d y i nter ve nti o n gr o u p. 
2. 3 Be nefit/ Ris k 
Assess me nt A d de d “ N o cli nicall y rele va nt 
off -tar get bi n di n g has bee n 
o bser ve d i n tiss ue cr oss reacti vit y 
st u dies of me m bra ne tar gets i n 
h u ma n tiss ues.” A d de d i nf or mati o n o n a p ote ntial ris k. 
Re m o ve d “ L Y 3 8 1 9 2 5 3 will be 
a d mi nistere d t o partici pa nts at 
s ufficie ntl y hi g h d ose le vels t o 
ne utralize S A R S -C o V -2.” Rati o nale f or d ose descri be d i n Secti o n 
4. 3.  
A d de d details o n ris k o f cli nical 
A D E a n d reas o ns f or c o nsi deri n g 
sai d ris k as l o w. A d de d i nf or mati o n o n a p ote ntial ris k. 
A d de d refere nces a n d be nefit/ris k 
i nf or mati o n f or L Y 3 8 3 2 4 7 9. C o m bi nati o n t hera p y has bee n a d de d as a 
st u d y i nter ve nti o n gr o u p. 
3 O bjecti ves a n d 
E n d p oi nts C ha n ge d t he pri mar y e n d p oi nt 
f or t he Part 1 Pre ve nti o n 
P o p ulati o n t o: 
C u m ulati ve i nci de nce of 
S A R S -C o V - 2 C O VI D - 1 9 
defi ne d as t he detecti o n of 
S A R S -C o V -2 b y R T -P C R 
A N D mil d or w orse disease 
se verit y awit hi n 2 1 da ys of 
detecti o n 
Ti me fra me f or e n d p oi nt 
e val uati o n: 8 wee ks fr o m 
ra n d o mizati o n E n d p oi nt ali g ns wit h F D A G ui d a nce f or 
I n d ustry: C O VI D -1 9: Devel o pi n g Dr u gs 
a n d Bi ol o gic al Pr o d ucts f or Tre at me nts 
or Preve nti o n, III. C, a n d wit h t he 
pri m ar y e n d p oi nts f or o n g oi n g S A R S -
C o V -2 vacci ne trials. 
C ha n ge d t he ke y sec o n dar y 
e n d p oi nt f or Part 1 Pre ve nti o n 
P o p ulati o n t o: U p date d t he sec o n dar y e n d p oi nt t o 
e val uate pri or pri mar y e n d p oi nt. 
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
103Section # and Name Description of Change Brief Rationale
Cumulative incidence of 
COVID -19SA RS-CoV-2; 
defined as the detection of 
SARS -CoV-2 by RT -PCR, 
AND mild or worse disease 
severityawithin 21 days of 
detection
Time frame for endpoint 
evaluation: 4 weeks from 
randomization
Modified other secondary and 
exploratory endpoints, “Compare 
the frequency of hospitalization 
or death due to COVID -19.”Added “death ”to capture serious disease 
not captured by hospitalization.
Added the objectives and 
endpoints for Part 2 of Study 
PYADAdded objectives and endpoints for Part 
2 to align with the design of Part 2.
4.1 Overall Design Added “prophylaxis ”to overall 
study description.Alignment with synopsis.
Added “…alone and in 
combination with LY3832479…” 
to study description.Combination therapy with LY3832479 
has been added as a study intervention 
group.
4.1.1 Screening Period Added, “Prior to randomization 
in Part 2, participants will receive 
a point of care (POC) test for 
SARS -CoV-2 infection.  
Participants will be allocated to 
either Prevention or Treatment 
Cohorts based on the result.”The POC test is used to determine 
allocation to the Prev ention or Treatment 
Cohort in Part 2.
4.1.2 Evaluation 
PeriodAdded, “Participants in Part 1 
will be randomized to placebo or 
LY3819253.  When the needed 
events for the primary and key 
secondary endpoints are 
achieved, and the minimum 
number of residents enroll, the 
sponsor will trigger activation of 
Part 2.”Ensures that Part 2 occurs after the 
primary endpoint for Part 1 can be 
evaluated.
Added description of the 
Prevention and Treatment 
Cohorts.Activation of Part 2.
Added a visit type information 
table.Clarification of visit types.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
104Section # and Name Description of Change Brief Rationale
Updated Table 1 Definitions for 
COVID -19 Severity:  removed 
definition of Shock.The definition did not define participants 
in shock.  Clinical judgement will be 
relied on.
4.1.3 Follow -up Period Provided information on the 
follow -up period for Part 2.Activation of Part 2.
4.2 Scientific 
Rationale for Study 
DesignAdded “alone or in combination 
with LY3832479”.Combination therapy with LY3832479 
has been added as a study intervention 
group.
Added study design descr iptions 
for POC and RT -PCR tests.Activation of Part 2.
4.3 Justification for 
DoseUpdated to include justification 
for doses used in Part 2.Activation of Part 2.
5.2 Exclusion Criteria Added to criterion 7, “Recovered 
from confirmed COVID -19 
disease orasymptomatic 
infection ”.Included recovered from asymptomatic 
infection in exclusion as it is possible 
immunity could be established in people 
with symptomatic or asymptomatic 
disease.  Removed “confirmed” because 
there is no specific definition.
Added to criterion 11, 
“Participation in a previous 
SARS -CoV-2 vaccine trial or 
received an approved SARS -
CoV-2 vaccine. ”Anticipation of an EUA or approved 
vaccine during the study.
Added LY3832479 to 
criterion 16.Addition of LY3832479 to study.
6.1 Study 
Intervention(s) 
AdministeredAdded information that describes 
Part 2 treatment groups.Activation of Part 2.
Changed monitoring from 2 
hours after completion of the 
infusion to 1 hourBased on available safety data.
6.1.1.1 Premedication 
for InfusionsModified text, “Premedication 
for infusions is not planned.  
However, if an infusion reaction 
occurs during administration or if 
the participant…”.Clarity:  participants receive a single 
infusion in this study, so the text is not 
applicable.
6.3 Measures to 
Minimize Bias: 
Randomization and 
BlindingAdded information that describes 
blinding for Part 2.Activation of Part 2.
Updated table for general 
procedures for unblinding:  
“The date and reason that the Clarification.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
105Section # and Name Description of Change Brief Rationale
blind was broken must be 
recorded in the source
documentation and case report 
form.”
Added to the general procedures 
for unblinding table, 
“Participants who test negative at 
screening POC testing, then test 
positive at baseline PCR testing, 
will be unblinded.  Unblinding is 
recorded and reported by the 
IWRS.”Clarification.
6.5 Concomitant 
TherapyUpdated language on remdesivir, 
“Therefore, remdesivir may be 
initiated as standard of care for 
participants requiring
hospitaliz ation ed with severe 
disease (if available through the 
FDA Emergency Use 
Authorizations) outside of local 
standard of care per written 
policies or guidelines .”Remdesivir is now approved for 
treatment of hospitalized COV ID-19 
patients.
Added, “Vaccines for SARS -
CoV-2 should not be used prior 
to Week 8 of the evaluation 
period for the prevention cohort 
of Part 2.”SARS -CoV-2 vaccines are prohibited 
during the evaluation period of the 
prevention cohort to maintain 
interpr etability of study endpoints.
8.1.1 SARS- CoV-2 
Viral Swab and 
SerologyAdded information on the POC 
test.  Edited language to clarify 
test usage in study.Activation of Part 2.
Added “However, for Part 1, a 
positive result from any baseline 
swab will be sufficient for 
positive baseline RT -PCR 
status.”Clarification.
8.4 Treatment of 
Over doseAdded “alone or in combination 
with LY3832479.Activation of Part 2.
8.5 Pharmacokinetics Added LY3832479. Activation of Part 2.
8.5.1 Bioanalytical Added LY38324 79. Activation of Part 2.
8.6 
PharmacodynamicsAdded LY3832479. Activation of Part 2.
8.8 Biomarkers Added LY3832479. Activation of Part 2.
8.9 Immunogenicity Added LY3832479. Activation of Part 2.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
106Section # and Name Description of Change Brief Rationale
9.1 Statistical 
HypothesesAdded reference to LY3832479. Activation of Part 2.
Updated primary endpoint 
description.Endpoint aligns with FDA Guidance for 
Industry: COVID -19: Developing Drugs 
and Biological Products for Treatments 
or Prevention, III.C, and with the 
primary endpoints for ongoing SARS -
CoV-2 vaccine trials.
9.2 Sample Size 
DeterminationAdded sample size information 
for Part 2.Activation of Part 2.
Added dose strength (4200 mg) 
to describe primary endpoint.Clarification. 
9.3 Populations for 
AnalysesUpdated table to include relevant 
Part 2 populations.Activation of Part 2.
Added table to define study arms 
for purposes of comparison.Clarity.  
Added description for use of 
specified terms.  Clarity. 
9.4 Statistical 
AnalysesAdded analysis information for 
Part 2.Activation of Part 2.
9.4.1. General 
ConsiderationsModified language, “… for the 
difference between 
LY3819253 each study  
intervent ionand placebo will 
be reported.”Addition of LY3832479.
9.4.5 Primary 
EndpointUpdated primary endpoint. Endpoint aligns w ith FDA Guidance for 
Industry: COVID -19: Developing Drugs 
and Biological Products for Treatments 
or Prevention, III.C, and with the 
primary endpoints for ongoing SARS -
CoV-2 vaccine trials.
9.4.6 Secondary 
EndpointsUpdated secondary endpoints. As described in Section 3.
9.4.6.1 Safety 
AnalysesRemoved study drug overdose  
languageOver dose is described in Section 8.4.  
AE definitions are detailed in 
Section 10.3.  
9.4.6.2 
Pharmacokinetic 
AnalysesAdded subsection to describe PK 
analyses.Clarit y.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
107Section # and Name Description of Change Brief Rationale
9.4.7 Exploratory 
EndpointsModified language to be 
inclusive of all study 
interventions.Addition of LY3832479.
9.4.8 Other Safety 
AnalysesUpdated: “safety measures will 
be summarized with incidence 
rates counts and proportions of 
participants ”Correction.  
9.4.9 Immunogenicity 
AnalysisModified language to be 
inclusive of all study 
interventions.Addition of LY3832479.
10.1.7 Data Quality 
AssuranceAdded information on the data 
capture system: “If there are 
clinical or business continuity 
needs that do not enable these 
data to be direct data captured, 
these data will be captured as 
source via paper and transcribed 
into EDC.”  Flexibility.  
10.2 Cl inical 
Laboratory TestsAdded “Anti -LY3832479 
antibodies” to immunogenicity 
samples collectedAddition of LY3832479.
10.5 Genetics Added LY3832479. Activation of Part 2.
10.6 Recommended 
Laboratory Testing for 
Hypersensitivity 
EventsAdded LY3832479. Activation of Part 2.
10.8 Abbreviations Added definitions for Prevention 
Cohort and Treatment Cohort.Clarity.
Throughout the 
protocolMinor editorial and formatting 
changesMinor, therefore not described.
CONFIDENTIAL J2X-MC-PYAD(d); CoVPN #3501
10811. References
Arons MM, Hatfiel d KM, Reddy  SC, et al . Presymptom atic SARS -CoV -2 infections and 
transmissio n in a skilled nursing facilit y. NEJM . 2020;382(22):2081 -90. 
https://doi .org/ 10.1056/NEJMoa2008457
[CDC] Centers for Disease Control and Prevent ion. Nursing home care. U pdated 11 March 2016. 
https://www.cdc.gov/nchs/fastats/nursing -home-care.htm . Accessed 1 June 2020. 
[CDC] Centers for Disease Control and Prevent ion. Ol der adul ts. Updated 30 April 2020. 
https://www.cdc.gov/coronavirus/2019 -ncov/need -extra -precauti ons/o lder-adults.html. 
Accessed 1 June 2020. 
Chen P, Ni rula A, Heller B, et al. SARS -CoV -2 neutralizing ant ibody  LY-CoV555 in outpatients 
with Covid -19. NEJM . Published 28 October 2020. https://doi.org /10.1056/NEJMoa2029849
[DAIDS] Divisio n of AIDS , Nati onal Institutes of Health . Divisio n of AIDS, US Department of 
Health and Human Services. Table for Grading the Severit y of Adult and Pediatri c Adverse 
Events. National Inst itute of Allergy and Infect ious Di seases. Corrected versio n 2.1. July 2017. 
Available at: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf . 
Accessed: 14 April 2020.
FDA EUA fact sheet.  Fact sheet for health care providers, Emergency Use Authorizat ion (EUA) 
of bamlanivimab. Available at: https://www.fda.gov/media/1436 03/downl oad. Accessed: 16 
November 2020. 
[FDA] Food and Drug Administration. COVID- 19: developing drugs and bio logical products for 
treatm ent or prevent ion. May  2020. Available at 
https://www.fda.gov/media/137926/download. Accessed 1 June 2020.
Gottlieb R L, Ni rula A, Chen P, et al. Effect of neutralizing monoclonal ant ibody  bamlanivimab 
as monotherapy  or in combinat ion with etesevimab on viral load amo ng patients with mild -to-
moderate COVID -19: A randomized clinical trial . [published online 21 Jan 2021]. JAMA
https:// doi.org/ 10.1001/jama.2021.0202
Grabowski DC and Mor V. Nursing ho me care in crisis in the wake o f COVID -19. [published 
online 22 May  2020]. JAMA . https:// doi.org/ 10.1001/jama.2020.8524
Graham NSN, Junghans C, Downes R, et al. SARS- CoV -2 infect ion, clinical features and 
outcom e of COVID -19 in Uni ted Kingdom  nursing homes [published online ahead of print, 
2020 Jun 3]. J Infect. 2020;S0163 -4453(20)30348- 0. https://doi.org/ 10.1016/j.jinf.2020.05.073
Schoenfeld DA. Sam ple-size form ula for the proporti onal-hazards regressio n model. Biometrics.
1983 ; 39(2):499-503.
Werner RM, Hoffman AK, Coe MB. Long -term care policy after Covid -19 — s olving the 
nursing h ome crisis. [Published online 27 May  2020]. NEJM.
https:// doi.org/ 10.1056/NEJMp2014811
L e o  D o c u m e n t  I D  =  a c 9 d 3 0 9 0 - b f 2 d - 4 8 8 c - a 5 d e - c f 5 1 b 3 0 7 5 c a 0 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 2 - J a n - 2 0 2 1  1 4 : 5 3 : 4 9  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 2 - J a n - 2 0 2 1  1 4 : 5 7 : 1 9  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 